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Abstract
p53 is frequently altered in human tumors through missense mutations that result in
accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-
function properties to p53. To ascertain the physiological effects of tumor-associated point-
mutations in p53, the structural mutant p5 3R172H and the contact mutant p53R27 °H (codons 175 and
273 in humans) were engineered into the endogenous p53 locus in mice. p53R270H/+ and
p53R 17 2H /+ mice are mouse models of Li-Fraumeni Syndrome (LFS). They developed allele-
specific tumor spectra that were distinct from p53 +/ - mice and that better reflect the broad
spectrum of tumors found in LFS patients. Dominant effects that varied by allele and function
were observed in primary cells derived from these mice. In addition, p 53 R270H/ - and p5 3 R172H/ -
mice developed novel tumors compared to p53 -- mice, including hemangiosarcomas and variety
of carcinomas. These data support a gain-of-function effect by mutant p53 toward the
development of epithelial and endothelial tumors.
Furthermore, conditional mutant p53 alleles were used in combination with a conditional
activated K-ras allele to generate mouse models of advanced lung adenocarcinoma. In this
system, the effects of endogenous mutant p53 were found to be both allele-specific and tissue-
specific. This work provides insight into the spectrum of p53 mutations in human cancers and
demonstrates that point-mutant p53 alleles expressed under physiological control have enhanced
oncogenic potential beyond the simple loss ofp53 function.
Thesis supervisor: Tyler Jacks
Position: Professor of Biology
Director of the MIT Center for Cancer Research
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Chapter 1
Introduction
11
MODELING CANCER IN MICE
In the past six years, substantial advances have been made in the accurate modeling of human
cancers using genetically engineered mouse strains. As mouse models have improved in their
sophistication and faithfulness to the genetic lesions observed in human tumors, their accuracy in
recapitulating the phenotypes of these tumors has also improved. Analysis of carefully designed
mouse strains has allowed for explorations into the biology of hundreds of different cancer
genes, elucidating many of the basic principles of cancer described above. The following is a
discussion of the various classes of genetically engineered mouse strains and the challenges that
remain in mouse modeling (Figure 1).
The earliest genetically engineered mouse models were transgenic mice into which recombinant
DNA was randomly inserted (Gordon et al., 1980). Transgenic mice are still frequently utilized
as a quick means of assessing the effects of gene overexpression or as a component of a more
complicated regulatory system. The former generally involve the expression of a cDNA from an
exogenous promoter. The principal drawback to cDNA trangenics is that they lack proper
temporal and spatial control of gene expression. All of the subtle details of gene regulation
inherent in the endogenous gene are lost and the transgene is often expressed at levels vastly
greater than physiological. A variation of this approach is to place a cDNA under the control of
the promoter from a gene with a desired expression pattern (Chada et al., 1985). When using this
strategy, great care must be taken to confirm the expression pattern of the transgene; missing
intronic or distal upstream regulatory elements can affect the expression pattern of a gene, as can
epigenetic effects arising from the site of genome integration. More recently, bacterial artificial
chromosomes (BACs) have been used to overcome the inherent insert size restrictions of
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traditional cloning techniques (Yang et al., 1997). Using this technique, BAC transgenic mice
can be constructed that incorporate large fragments of DNA (up to -100kb) into the mammalian
genome, allowing for an extra copy of a gene to be expressed from its endogenous promoter and
with intact non-coding sequences. However, even in this case, epigenetic effects, such as the
precise state of the chromatin surrounding the endogenous gene, may not be accurately
recapitulated.
In order to assess the effects of loss of gene expression, methods for precisely targeting
endogenous loci were developed using homologous recombination in embryonic stem cells
followed by blastocyst injection and implantation (Thompson et al., 1989). The results of this
approach were knockout mice, which harbor null mutations of targeted genes in the endogenous
locus. Knockout mice have been highly successful aids to understanding the functions of tumor
suppressor genes or for investigating the developmental roles played by oncogenes. One of the
major drawbacks of using knockout mice to model human tumors is that many cancer genes have
important developmental roles, the loss of which can result in embryonic lethality. The second
major drawback is that tumor suppressor genes are not always lost through large deletions. p53,
for example, is generally found to harbor single base-pair point-mutations rather than loss-of-
function mutations. A variation on the knockout mouse addresses this second point by targeting
subtle mutations into the endogenous locus. These targeted mutants express altered gene
products under the control of the endogenous gene promoter, allowing for physiologically
accurate expression of mutant proteins at the appropriate time and place in development. This
approach is particularly useful for determining the functional effects of particular mutant alleles
found in human tumors.
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Targeted mutant mice are to be distinguished from knockin mice, in which a foreign gene or
cDNA is targeted into an existing gene locus. For example, a cDNA encoding the ,fi
galactosidase gene was targeted into the ROSA26 locus, replacing the ROSA26 gene product
but keeping the ROSA26 gene promoter (Friedrich and Soriano, 1991; Zambrowicz et al., 1997).
This allows the widespread expression 3-galactosidase (commonly used in reporter systems) by
placing it under the control of a ubiquitously expressed gene that is known to exist in a region of
open chromatin.
Targeted mutants are still prone to embryonic lethal phenotypes, especially in the case of
activated oncogenes. In order to circumvent this issue, conditional knockout mice were
developed in which the loss of a gene is achieved through the action of a site-specific
recombinase in vivo (Orban et al., 1992). The most common example of this is the use of the
bacterial Cre recombinase to excise the region situated between two similarly oriented LoxP
sites. Alleles targeted in this way are referred to as floxed (flanked by LoxP) and are used to
target gene loss to a particular place or time through the managed expression of Cre
recombinase. This can be achieved by expressing Cre recombinase from a tissue-specific
promoter or by delivering Cre ectopically through the use of viral vectors or protein transduction.
Several viral vectors for Cre delivery have been developed including adenoviral, retroviral and
lentiviral systems. Likewise, purified HIV-TAT-Cre fusion proteins have also been successfully
used to achieve directed recombination (Jo et al., 2001).
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In order to investigate the effects of re-activation of a gene, targeted alleles have been developed
that incorporate a floxed gene-silencing cassette to prevent expression of the allele until after
Cre-mediated excision. A Lox-STOP-Lox (LSL) cassette developed in this laboratory
effectively prevents gene expression by using four tandem polyadenylation sequences to block
transcription paired with a splice acceptor and mutant splice donor to block translation (Tuveson
et al., 2004). Such conditional activatable alleles are useful for investigations into the effects of
re-expression of a wild-type tumor suppressor gene in a tumor caused by its absence.
Alternatively, conditional mutant alleles can be constructed to express activated oncogenes from
the endogenous promoter in a tissue-specific manner. In this case, heterozygous conditional
mutant animals can be used to examine the effects of a dominant oncogene while avoiding the
embryonic lethal phenotypes of widespread mutation or homozygous deletion of the targeted
locus.
Site-directed recombination technology has been refined in several areas. Multiple LoxP sites
have been described that are all effectively recombined by Cre but are mutually incompatible
with one another, allowing for the simultaneous directed recombination of multiple Cre-mediated
events within a single cell (Sauer, 1996). Furthermore, other bacterial recombinase systems,
such as Flp/Frt, have been described and, in some cases, are being utilized in mammalian
systems (Vooijs et al., 1998). The combination of multiple recombinase systems targeted to
different gene loci within a single animal will allow of the sequential inactivation of several
genes in a controlled manner. This will facilitate the ordered dissection of gene function with
regards to tumor initiation and progression.
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Another approach to targeted gene expression is through the RCAS/TVA system (Federspiel et
al., 1994). In this system, an avian retroviral vector is used to express a cDNA in infected cells.
What makes this system useful is the fact that the particular avian leukosis virus utilized does not
infect mammalian cells. By targeting the expression of the avian retroviral receptor TVA,
infection by RCAS can be directed specifically to cells of interest. This system has the
advantage that once the TVA transgenic mice are established, many different genes can be
swapped into the viral vector for testing.
One of the principal drawbacks to conditional control of gene expression using tissue-specific
recombinase expression is that the cells harboring the recombined mutant genes are frequently
surrounded by other mutant cells. In contrast, it is thought that most human tumors begin as a
single mutant cell surrounded by a wild-type cellular context. In order to mimic this effect, a
latent mouse model was designed that relies on the stochastic homologous recombination of a
gene segment duplication to express a mutant gene product (Johnson et al., 2001a). In this case,
the allele is null prior to the spontaneous rearrangement of the gene locus in somatic cells,
resulting in mutant gene expression in an individual cell surrounded by other cells that are
heterozygous knockouts. This strategy could be useful for investigations into tumor surveillance
but it is currently hindered by a lack of simple techniques for assessing which cells have
undergone rearrangement. This is necessary because it is likely that different cell types will
recombine and activate the mutant allele at different rates. It has also been suggested that this
model could be useful as an in vivo assay for genes that affect genomic stability since any
mutation that affected the rate of homologous recombination should influence that rate
accumulation of cells with the targeted rearrangement.
16
Another approach to controlling gene expression in vivo is through the use of a drug-sensitive
regulatory system. An example of this is the tetracycline regulatory system in which a cDNA of
interest is expressed from an inducible promoter that is sensitive to a tetracycline-regulated
fusion protein (rtTA-VP16)(Kistner et al., 1996). Variants of this system allow for tetracycline-
regulated activation or repression of gene expression (rtTA or tTA). Expression of the rtTA-
VP16 or tTA-VP16 fusion proteins from a tissue-specific promoter allow for control of gene
expression both spatially and temporally within an animal. The one drawback to this approach
is that the gene of interest is expressed from an exogenous promoter. Attempts to combine the
Cre/Lox system with the Tet responsive system into a Tet/Cre approach have been confounded
by the "leakiness" of tetracycline response elements. Since Cre-mediated recombination is an
irreversible binary event, even a very low level of Cre expression can result in full activation of
the targeted locus.
In another drug-inducible system, a fusion is created between the gene of interest and the ligand-
binding domain of the estrogen receptor. This results in the sequestration of the protein of
interest in the cytoplasm until binding of 4-hydroxy-tamoxifen (OHT) induces its translocation
into the nucleus. This system is very clean with regards to background activity and was
therefore successfully utilized as a method of activating Cre using OHT, allowing for drug
inducible expression of targeted conditional loci from their endogenous promoters (Indra et al.,
1999).
17
One of the most recent developments in mouse modeling has been the use of short hairpin RNAs
(shRNAs) to knock down the expression of a target gene. shRNAs allow for stable expression of
small interfering RNAs (siRNAs) which target transcripts for destruction by the RNA-induced
silencing complex (RISC). shRNA transgenes can be used to stably knock down a targeted gene
in mice. Furthermore, since some siRNA sequences are more effective than others, an allelic
series can be produced showing the effects of various levels of gene expression from the
endogenous promoter (Hemann et al., 2003).
Another recently developed tool has been the use of lentiviruses to transduce mouse embryonic
stem cells (ES cells). By arranging a multiple cloning site within a lentiviral expression vector,
shRNA cassettes can be rapidly cloned into the viral transduction system and integrated into ES
cells, allowing for the rapid generation of transgenic mouse lines. In elegant work, conditional
versions of the lentiviral promoter were created by altering the LoxP site to include a TATA box
element. This "lentilox" site was then combined with an shRNA expression cassette to allow for
Cre-mediated activation or inactivation of shRNA expression in vivo (Ventura et al., 2004). This
approach allows for the rapid generation of conditional gene knockdown mice.
Summary
The recent explosion in gene targeting strategies has resulted in some truly impressive mouse
models that almost fully recapitulate the biology and pathology of human tumors. Nonetheless,
several hurdles remain. For example, the ability to conditionally introduce subtle mutations into
the endogenous locus while retaining a wild-type allele prior to induction would allow one to
assess the effects of mutations in a fully wild-type cellular context. Furthermore, such a system
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would make it possible to homozygose alleles that are embryonic lethal when deleted, making
the breeding schemes to produce double- and triple- compound mutant mice vastly more
efficient. Another frontier is that of combining imaging modalities with mouse models of
cancer. Currently, fluorescence and luminescence technologies are being used at a very basic
level to observe tumor growth and to act as a reporter for the activation of inducible systems.
However, at this time these systems lack finesse and are plagued by technical glitches (for
example, GFP is inactive in tissues processed for histology by most standard techniques). The
refinement of these technologies and the adaptation of other imaging systems for use with mice,
including magnetic resonance (MR), computed tomography (CT), positron emission
spectroscopy (PET) and single photon emission computed tomography (SPECT), will allow for
the observation of neoplastic processes as they occur in a living animal. Finally, the role of
epigenetics in tumor development has not yet been thoroughly explored using mouse models. As
noted previously, many tumor cells exhibit widespread changes in chromatin configuration, and
epigenetic silencing is a common mechanism of tumor suppressor gene inactivation. Models that
allow the precise control of epigenetic regulatory systems could be extremely useful in
generating accurate mouse models of human cancers.
With the great variety of genetic tools either at their disposal or in development, the onus is now
on researchers to put them to use in clever and meaningful ways. In creating mouse models of
cancer, one should at all times be guided by the human disease. Dozens of mouse models have
been generated that fail to adhere to this rule. These models rarely produce pathology even
remotely related to that seen in human cancers and the lessons to be derived from them are
dubious at best and misleading at worst. The early failure of such models to respond to
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therapeutics in a predictive manner set back the entire field of mouse modeling by fostering the
belief among clinical investigators and drug companies that mouse models of cancer are not
useful in preclinical drug development. Although genetically engineered mice have been
extraordinarily successful in providing information about the basic biology of tumorigenesis, it is
the additional responsibility of mouse modelers to correct this misconception by creating truly
predictive tools for drug discovery and development.
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Figure 1. A summary of mouse modeling strategies. Abbreviations: TSP, tissue specific
promoter; CMV, cytomegalovirus promoter (a strong constitutive promoter); Pro, an endogenous
gene promoter; NeoR, neomycin resistance cassette.
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THE P53 TUMOR SUPPRESSOR GENE
The p53 tumor suppressor gene is the most extensively studied gene in the human genome.
Referenced in over 33,000 papers, our understanding of this critical gene is both extensive and
incomplete. The most compelling reason for this intense focus is that p53 is mutated in over
50% of all human tumors, making it one of the most frequently altered genes in cancer. Indeed,
it appears likely that alteration of the p53 pathway, through any of a multitude of mechanisms,
may be a requisite event in the development or progression of nearly all forms of cancer.
Furthermore, p53 mutations occur in distinct locations within the gene and the mutational spectra
of p53 vary with different classes of tumors. Mutant p53 alleles also yield a mutant protein that
is stabilized relative to wild-type p53 leading to the frequent observation of p53 overexpression
in human tumors. These alleles appear to be something more than null alleles yet less than true
dominant-negative alleles; cells heterozygous for mutant p53 still frequently select for loss of the
remaining wild-type allele. Some mutant p53 alleles may even actively promote tumorigenesis,
independent of wild-type p53 function. For this reason, a thorough understanding of the structure
and function of p53, both wild-type and mutant, is essential. Through such an understanding,
rational strategies for the treatment of cancer can be pursued that account for and counter-act the
alteration of p53 pathway function.
A Brief History
p53 was described 25 years ago as a cellular protein bound by the SV40 large T-antigen and as a
tumor antigen expressed in carcinogen-induced mouse tumors (DeLeo et al., 1979; Lane and
Crawford, 1979; Linzer and Levine, 1979). p53 expression was soon found in human tumors
(Crawford et al., 1981; Dippold et al., 1981) and the presence of anti-p53 antibodies was
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discovered in sera from breast cancer patients (Crawford et al., 1981). Following this, several
observations led logically to the hypothesis that p53 was a cellular oncogene, similar in nature to
known retroviral transforming proteins such as p60srC. It was also found that p53 levels fell
dramatically during the retinoic acid-induced differentiation of F9 embryonal carcinoma cells
(Oren et al., 1982); similar treatment of mice injected with F9 cells resulted in prolonged
survival, supporting a correlation between p53 expression and tumorigenicity (Strickland and
Sawey, 1980). In a separate experiment, microinjection of anti-p53 antibodies into Swiss 3T3
cells resulted in a decrease in DNA synthesis; this was interpreted as a correlation between the
inactivation of p53 through antibody-binding and a decrease in cellular proliferation. Finally,
p53 was found to cooperate with H-ras in the transformation of primary rat embryo fibroblasts
(Eliyahu et al., 1984; Parada et al., 1984b).
Eventually, a series of observations changed the perception of p53 function in tumorigenesis,
suggesting it acted instead as a tumor suppressor gene. First, p53 cDNAs that had been used in
oncogene cooperation assays were found to be mutant, and wild-type p53 cDNAs were shown to
inhibit cellular transformation (Finlay et al., 1989; Hinds et al., 1989). Second, p53 was
determined to be mutated frequently and at numerous codons in a wide range of human tumors
and was seen to undergo loss-of-heterozygosity with high frequency (Baker et al., 1990;
Hollstein et al., 1991). Finally, loss-of-function mutations in p53 in the mouse led to profound
cancer predispositions (Harvey et al., 1993a; Jacks et al., 1994; Purdie et al., 1994).
In this light, p53 came to be viewed a tumor suppressor gene and tumor-associated point-
mutations in p53 were generally viewed to be acting in a dominant-negative manner to inhibit
wild-type p53. It is now understood that the decrease in wild-type p53 expression observed
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during F9 cell differentiation mirrors a similar decrease in p53 mRNA levels that occurs during
the normal embryonic development. Prior to differentiation (and in the absence of DNA
damage), F9 cells behave similarly to ES cells which express high levels of functionally inactive
p53. Furthermore, microinjection of anti-p53 antibodies induced cell cycle arrest in Swiss 3T3
cells because antibodies directed to the C-terminus of wild-type p53 activate its DNA-binding
function rather than inhibit its function (Hupp et al., 1995). Therefore, the results of both
experiments can be related to the activation of wild-type p53 tumor suppressor functions.
An Overview of p53 Structure and Function
A general understanding of the structure and functions of p53 has developed over the past
decade. p53 encodes a transcription factor that responds to cellular stresses by directly binding
to DNA and transcriptionally regulating genes involved in cell cycle arrest, apoptosis, and
genome maintenance. The p53 gene is comprised of eleven exons spanning approximately 20
kilobases and is translated into a 393 amino acid polypeptide. The p53 protein has five primary
functional domains: an N-terminal transactivation domain (TA, residues 1-63), a proline-rich
domain (PR, residues 64-94), a core sequence-specific DNA binding domain (DBD, residues
110-286), an oligomerization domain (OD, residues 326-355) and a regulatory domain (CTD,
residues 363-393)(Figure 2).
p53 Oligomerization
The regulation of target genes by p53 is dependent on its assembly into a homotetramer, which is
mediated by the oligomerization domain and is necessary for efficient binding of DNA (Hainaut
et al., 1994; Iwabuchi et al., 1993; Pavletich et al., 1993; Sturzbecher et al., 1992; Wang et al.,
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1993). Tetrameric p53 is organized as a dimer of dimers; monomeric p53 cannot bind DNA and
dimeric p53 does so only weakly. Although thermodynamic calculations suggest that p53 exists
in a monomeric state in undamaged cells (Sakaguchi et al., 1997), this model is based on an
analysis of a p53 OD fragment and does not take into account interactions between the OD and
other portions of the protein such as the DBD. Such interactions may act cooperatively to
stabilize the formation of p53 tetramers. More recently, an elegant set of experiments showed
that that the biogenesis of p53 dimers occurs through the association of elongating p53
monomers within a polysome (Nicholls et al., 2002). Mixing experiments suggested that this
cotranslational dimerization was irreversible. In contrast, the association of p53 dimers into a
tetramer was shown to be both post-translational and reversible. These observations have
important implications for the mixing of mutant and wild-type p53 in heterozygous tumor cells
(see Chapter 4).
DNA Binding by p53
Crystal structures of the human (Cho et al., 1994) or murine (Zhao et al., 2001) p53 DBD bound
to DNA depict a f3-sandwich that coordinates the position of a large loop (L3) to make contact
with the minor groove and a loop-sheet-helix motif to make contact with the major groove. This
structure incorporates one Zn2+ ion per monomer which helps to coordinate the L3 loop and is
necessary for binding to DNA (Pavletich et al., 1993). An analysis of the p53 DBD by solution
NMR found that binding of DNA by the core domain resulted in a substantial chemical shift of
the residues that form the DNA binding surface (Rippin et al., 2002). This work also found
cooperativity of binding by the DBD in the absence of an OD; two small surface regions that
were shifted during DNA binding may participate in DBD-DBD interactions within a tetramer.
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Another analysis of the DBD, based on phasing experiments using full length p53, details the
bending and twisting of the DNA bound by p53, leading to the supposition that p53 may bind
nucelosomal DNA (Nagaich et al., 1999). Finally, work from Carol Prives' laboratory found that
binding of several different antibodies against the N-terminal region of p53 greatly reduced the
dissociation of the DBD from DNA. Such antibodies may mimic the effects of protein-protein
interactions or post-translational modifications at the N-terminus, implying that intramolecular
interactions may occur between the N-terminus and the DBD (Cain et al., 2000).
Binding of the p53 DBD to DNA is sequence-specific and the architecture of the p53 binding site
reflects the quaternary structure of active p53. The p53 binding site is composed of two half-
sites separated by a 0-13 nucleotide linker. Each half-site contains two copies of the sequence
PuPuPuC(A/T) arranged in a head-to-head orientation (el-Deiry et al., 1992). This consensus
site is fairly degenerate and a large number of different specific binding sites have been found in
p53 target genes. Furthermore, p53 binding sites vary in their affinity, conformation, orientation
and relative location within target gene promoters or introns; multiple different p53 binding sites
are often located within a single p53 target gene. The variation in p53 binding sites may allow
for the subtle regulation of target gene choice by p53 under different conditions or in different
cell types. However, no clear correlation between gene function and the nature of p53 binding
sites has yet been described.
p53 Transcriptional Activation
The p53 transactivation domain is composed of two subdomains that act independently to
promote transcription. Activation subdomain 1 (ASD1) extends from residues 1-42 and contains
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a highly conserved region (BOX-I) that is necessary for transcription (Fields and Jang, 1990;
Raycroft et al., 1990). Transactivation subdomain 2 (ASD2) extends from residues 43-63 and is
less well conserved than ASD1 (Candau et al., 1997; Venot et al., 1999; Zhu et al., 1998).
Although the precise contribution of each domain to global p53 function is poorly understood, it
is clear that following DBD-mediated binding to target gene promoters, both transactivation
subdomains are capable of interacting with components of the transcriptional apparatus,
including TATA-binding protein (TBP), several TBP-associated factors (TAFs), transcription
factors IIB and IIF (TFIIB, TFIIF) and RNA polymerase II (Chang et al., 1995; Farmer et al.,
1996; Lu and Levine, 1995). Furthermore, both transactivation domains were found to be
necessary for interaction of p53 with the histone acetyltransferase p300 (Liu et al., 2003). p30 0
is one of several transcriptional coactivators that are recruited by p53 to modify histones near the
proximal promoters of p53 target genes. In recent work, chromatin reconstitution experiments
and chromatin immunoprecipitation (ChIP) were used to show that protein arginine N-
methyltransferase (PRMT1), p3 00 and coactivator-associated arginine methyltransferase
(CARM1) each bind to p53 and act cooperatively, through a temporally ordered mechanism, to
promote the transcription of p53 target genes (An et al., 2004). ChIP was also utilized, on a
stunningly large scale, to dissect the contribution of specific transcription initiation components
to p53-mediated transactivation (Espinosa et al., 2003). This work found that the composition
and mechanics of p53-induced transcriptional initiation varied dramatically based on the
promoter analyzed as well as the type of stress used to induce p53 function.
Although histone modification of p53 target genes correlates well with their level of
transcriptional upregulation following DNA damage, the exact mechanism by which histone
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modification contributes to transcription of p53 target genes is unclear. However, studies of
other systems suggest that modified histones may preferentially act as substrates for the
recruitment of other transcription factors to the initiation complex and, similarly, they may
prevent the association of transcriptional repressors (Strahl and Allis, 2000).
p53 Transcriptional Repression
While its most well known role is in the transactivation of target genes, p53 also has an
important role in the transcriptional repression. p53 has been shown to inhibit transcription
through three different potential mechanisms. First, p53 may have generalized effects on the
basal transcription machinery as studies of the cyclin B gene show that p53-mediated
transcriptional repression remains intact through successive deletions of all but the basal
promoter (Innocente et al., 1999; Krause et al., 2000). This mechanism is the least well
understood and may in fact reflect a lack of insight into other mechanisms. In recent years, p53
binding sites have been found in the intronic regions of several genes. The presence of an
intronic p53 binding site in cyclin B could provide an alternative explanation for the effects of
p53. Second, p53 may affect chromatin remodeling through the recruitment of histone
deacetylases (HDACs). For example, p53 was shown to recruit HDACs to the Map4 and
stathmin promoters by directly associating with the co-repressor mSin3a (Hoffman et al., 2002;
Murphy et al., 1999). This mechanism is reminiscent of the recruitment of the histone
acetyltransferase p300 during transcriptional activation. Finally, p53 may interfere with the
function of other transcriptional activators. For example, p53 inhibits the anti-apoptotic bcl-2
gene by binding to a p53 site within the bc1-2 promoter and displacing the transcriptional
activator Brn-3a (Budhram-Mahadeo et al., 1999). In another important example, p53 inhibits
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the transactivation of a number of genes including cdc2, topoisomerase II, chk2 and securin by
interfering with the function of NF-Y (Joshi et al., 2003; Matsui et al., 2004; Yun et al., 1999;
Zhou et al., 2003).
Given that p53 can either activate or repress different sets of genes following DNA binding,
there must be determinants that distinguish these two sets. Indeed, at least one group reported
the presence of a variant p53 binding site arranged in a head-to-tail orientation in the MDRI gene
that conferred responsiveness to transcriptional repression by p53. Substitution of this site with a
canonical head-to-head version of the same sequence reversed the effect of p53, resulting in
transactivation of MDRI following induction of p53 (Johnson et al., 2001b). Incidentally, a
nearly identical variant p53 binding site was also found in the cylcin B1, gene, although its
relevance to the transcriptional repression of cyclin BJ by p53 remains untested.
The Proline-Rich Domain ofp53
The 30 residue PR domain contains five different PXXP motifs and was originally described as a
domain necessary for the efficient induction of apoptosis (Venot et al., 1998; Zhu et al., 1999).
More recently, the PR domain has been shown to act as a second binding site for the
transcriptional cofactors mSin3a (Zilfou et al., 2001) and p300 (Dornan et al., 2003; Liu et al.,
2003). Interestingly, both mSin3a and p300 appear to bind to p53 in roughly the same place
implying their binding may be mutually exclusive. Given their respective roles as co-repressor
and co-activator, this could imply that the PR domain acts as a switch to determine whether p53
functions to activate or repress target genes.
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The C-Terminal Regulatory Domain
The p53 CTD has never been very clearly understood, but early work suggested that it functions
as a negative regulatory domain that interferes with sequence-specific binding by the core DBD.
This was thought to be the result of steric inhibition caused by the CTD folding back and
occluding the DBD (Gu and Roeder, 1997)(see below for discussion of allosteric regulation of
p53). However, recent work has focused primarily on the ability of the CTD to bind non-
specifically to various forms of DNA. The p53 CTD has variously been described as capable of
associating with RNA (Yoshida et al., 2004), single-stranded DNA overhangs (Bakalkin et al.,
1994), short single-stranded DNA (Jayaraman and Prives, 1995), DNA aggregates (Yakovleva et
al., 2001), stem-loops (Kim et al., 1997), supercoiled DNA (Fojta et al., 2004), complex
junctions and recombination intermediates (Dudenhoffer et al., 1998; Lee et al., 1997), as well as
to damaged DNA, including DNA mismatches (Lee et al., 1995), gaps (Zotchev et al., 2000), and
by gamma irradiated DNA (Reed et al., 1995). In each case, the p53 CTD recognizes a molecule
that in some way exhibits structural constraints that deviate from the conformation of B-DNA.
In a particularly elegant report, McKinney and Prives explored the binding of p53 to linear or
circularized 66-mers containing either a wild-type or mutated binding site for p53. They found
that the p53 DBD and CTD acted cooperatively to promote the high affinity recognition of p53
binding sites that were constrained by forced circularization (McKinney and Prives, 2002).
These and other data (discussed below) suggest that rather than negatively regulating DNA
binding by p53, the CTD in fact promotes DNA binding of constrained DNA.
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Regulation of p53 Activity
p53 activity is regulated through a vast array of different mechanisms. These can be grouped
broadly into protein-protein interactions, post-translational modifications, protein localization,
and variation in target sites. The aspects of p53 biochemistry that are regulated include the
stability of the p53 protein, its affinity for (and rate of dissociation from) DNA, the availability
of substrate and the choice of which target gene p53 will bind. The complexity of the regulatory
networks affecting p53 is staggering and the mechanisms by which these different regulatory
mechanisms are integrated are poorly understood.
Early work on p53 regulation led to an allosteric model of p53 function that included two
primary conformation states of p53 protein, "latent" and "active". This view of p53 regulation
was based on functional readouts rather than analysis of its physical state and several recent
works have challenged this view. An overview of the .llosteric model and its shortcomings is
presented below, followed by a review of known mechanisms of p53 post-translational
regulation. This section will conclude with a discussion of the upstream signaling pathways that
induce these modifications.
The Allosteric Model ofp53 Function
The allosteric model was proposed following observations that deletion of the CTD resulted in
activation of sequence-specific DNA binding by the core domain as measured by electrophoretic
mobility shift assay (EMSA)(Hupp and Lane, 1994; Hupp et al., 1992). It was also found that
binding of an antibody to the CTD, acetylation of lysine residues in the CTD by p300/CBP or
phosphorylation of serine residues in the CTD by protein kinase C (PKC) or casein kinase 2
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(CK2), increased DNA binding by p53. Furthermore, p53 expressed from bacteria was found to
be completely unable to bind to DNA in the absence of post-translational modifications such as
acetylation. This led to the idea that the p53 CTD acts as a negative regulatory domain that
inhibits the function of the DBD, either through direct association or by positioning the DBD
away from DNA. Competition experiments in which a peptide derived from the CTD was also
shown to activate DNA binding were argued to support this model.
However, several recent observations challenge the allosteric model of p53 latency. For
example, PAb 421 was found not to affect DNA binding by p53 when measured by DNAse I
protection assay rather than EMSA (Cain et al., 2000). Also, though bacterially expressed p53
cannot bind to oligonucleotides containing a p53 binding-site, it is fully competent for binding to
p53 response elements in chromatin, even in the absence of CTD acetylation (Espinosa et al.,
2003). Furthermore, experiments utilizing ChIP found that the amount p53 binding to DNA
following genotoxic stress correlated well with changes in total p53 protein levels, indicating that
a conformational change in pre-existing p53 tetramers did not play a substantial role in the
regulation of p53 (Kaeser and Iggo, 2002). Finally, latent p53 was found already associated with
target gene promoters in unstressed cells by ChIP allowing for the rapid assembly of
transcription machinery at certain promoters in response to certain genotoxic signals (Espinosa et
al., 2003). These data suggest that the activation of latent p53 is not dependent on an allosteric
regulation of sequence-specific DNA binding.
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Regulation ofp53 Protein Degradation
The most prominent mechanism by which p53 is regulated is through 26S proteasomal
degradation. The 26S proteasome is a large, multimeric, barrel-shaped complex that can actively
catalyze protein degradation (Crews, 2003; Voges et al., 1999). It consists of three primary
subunits: a central proteolytic chamber, called the 20S proteolytic complex, and two 19S
regulatory complexes. Proteins are targeted for proteasomal degradation through the covalent
ligation of a small protein moiety called ubiquitin. Ubiquitin acts as a molecular tag that is
recognized by the 19S complexes. A class of proteins called E3-ubiquitin ligases catalyzes the
monoubiquitylation of various target proteins. The ubiquitin tag is then itself ubiquitylated and it
is this polyubiquitylated form that is targeted to and degraded by the 26S proteasome.
The principal molecular determinant of p53 protein levels is a protein called mouse double-
minute 2 (MDM2, or HDM2 in humans)(Haupt et al., 1997). MDM2 acts as an E3-ubiquitin
ligase for p53 (Honda et al., 1997). The MDM2 protein contains a deep hydrophobic cleft that
specifically binds to a segment of the N-terminus of p53 extending from residue 17 to residue 27
(Kussie et al., 1996). In unstressed cells, MDM2 binds to p53 and catalyzes the
monoubiquitylation of p53 at six known lysine residues near its C-terminus: lysines 370, 372,
373, 381, 382 and 386 (Nakamura et al., 2000; Rodriguez et al., 2000). The monoubiquitin
conjugates are polymerized into polyubiquitin through the concerted action of MDM2 with
p300/CBP. Following activation by cellular stress, the interaction between MDM2 and p53 is
inhibited and p53 rapidly accumulates to higher levels.
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MDM2 itself is transcriptionally activated by p53 resulting in a negative feedback loop that
regulates the activity of p53 (Barak et al., 1993); a p53 DNA-binding site exists within the first
intron of the MDM2 gene that strongly regulates the expression of MDM2 (Wu et al., 1993).
The importance of this interaction was dramatically demonstrated through the analysis of MDM2
knockout mice. Mice lacking both copies of MDM2 die early in embryogenesis, shortly after
implantation (Jones et al., 1995). However, the further deletion of both copies of p53 fully
rescues the developmental defects of MDM2 loss, resulting in normal mice with an adult-onset
tumor predisposition (Montes de Oca Luna et al., 1995). Furthermore, heterozygosity for
MDM2 in the context of wild-type p53 dramatically extends the survival of Eu-myc transgenic
mice (Alt et al., 2003). Both of these observations are consistent with a model in which MDM2
deletion or haploinsufficiency results in the activation of p53 function.
As a result of this negative feedback circuit, the levels of p53 and MDM2 oscillate over time
following activation of p53 by DNA damage. Initially, a careful kinetic analysis of MDM2 and
p53 protein levels by immunoblotting suggested an analog model of damped oscillations after
high levels of DNA damage (Lev Bar-Or et al., 2000). More recently, an elegant report analyzed
fluorescently tagged p53 and MDM2 proteins by time-lapse video microscopy in single cells
(Lahav et al., 2004). This work revealed different cells within a single culture undergo varying
numbers of oscillations following DNA damage. Furthermore, the amplitude and duration of
each pulse in different cells was unchanged following treatment with escalating doses of ionizing
radiation. Rather, the number of consecutive pulses within a cell increased with higher levels of
DNA damage. This quantized or 'digital' response to DNA damage could imply that p53 and
MDM2 act as a circuit that continues to monitor the cell following DNA damage, activating
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fresh rounds of stress response pathway signaling until all DNA damage events have been
resolved. It remains to be seen if the variation in the numbers of oscillations occurring in
different cells reflects varying levels of actual DNA damage experienced by those individual
cells or whether successive rounds of p53 activation regulate different subsets of p53 target
genes.
The interaction between MDM2 and p53 forms a nexus of integration for a variety of different
upstream signaling pathways. Several DNA damage response pathways modulate this
interaction by post-translationally modifying p53 (see Post-Translational Modifications of p53,
below). Phosphorylation of MDM2 (such as by cyclin A/CDK) can also inhibit the p53/MDM2
interaction (Zhang and Prives, 2001). MDM2 is also regulated through changes in its subcellular
localization. pl 9ARF (p14ARF in humans), a tumor suppressor protein produced from the
alternative reading frame of the CDKN2 gene locus, functions primarily by binding to MDM2
and sequestering it away from p53 (Honda and Yasuda, 1999; Weber et al., 1999). This connects
p53 to core components of the cell cycle pathway and positions p53 as an important regulator of
oncogenic stress.
In addition to ubquitylating p53, MDM2 was recently found to mediate the conjugation of p53
with NEDD8, another small protein moiety similar to ubiquitin (Xirodimas et al., 2004).
Following DNA damage, NEDD8 was ligated to p53 at lysines 370, 372 and 373. These are
three of the six lysine residues that have been reported to be ubiquitylated by MDM2.
Interestingly, neddylation was found to inhibit the ability of p53 to transactivate target genes
rather than to affect the ubiquitylation and turnover of p53. The precise mechanism by which
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this occurs is poorly understood but this initial work adds yet another layer of complexity to the
regulation of p53 function.
A third ubiquitin-like protein, SUMO1, has also been found to be covalently ligated to p53.
Sumoylation of p53 occurs at Lys386, a site that is also ubiquitylated by mdm2. It is unclear
what effect the sumoylation of p53 has on its function.
Other Post-Translational Modifications ofp53
The p53 protein is the subject of a variety of post-translational modifications at numerous
different sites. In addition to being ubiquitylated, neddylated and sumoylated, p53 has also been
reported to be phosphorylated (Jay et al., 1981), acetylated (Gu and Roeder, 1997), methylated
(Chuikov et al., 2004), glycosylated (Shaw et al., 1996) and ribosylated (Wesierska-Gadek et al.,
1996). Although the role of glycosylation and ribosylation of p53 have not been further
explored, it is clear that acetylation and methylation play an important role in the regulation of
p53 function. The kinases, methyltransferases, acetyltransferases and ligases that effect these
modifications form the basis of a vast upstream regulatory network feeding into p53. More
recently the roles of p53 phosphatases and deacetylases in p53 regulation have also been
investigated.
Phosphorylation ofp53
p53 is phosphorylated on multiple serine and threonine residues throughout the protein; there is
no evidence of phosphorylation of p53 on tyrosine residues (Figure 2). In several cases, a single
phosphorylation site is the target of several different known kinases and some kinases are known
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to phosphorylate more than one residue on p53. For many of these sites, kinases have been
identified that catalyze their phosphorylation in response to stimuli. All of the phosphorylation
sites in p53 are found within known functional domains and discrete effects on p53 function
have been determined for several of them. The phosphorylation of several sites in the N-
terminus of p53 can interrupt or diminish the association of p53 with its primary negative
regulator MDM2 (see section of the role of MDM2 in p53 regulation). The phosphorylation of
some sites in the C-terminus can directly influence the ubiquitylation of p53 and its subsequent
degradation while other sites may directly influence the transactivation activity of p53.
Casein Kinase I (CK1) is the only known kinase for Ser6, Ser9 and Thrl8 (Higashimoto et al.,
2000; Knippschild et al., 1997; Sakaguchi et al., 2000); the phosphorylation of Thrl8 by CK1 is
dependent on prior phosphorylation of SerlS (Dumaz et al., 1999). CK1 is actually a family of
serine/threonine protein kinases, of which CK16 and CK1s have been shown to phosphorylate
p53. Little is known about the direct role of CK1 in cancer but recently, CK1s was shown to be
activated by the wnt signaling pathway, tying it to a major pathway involved in development and
cancer (Liu et al., 2002). The observation that Ser6, Ser9 and Thrl8 are each phosphorylated in
response to DNA damage implies either that CK1 kinase activity is also DNA-damage
responsive or other kinases for these sites remain to be identified. No specific effect has been
ascribed to phosphorylation of Ser6 and Ser9. However, Thrl8 is part of the binding site of the
MDM2 and phosphorylation of this residue inhibits the binding of MDM2 to p53 (Kussie et al.,
1996; Sakaguchi et al., 2000).
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p53 is one of over a dozen different substrates of ATM (mutated in ataxia telangiectasia). ATM,
and two related proteins, ATR and ATX, are members of the phosphoinositol-3-kinase (PI3K)
family and are all capable of phosphorylating p53 at SerlS, resulting in its accumulation and
activation (Canman et al., 1994; Shiloh, 2003; Tibbetts et al., 1999). ATM, ATR and ATX are
key players in the cellular response to a variety of different forms of DNA damage. ATM is
inactive in undamaged cells and rapidly responds to certain forms of DNA damage by
relocalizing to the site of damage and by phosphorylating a variety of proteins involved in cell
cycle arrest and DNA damage repair pathways (Bakkenist and Kastan, 2003). ATM and ATR
are known to respond to different types of DNA damage and there is some indication that this
information is communicated to p53 through differential phosphorylation as ATM can
additionally phosphorylate Ser9 and Ser46 (Saito et al., 2002) while ATR has been shown to
phosphorylate Ser37 (Tibbetts et al., 1999).
ATM also phosphorylates checkpoint kinase 2 (CHK2), which in turn phosphorylates p53 at
Ser20. Ser20, like SerI5 and Thrl8, makes up part of the binding interface between MDM2 and
p53. Phosphorylation of either Thrl 8 or Ser20 has been shown to interfere with this interaction
resulting in the stabilization of p53 protein. In contrast, phosphorylation of Serl 5 was shown not
to directly affect the binding of a p53 polypeptide to MDM2. Rather, phospho-Serl 5 appears to
form a component of CK1 binding site, thereby encouraging the phosphorylation of p53 on
Thrl8 (Chehab et al., 1999; Sakaguchi et al., 2000).
Another member of the PI3K family, DNA-dependent protein kinase (DNA-PK), is also capable
of phosphorylating p53 at SerlS as well as at Ser37 (Shieh et al., 1997). The kinase function of
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DNA-PK is dependent on its association with double-stranded DNA breaks. DNA-PK functions
in the non-homologous end joining (NHEJ) pathway where it cooperates with Ku70 and Ku86 in
synapse formation (the positioning of two DNA ends for ligation) (Lieber et al., 2003).
Recently, these three proteins, and specifically the kinase activity of DNA-PK, were shown also
to be required for normal telomere end-capping (Bailey et al., 2004). Therefore, DNA-PK has
three critical and inter-related functions: sensor of DNA damage, participant in the NHEJ DNA
damage response and the initiator of the p53-dependent DNA damage responses.
Several mitogen-activated protein kinases (MAPKs), including ERK1/2 and p38 kinase, have
been shown to physically associate with and phosphorylate p53 in response to DNA damage,
particularly UV irradiation. For example, p38 has been shown to phosphorylate p53 at Serl5,
Ser33, Ser46 and Ser392 while ERK2 was shown to phosphorylate p53 at Thr55 in response to
doxorubicin (She et al., 2000; Yeh et al., 2001). Phosphorylation of p53 at these residues was
shown to correlate with increased transactivation by p53. While the immediate effects of Ser33
phosphorylation are unclear, one might speculate that phosphorylation of Thr55 may directly
influence the transactivation activity of p53 as Thr55 is located directly adjacent to two residues
that are critical for the function of activation subdomain 2; the mutation of Trp53/Phe54 to
Gln/Ser (53/54QS) results in complete inactivation of ASD2 (Candau et al., 1997).
p53 Ser46 was also shown to be phosphorylated by homeodomain-interacting protein kinase 2
(HIPK2) in response to cisplatin treatment or UV irradiation (D'Orazi et al., 2002; Hofmann et
al., 2002). HIPK2 was also found to associate with creb-binding protein (CBP) and was shown
to be necessary for CBP-mediated acetylation of the p53 CTD. Given the clear effects of CTD
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acetylation of p53 function (see below) the Ser46 phosphorylation should have a substantial
effect on p53 function. Indeed, recent follow-up work has found that the inhibition of HIPK2 by
RNAi resulted in decreased induction of p53-dependent apoptosis following cisplatin treatment
(Di Stefano et al., 2004).
In contrast to the phosphorylation of N-terminal sites, which generally activate p53, the
phosphorylation of p53 at Ser376 and Ser378 negatively regulates p53 activity. Phosphorylation
of these sites in unstressed cells is constitutive and the advent of DNA damage (in the form of
ionizing radiation) results in the dephosphorylation of p53 at these sites. The identity of the
phosphatase(s) responsible for this dephosphorylation is unknown. The constitutive
phosphorylation of Ser376 and 378 is mediated by protein kinase C (PKC) and stimulates the
MDM2-mediated ubiquitylation of p53, resulting in increased p53 degradation (Chernov et al.,
2001).
Finally, phosphorylation of p53 can affect its activity through changes in its subcellular
localization. The phosphorylation of nuclear p53 at Ser315 or Ser376 by glycogen synthase
kinase-303 (GSK30) results in its relocalization to the cytoplasm and correlates with decreased
p53-mediated apoptosis (Qu et al., 2004). Ser315 and Ser376 phosphorylation may interfere
with the normal import of p53 as both residues are situated within nuclear localization sequences
(NLS's). Aurora kinase A (AURKA) has also been shown to phosphorylate p53 at Ser315;
however, in this case, the authors found that Ser315 phosphorylation resulted in the increased
ubiquitylation and degradation of p53 rather than a relocalization.
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A number of other kinases have also been reported to phosphorylate p53 at some of the same
residues described above. These include CDK2 and CDC2 (Blaydes et al., 2001), TAF1 (Li et
al., 2004), PKR (Cuddihy and Bristow, 2004), and FACT (Keller et al., 2001). The cop9
signallosome-associated kinase complex (CSN kinase) was reported to phosphorylate a cluster of
three residues in the DBD (Serl49, Thrl50, Thr155) resulting in increased 26S proteasome-
mediated degradation of p53 (Bech-Otschir et al., 2001). Finally, c-jun N-terminal kinase (JNK)
has a complicated role in regulating p53 protein levels that includes phosphorylating p53 at
Ser20 and Thr81 in addition to regulating its levels through ubiquitylation (Buschmann et al.,
2000; Fuchs et al., 1998).
Acetylation
The acetyltransferases p300/CBP and PCAF figure largely in the p53 pathway. In additional to
acting as coactivators for p53-mediated transcriptional regulation by acetylating histone residues
in target gene promoters (described above), they also can help to regulate p53 function and
stability by directly acetylating p53 itself (Gu and Roeder, 1997; Lill et al., 1997). The
acetylation of p53 in the C-terminus by p300/CBP helps to regulate the stability of the p53
protein by directly interfering with its ubiquitylation by MDM2. Of the six lysine residues at
which p53 has been found to be ubiquitylated, Lys372, Lys373 and Lys382 have been each
found to be acetylated by p300/CBP. Ubiquitylation and acetylation of the same residue are
mutually exclusive.
In addition to these three residues, p53 may also be acetylated at Lys 305 by p300/CBP and at
Lys320 by PCAF. The acetylation of these residues appears to augment the sequence-specific
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binding of DNA by p53, thereby positively regulating its function (Luo et al., 2004; Wang et al.,
2003). However, the mechanism by which this occurs is unclear. The acetylation status of p53
is also regulated by SIR2, a protein deacetylase (Vaziri et al., 2001). SIR2 has been shown to
directly deacetylate p53 at Lys382 in an NAD-dependant manner and evidence suggests that
other deacetylases also actively regulate p53 function.
Methylation
Finally, during the preparation of this thesis, p53 was reported to be methylated at Lys373 by
Set9 methyltransferase (Chuikov et al., 2004). The effect of methylation of p53 appears to be
somewhat similar to that of acetylation in that methylated p53 has increased stability and
elevated transactivation activity. It is unclear by what mechanism this is achieved. However, it
is striking that at a single residue, p53 can be ubiquitylated, neddylated, acetylated or methylated.
The observation that a single amino acid lies at the intersection of four different upstream
signaling pathways begs for further analysis, although effectively dissecting the distinct effects
of each of these modifications will be technically challenging.
Downstream Effectors and p53 Function
The classic function of p53 is as a transcription factor that regulates target genes involved in cell
cycle arrest and apoptosis following cellular stress. However, the complete story of p53 function
is substantially broader. Expression analysis experiments using oligonucleotide or cDNA arrays
to assay the responses of thousands of genes to p53 activation suggest that between 1-5% of the
mammalian genome responds to p53 activation (Mirza et al., 2003; Wang et al., 2001; Zhao et
al., 2000). Assuredly, a large portion of these genes are altered indirectly due to the effects of
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p53 on cell proliferation and viability. Nonetheless, hundreds of different genes have been
reported to harbor p53 response elements and to respond directly to p53 activity. Many of these
genes participate in functional pathways distinct from those traditionally associated with p53
function, including cytoskeletal proteins, cell matrix and adhesion molecules, and growth factors
and their inhibitors. Functional studies have also implicated p53 in maintaining genome stability
by affecting DNA repair pathways and centrosome regulation. A comprehensive picture of p53
function is not yet available, but is slowly coming into focus.
Cell Cycle Arrest
p53 contributes to the regulation of cell cycle progression by initiating cell cycle arrest in
response to DNA damage as well as monitoring the cell for aberrant proliferative signals.
Following activation by cellular stresses, p53 rapidly induces both G1 and G2 arrest through
several different pathways. The primary mediator of the DNA damage dependent G1 arrest is the
cyclin-dependent kinase inhibitor p21 (CIP1/WAF1). p21 is a generalized cyclin-dependent
kinase inhibitor that is capable of targeting both the GI-specific cyclin E/Cdk2 complexes as well
as the G2-specific cyclin B/Cdc2 complexes. p21 expression is strongly dependent on p53-
mediated transactivation both under basal conditions and following DNA damage. The
significance of this pathway is evident from the observations that both p53' / and p21-/- mouse
embryo fibroblasts fail to undergo a G1 arrest following DNA damage (Brugarolas et al., 1995;
Kastan et al., 1992). In contrast, untreated p21 -/ MEFs proliferate at the same rate as wild-type
MEFs while p53'/ MEFs proliferate for more rapidly. Therefore, p21 is not involved the p53-
mediated surveillance of basal proliferation. Although there is a general understanding that p53
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monitors proliferative signals via E2F-mediated transactivation of p1 9ARF, the mechanism by
which p53 restrains basal proliferation remains to be determined.
p53 also exerts some influence on the G2 checkpoint, although there are also important p53-
independent pathways that affect G2 progression. In addition to p21, two prominent p53 target
genes GADD45 and 14-3-3a, have been implicated in control of the G2/M checkpoint. Both
GADD45 and 14-3-3a cause the inhibition of cyclin B/cdc2 complexes. GADD45 directly binds
to cyclin B resulting in its translocation from the nucleus while 14-3-3a binds to and sequesters
the cdc25c phosphatase, which is required for activation of cyclin B/cdc2 complexes (Chan et
al., 1999; Jin et al., 2002; Yang et al., 2000).
Apoptosis
p53 is one of the primary regulators of the apoptotic response in many mammalian cells. This is
particularly apparent in primary murine thymocytes which are fully protected from apoptosis
induced by ionizing radiation in cells lacking p53 (Lowe et al., 1993b). p53 regulates apoptosis
by transcriptionally regulating a number of different apoptotic genes including important
mediators of both the intrinsic and extrinsic apoptotic pathways. p53 may also directly
participate in the intrinsic apoptotic pathway in a transcription-independent manner.
p53 can directly transactivate three different cell surface receptors involved in apoptosis. The
death-domain containing receptor DR5/KILLER contains a p53 response element and is
activated by p53 in response to DNA damage (Bums et al., 2001). Similarly, FAS, a member of
the TNF receptor family, is also a p53 target gene. The third receptor, PERP, is a tetraspan
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transmembrane receptor related to PMP-22. Although PERP is required for p53-mediated
apoptosis in several different cell types, the mechanism by which PERP functions in apoptosis is
unclear (Attardi et al., 2000; Ihrie et al., 2003).
p53 also directly activates several genes involved in the intrinsic apoptotic pathway including
Bax (Thomborrow et al., 2002), Bid (Sax et al., 2002), Puma (Nakano and Vousden, 2001), and
Noxa (Oda et al., 2000). Each of these proteins localizes to and promotes the permeabilization
of the outer mitochondrial membrane, resulting in the release of cytochrome c and Apaf 1 from
the mitochondria. p53 can also repress the activation of Bcl-2, an inhibitor of this process
(Budhram-Mahadeo et al., 1999). Once released from the mitochondria, cytochrome c binds to
APAF1, which is itself a p53 target gene, and causes the activation of two initiator caspases
(caspase-9 and caspase-3), followed by downstream activation of the effecter caspases, caspase-6
and caspase-7 (Kannan et al., 2001; Moroni et al., 2001; Robles et al., 2001). Caspase-6 is also a
transcriptional target of p53.
Finally, recent work has found that p53 itself participates in the intrinsic apoptotic pathway by
translocating from the nucleus to the outer mitochondrial membrane (Chipuk et al., 2003).
Although controversial at first, the work of several different groups has begun to establish this
activity of p53. For example, y-irradiation of mice was found to induce a rapid wave of p53-
dependent apoptosis that preceded the transactivation of target genes by p53 while the
translocation of p53 to mitochondria occurs as early as 30 minutes after irradiation (Erster et al.,
2004). Careful cell fractionation experiments have recently established the presence of an
endogenous complex in the mitochondria containing p53, Bcl-2 and Bcl-XL and gold-tagged
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antibodies were used to observe p53 localization to the outer mitochondrial membrane by
electron microscopy (Ute Moll, unpublished results presented at the 12th International p53
Workshop, Dunedin, New Zealand). Furthermore, p53 can directly induce Bak oligomerization
following cell stress, an important step in the pathway leading to cytochrome c release (Leu et
al., 2004). Importantly, tumor-associated mutants of p53 are defective in these activities.
In a related story, human p53 contains a polymorphism between arginine and proline at codon
72. The frequency of this polymorphism varies by latitude, with the proline allele being
substantially more common in equatorial populations than in those found at higher latitudes
(Beckman et al., 1994). The arginine allele has an up to 15-fold greater ability to induce
apoptosis compared to the proline allele despite the fact that there is no difference in the ability
of the two variants to bind to DNA and transactivate target genes (Dumont et al., 2003; Thomas
et al., 1999). Interestingly, the Arg72 variant is translocated from the nucleus to mitochondria
more readily than the Pro72 variant. Bak oligomerization is also increased in cells with the
Arg72 variant (Maureen Murphy, unpublished results presented at the 12 th International p53
Workshop, Dunedin, New Zealand). These data strongly suggest that the effect of the codon 72
polymorphism of p53 is to fine-tune the induction of apoptosis by altering the fraction of p53
protein at the outer mitochondrial membrane.
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Figure 2- Mutations, modifications and functional domains of the p53 tumor suppressor gene.
The frequency of p53 mutations in human tumors by amino acid is depicted at bottom with black
bars. Above this, the positions of evolutionarily conserved regions in the p53 protein are shown
in blue boxes. In the middle, the functional domains are shown in colored boxes: ASD,
activation subdomains; PR, proline-rich region; DBD; sequence-specific DNA binding domain;
OD, oligomerization domain; RD, regulatory domain. Above this, black bars indicate the sites of
binding by HDM2 and JNK as well as the positions of nuclear export and nuclear localization
signals. The diagram at top demonstrates the positions of various post-translational
modifications of p53 as well as the proteins that regulate the modifications.
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P53 FAMILY-MEMBERS
In 1997, two genes with substantial homology to p53 were discovered. Called p63 and p73, they
share the general structure and function of the primary p53 functional domains and are
particularly well conserved in the region corresponding to the p53 DBD. Both p63 and p73 also
contain an extreme C-terminal region with an SAM protein-protein interaction domain. They are
capable of binding to p53 response elements in DNA and transactivating p53 target genes in
response to DNA damage. Yet for all of these similarities, p63 and p73 were not found to be
mutated in human tumors as frequently as p53.
Both p63 and p73 encode multiple variants due to the use of alternative promoters and
alternative splicing. In particular, certain variants lack a large region of their N-terminus
including most of the transactivation domains of these proteins. These AN-p63 and ANA p73
variants may act as dominant negative variants by hetero-oligomerizing with the full-length
TAp63 and TAp73 variants. In vitro experiments suggest that p63 and p73 polypeptides can
weakly hetero-oligomerize with one another but not with p53.
Following the reports of multiple p63 and p73 variants, speculation arose concerning whether
p53 might also express multiple variants. Shockingly, an analysis of p53 transcripts recently
found that p53 also has a number of different variants, including three different N-terminal
variants and three different C-terminal alternative splice variants (Jean-Christophe Bourdon, 12th
International p53 Workshop, Dunedin, New Zealand). Many of the other variants are poorly
recognized by the common p53 antibodies because in the earliest days of the p53 research,
antibodies that produced multiple bands for p53 were regarded as low-quality. It is embarrassing
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that the p53 field has pretty much ignored the scattered reports of p53 alternative splice variants
over the years despite the presence of extra bands appearing on our gels the whole time (Arai et
al., 1986; Han and Kulesz-Martin, 1992; Matlashewski et al., 1987; Wu et al., 1994).
Knockout mice have been constructed for both p63 and p73. p63 null mice die perinatally from
desiccation resulting from a developmental defect in their skin. They also have craniofacial
abnormalities and limb truncations. p73 null mice are viable at birth, but are susceptible to
infections making it difficult to raise them through adulthood. They also have hippocampal
dysgenesis and defects in the vomeronasal organs. Furthermore, the initial publications
describing p63+/', p73+/' or p73'/ ' mice reported that they do not develop cancer. These
observations threw into doubt the status of p63 and p73 as tumor suppressor genes.
A collection of related familial disorders was recently found to result from the germline mutation
of p63. The symptoms of these disorders bear a striking resemblance to those of the p63
knockout mouse. These include ectodermal dysplasia-cleft lip/palate (EEC) syndrome (Celli et
al., 1999), limb-mammary syndrome (LMS), Hay-Wells syndrome (McGrath et al., 2001), acro-
dermato-ungual-lacrimal-tooth (ADULT) syndrome (Chan et al., 2004), Rapp-Hodgkin
syndrome (RHS)(Kantaputra et al., 2003) and split-hand/split-foot malformation
(SHFM)(Ianakiev et al., 2000). Although these syndromes are not generally reported to be
associated with a cancer predisposition, they are so extremely rare that an association may not
have been noted. There are several individual case reports of patients with these disorders
developing tumors, including malignant lymphoma, malignant melanoma, bilateral
nephroblastoma, esophageal carcinoma, non-Hodgkin's lymphoma and perioral papillomatosis
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(Akahoshi et al., 2003; Drut et al., 2002; KasImann and Ruprecht, 1997; Ogutcen-Toller et al.,
2000). No familial syndrome has yet been associated with mutations in p73.
Furthermore, alterations in p63 and p73 in spontaneous tumors have begun to be reported more
widely in the literature. For example, overexpression of ANp63 (see below) is a relatively
frequent event in squamous cell carcinomas while ANp73 overexpression correlates with poor
prognosis in lung cancer (Choi et al., 2002; Uramoto et al., 2004). Also, a more thorough
analysis of p73 knockout mice revealed an elevated tumor incidence compared to wild type and
compound heterozygous mutation of any two members of the p53 family in mice resulted in a
substantial increase in tumorigenesis compared to the single mutants (Elsa Flores, submitted to
Cancer Cell). Taken together, these data support classification of p63 and p73 as tumor
suppressor genes.
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MOUSE MODELS OF P53
Over a dozen different alleles of p53 have been engineered into mice in the past fifteen years,
leading to dramatic progress in the understanding of both mutant and wild-type p53 function.
Many of the principles described above were derived from studies genetically engineered strains
of mice or cells derived from them. The various p53 mouse strains can be classified into four
general groups: transgenic strains, knockout/knockdown strains, reporter strains and those with
non-tumor-associated mutations.
Transgenic Mice
The first two genetically engineered p53 mouse strains carried genomic fragments of p53 derived
either from a mouse liver tumor (p53 A 3 5V) or from the Friend cell line CB7 (p53R1 93 P, although
the presence of this mutation in CB7 cells was not discovered until a year later)(Lavigueur et al.,
1989; Munroe et al., 1990). At the time these mice were described, p53 was thought to be a
cellular oncogene rather than a tumor suppressor gene. The fact that these mice that
overexpressed various fragments of p53 developed tumors actually supported this notion. It was
not until about a year later, when wild-type p53 was found suppress transformation, that it was
realized that the mutations present in these mice and in many tumors and cell lines were actually
dominantly interfering with the function of wild-type p53. In 1995, the p53A135v mouse was
crossed onto p53+/' and p53'/ backgrounds (see below) to address the possibility of dominant-
negative or gain-of-function effects by mutant p53 (Harvey et al., 1995). In this case, it was
found that mutant p53 accelerated tumorigenesis and changed the tumor spectrum of p53+/' mice,
but did not affect the phenotype of p53 knockout mice. This was interpreted as supporting the
dominant-negative hypothesis and refuting the p53 gain-of-function hypothesis.
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However, it is difficult to accept these interpretations. The mutant p53 transgene in these mice
was expressed at extraordinarily high levels. Northern analysis of p53 levels in the tissues of
these animals found approximately 40- to 50-fold more p53 mRNA in the transgenic mice than
in wild-type mice. Furthermore, p53 protein levels were elevated even in normal tissues. In
contrast, Li-Fraumeni Syndrome patients show no accumulation of p53 protein in their normal
tissues. Therefore, rather than acting as a dominant-negative allele, the mutant p53 protein might
be interpreted as simply overwhelming the small fraction of p53 protein that is wild-type in these
animals. The chance of there being any fully wild-type p53 tetramers in the cells of these mice is
very low.
The lack of an effect by the mutant p53 transgene on the p53 null mouse phenotype does not
disprove the mutant p53 gain-of-function hypothesis. Absence of evidence is not evidence of
absence. The rapid development of lymphomas and sarcomas in p53 null mice could mask a
gain-of-function effect on the development of other tumor types. Furthermore, the p 53A135v
mutation is not a particularly potent mutation. Indeed, it has been shown to be a temperature
sensitive allele and a subsequent mouse model targeting expression of p53A135V to the kidney
found that it actually protected the animal from an activated K-ras transgene targeted to the same
tissue (Schaffner et al., 1996). Both of these caveats were noted by the authors in the 1995
paper. Nonetheless, this work fostered a general suspicion within the p53 field of the mutant p53
gain-of-function hypothesis.
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In addition to the kidney-specific transgene described above, mutant p53 transgenes have also
been targeted to the mammary epithelium using the whey acidic protein promoter (WAP-
p53R1 7 2H), the epidermis using the human keratin 1 promoter (HKl-p53Rl72 H) and the lung using
the surfactant protein C promoter (SPC-p53R7°0H)(Duan et al., 2002; Li et al., 1998; Murphy and
Rosen, 2000; Takahashi et al., 1989; Wang et al., 1998a). Due to the non-physiological levels of
protein expression (and in one case, the lack of even remotely relevant controls), these strains are
primarily useful as models of particular tumor types rather than for investigating the functional
properties of mutant p53.
The final transgenic mouse strain harbors extra copies of wild-type p53 in the form of large
genomic transgenes (Garcia-Cao et al., 2002). These "super p53" mice were resistant to two
types of carcinogen induced cancers and had enhanced cellular responses to DNA damage. A
small number of mice had been aged for up to two years with no dramatic loss of viability or
other phenotypes. However, a large-scale aging study has not yet been reported for these mice.
p53 Knockout Mice and Knockdown Mice
p53 knockout mice have been generated by several different groups, each with similar
phenotypes (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994). p53'/ ' mice are born
at slightly sub-Mendelian ratios due the occurrence of female-specific exencephaly in a subset of
p53 null embryos (Sah et al., 1995). p 53 null mice that survive to birth develop normally but
develop tumors with a mean latency of roughly 4.5 months. In most studies, -95% of p53 null
mice succumb to cancer by six months of age. p53 knockout mice develop primarily lymphomas
and sarcomas, although there is some influence of strain background (Harvey et al., 1993b).
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p53 +/' mice survive an average of-18 months and primarily develop sarcomas and lymphomas
although their tumor spectrum is broader than that of p53' mice. Furthermore, when crossed
onto the BALB/c genetic background, 100% of p53+/' female mice developed either mammary
adenocarcinomas (55%) or mammary hyperplasias (45%), suggesting that a powerful genetic
modifier may be present in the BALB/c strain (Kuperwasser et al., 2000). Analysis of p53+ '
mice also found that the wild-type p53 allele is frequently, but not inevitably, inactivated in
tumors. In fact, tumors that arise in p53+/ ' mice that survive past 18 months usually retain wild-
type p53 function, arguing that a reduced gene dosage of p53 is sufficient to sensitize mice to
tumorigenesis (Venkatachalam et al., 1998).
Finally, an epi-allelic series of lentiviral shRNA expressing mice was described in which
different p53-directed siRNAs were used to generate mice with intermediate levels of p53
expression (Hemann et al., 2003). Strikingly, the different strains of mice (crossed with the Eut-
Myc transgenic strain) developed a range of tumor phenotypes that directly correlated with the
expression levels of the p53 protein. The use of such mice allows for a careful assessment of the
effects of different levels of p53 on in vivo tumorigenic processes.
Reporter Mice
Two strains of mice have been developed to facilitate p53 mouse research. The first features a
targeted allele of p53 that has been tagged with a coat color marker (Zheng et al., 2002). This
allows for visual distinction of wild-type, heterozygous and homozygous knockout mice rather
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than using PCR analysis. The second strain harbors a p53-tesponsive lacZ transgene. This strain
is useful for analyzing p53 transactivation activity by histology (Komarova et al., 1997).
Non-Tumor-Associated Targeted Mutations
Four strains of mice have been generated with targeted mutations for the purpose of exploring
specific biochemical properties of p53. In the first of these strains, exons 4-9 of the murine p53
gene were replaced with exons 4-9 of the human p53 gene. These human p53 knock-in (hupki)
mice were generated because mice and humans do not develop identical mutational spectra in
p53 following exposure to carcinogens. Indeed, when small sections of the skin of homozygous
hupki mice were chronically exposed with UVB radiation, they developed a spectrum of
mutations in p53 that matched that seen in humans rather than in mice. These differences can be
attributed to the lack of transcribed-5trand dipyrimidines at some the sites where they are found
in human p53 (Luo et al., 2001a; Luo et al., 200lb).
The other three targeted strains harbor single base-pair mutations in the p53 coding sequence.
These include the phosphorylation site mutants p53s23A (analogous the human p5320A), p53 s389A
(analogous to human p53S392A) and the apoptosis-defective p53R l72P (analogous human p5 3R75P).
p53s23A/ S 23A mice have a mean survival of -15 months and develop primarily B-cell lineage
tumors rather than the T-cell lineage lymphomas commonly found in p53 knockout mice
(MacPherson et al., 2004). Primary cells and tissues from these mice exhibit partial defects in
p53 mediated apoptosis but appear. to have an intact cell cycle arrest in response to ionizing
radiation. This is similar to the phenotype of p53R172P/ R I72P mice, which are also fully defective
for apoptosis induced by ionizing radiation but retain a partial ability to induce cell cycle arrest
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(Liu et al., 2004). In contrast, p53s389A/S389A rimary ceils have an intact ionizing radiation
response but are partially compromised in their response to UV irradiation. p53 s389A/S389A also
have an increased sensitivity to UV-induced skin tumor development (Bruins et al., 2004).
Other p53 Mouse Strains
Finally, three lines of mice have been described that harbor p53 alleles with unintended
mutations. The first strain was reported as a transactivation-deficient mouse model of p53. The
double amino acid mutation substitution (p53 L2 5Q /W26 s) has been shown to abrogate the function
of the transactivation subdomain 1 of p53. This mutation was targeted into murine embryonic
stem cells and reported to cause constitutive binding of p53 to DNA (Jimenez et al., 2000).
However, at a recent meeting the primary investigator of this work disclosed that his laboratory
had discovered an extraneous mutation in the p53 coding sequence (12th International p53
Workshop, Dunedin, New Zealand). At the same meeting, another investigator reported
unpublished data on an independently targeted mouse with the p53L 25Q/I 26s mutation (Laura
Attardi, 12th International p53 Workshop, Dunedin, New Zealand). In this case, the mutant p53
protein was found to be both stabilized, due to a disruption of its interaction with MDM2, and
compromised in its ability to activate many target genes. The effect on p53 transactivation was
selective as some p53 target genes were found to be regulated in a manner similar to wild-type
mice. Further work on this and other transactivation mutant mice should provide insight into the
complex differential regulation of p53 target genes.
The second strain of mis-targeted mice harbors a >20 kilobase deletion 5' to the p53 gene and
extending through exon 6 of the p53 coding sequence. The deleted region includes other gene
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loci. The rearrangement produced a transcript with a 55bp leader of unknown origin fused to the
3' end of the p53 gene with the amino acid that would normally be Met243 serving as the
translational start site. In addition, the mutant allele also contains a p53R245w mutation that was
engineered in the initial targeting construct. Analysis of mice heterozygous for this allele found
that although they survived longer than p53+/' mice, the p53+/ m mice developed far fewer tumors
(6% versus >80% for p53+/ m and p53+/' mice respectively). The precise cause of death of the
mice was not determined but the authors presented evidence that the mice suffered from a
premature aging syndrome. They argued that the C-terminal fragment of p53 that was expressed
in these mice activates the function of the wild-type p53 allele similar to the p53 C-terminal
peptides that have been described in cell culture assays (Hupp et al., 1995). The authors put
forth the hypothesis that tumor suppression is a balancing act between preventing cancer and
inflicting organismal aging. This hypothesis seems to be counteracted by the phenotype of the
super-p53 mice, which did not show signs of premature aging.
The final mouse model of p53 harbors a targeted tumor-associated mutation but also has an
extraneous splice acceptor mutation that arose inadvertently during cloning. Mice heterozygous
for this p53 R172HAg allele, developed an increased incidence of carcinomas compared to p53+/'
mice and had a very high rate of metastases from carcinomas and osteosarcomas. However,
interpreting these results is difficult because the mutant p53 protein is expressed only at very low
levels (Liu et al., 2000).
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Summary- Mouse Models of p53
The tools described above have, are and will continue to provide invaluable tools for the study of
p53 function and dysfunction. Future models, including, I hope, those described in this thesis
will further contribute to this effort. One tool that would be useful would be a targeted p53
fusion with a purification tag (e.g. FLAG) for use in biochemical studies on endogenous
proteins. Similar tagged versions of other endogenous proteins could facilitate characterization
of protein-protein interactions under endogenous conditions.
On another note, the occurrence of three independent lines of mice with unexpected mutations in
p53 is disconcerting. Two of the three rearranged alleles were attempts to create tumor-
associated mutant p53 mice using standard gene targeting techniques. This prompts me to relate
an anecdote from our own initial efforts to target mutant p53 into mice. Prior to my arrival in the
Jacks Lab, Annemieke deVries generated ES cells with the targeted tumor-associated mutation
p53R270H. These ES cells were injected into blastocyts and produced high contribution chimeras.
However, in repeated attempts, these chimeras never transmitted the mutant allele. The effort to
derive mice from these ES cells was eventually abandoned.
When I joined the Jacks Lab in 1999, it was our opinion that mutant p53 was associated either
with a developmental defect or a spermatogenic defect in mice that was not found in human Li-
Fraumeni Syndrome patients. The conditional mutant p53 mice designed by David Tuveson and
described in Chapters 2 and 3 of this work were engineered to circumvent this potential defect.
However, my initial project in the lab was to determine whether such a defect occurred in mice.
To this end, I activated the conditional p53R270H allele in Dave's ES cells to recapitulate the
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experiment that Annemieke performed using targeted ES cells that had already been shown to be
competent for germline transmission. Once again, we failed to achieve germline transmission
with high contribution chimeras. The mystery is even greater now that we know that when the
recombination occurs in vivo through the action of a germline-specific Cre, the mutant p53 allele
is inherited as readily as a null p53 allele. The implication is extremely odd. The only difference
between a chimeric animal and a conditional mutant p53 mouse with a germline-specific Cre is
that the chimeras have wild-type cells in direct contact with mutant p53-bearing cells during
development. It is as if the wild-type cells prevent the mutant cells from contributing to the germ
cell compartment.
Around the same time that I made this observation, my cross of the conditional germline mutant
p53 mice to the germline-Cre transgenic mice unexpectedly yielded the first germline mutant
p53 mice. I never did return to the question of why directly targeted mutant p53 mice don't
achieve germline transmission. The experiment that I would propose to anyone interested in this
phenomenon is simple: derive ES cells and blastocysts from both wild-type and germline mutant
p53 mice and combine them pair-wise in each of the four possible combinations. If the
homotypic combinations successfully achieve germline transmission and the heterotypic
combinations do not, there is an interesting story at hand that would be worth pursuing.
APPROACHES TO THERAPEUTIC INTERVENTION
From the standpoint of therapeutic potential, oncogenes have always been viewed more
favorably than tumor suppressor genes. It stands to reason that it should be easier to find a
therapeutic to inhibit the function of an extant protein than to replace the function of a protein
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that has been deleted. However, unlike other tumors suppressor genes, p53 is generally altered
through mutation rather than deletion. This has lead to a great deal of interest in molecules that
might "reactivate" the normal tumor-suppressive functions of mutated p53. Several compounds
have been reported to be capable of reactivating p53, although it is far from clear whether they
truly accomplish this feat. For example, a compound called PRIMA1 was reported to restore
function to mutant p53 proteins (Bykov et al., 2002a; Bykov et al., 2002b). However, in a small
series of unpublished experiments performed in collaboration with Andrea Venture in our
laboratory, PRIMAl had no effect on the accumulation of p53 protein, cell cycle progression or
transactivation of p53 target genes in p53M/' MEFs. Therefore, it is therefore unclear whether
PRIMAl actually targets mutant p53. Other drugs have been reported to reactivate mutant p53
but require impractically high cellular concentrations for biological activity.
One caveat to the search for a mutant p53 drug is that different mutations in p53 have different
effects on the function of the protein. A drug that shifts the conformational equilibrium of
structural mutant p53 proteins back to a wild-type conformation may not be effective against a
contact mutant p53 protein. Contact mutants often do not assume a "mutant" conformation.
Their defect lies in their inability to make important direct contacts with the DNA backbone, an
activity that may be difficult to complement in trans with a drug. This suggests that mutant p53
reactivating therapies may need to be combined with diagnostic screening techniques in order to
match the specific function of the drug with the particular mutation present in a tumor. In a large
genomically unstable tumor, this may simply select for mutations of a different class to emerge,
similar to the way CML mutates other residues of the BCR-ABL fusion protein to evade the
effects of Gleevec. Nonetheless, even a transient reprieve from tumor progression is an
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improvement over none and so the search for p53 reactivating drugs remains a promising avenue
of research.
For those tumors harboring wild-type p53, several therapeutic approaches have recently been
described for activating p53 function in the absence of DNA damage. A transducible p53
peptide derived from the CTD and composed of a D-isomer polypeptide fused to HIV-TAT was
found to potently activate p53 activity and extend lifespan in a tumor xenograft model (Snyder et
al., 2004). In separate work, a class of small molecule inhibitors of the p53/MDM2 interaction
called nutlins was found to potently activate p53 function in tumor cells but to have little or no
effect on normal cells (Snyder et al., 2004). Nutlins or related compounds may be
extraordinarily useful in treating those tumors that respond well to standard genotoxic agents in a
p53-dependent manner. The substitution of nutlins for classical chemotherapeutics may spare
patients some of the substantial morbidity associated with genotoxic treatments.
Finally, there may be an important role for the stratification of patient populations based on p53
mutation status. For some types of tumors, p53 mutations are known to impact the efficacy of
chemotherapeutic regimens (Lowe et al., 1993a; Peller, 1998). In this case, the rapid
determination of p53 mutation status could save patients from being treated with ineffectual
drugs. To this end, a DNA oligonucleotide array protocol was developed that can detect p53
mutations with extremely high sensitivity (Fouquet et al., 2004). For samples contaminated with
high proportions of normal stromal tissue, this array protocol outperformed direct sequencing
protocols in detecting rare p53 mutant cells. Such an approach may have an important place in
the clinic although cost of implementation may preclude this particular strategy.
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The search for therapeutic approaches targeted to the p, 3 pathway is somewhat hampered by a
lack of understanding of the basic functions of the common tumor-associated mutant alleles of
p53. Thousands of clinical publications have examined p53 protein expression in different types
of tumors in order to discern a correlation with prognosis or outcome. However the molecular
determinants and consequences of mutant p53 overexpression is poorly understood, as are the
implications of a lack of mutant p53 overexpression. Furthermore, the different clinical
implications of specific mutations have rarely been explored. A more complete understanding of
the functional effects of mutant p53 may allow for the development of a panel of drugs targeted
to different potential alterations in the p53 pathway. Such a panel of drugs would have broad
applications in treating a very large variety of different human tumors.
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ABSTRACT
The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through
missense mutations that result in accumulation of mutant p53 protein. These mutations may
confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological
effects of p53 point-mutation, the structural mutant p5 3 R172H and the contact mutant p5 3 R270H
(codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice.
p53R 270H/ + and p5 3R72H / + mice are models of Li-Fraumeni Syndrome; they developed allele-
specific tumor spectra distinct from p53 +1- mice. In addition, p53R 270H/- and p53 RJ7 2H/ - mice
developed novel tumors compared to p53-1- mice, including a variety of carcinomas and more
frequent endothelial tumors. Dominant effects that varied by allele and function were observed
in primary cells derived from p53R 27 0H/ + and p5 3 R I72H/+ mice. These results demonstrate that
point-mutant p53 alleles expressed under physiological control have enhanced oncogenic
potential beyond the simple loss ofp53 function.
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INTRODUCTION
The p53 tumor suppressor gene encodes a transcription factor that responds to cellular stresses
by regulating genes involved in cell cycle arrest, apoptosis, genome maintenance and other
pathways (Chang and Kornberg, 2000; Lu and Levine, 1995; Seto et al., 1992; Thut et al., 1995;
Xiao et al., 1994). The p53 protein contains a core sequence-specific DNA-binding domain
(DBD) that directly binds to sequence elements in target gene promoters (Cho et al., 1994;
Pavletich et al., 1993; Zambetti et al., 1992). Missense mutations in the pS3 DBD occur in a
large fraction of spontaneous human tumors and have been documented in over 50 different
types of cancer. Large deletions, though commonly seen in other tumor suppressor genes, occur
rarely in p53 (Olivier et al., 2002).
The detection of specific p53 mutations in human tumor samples has been reported in nearly
2000 publications. In order to aid in their analysis, two separate p53 mutation databases have
been constructed that catalogue data on each of reported mutation: the Universal Mutation
Database (UMD) and the International Agency for Research on Cancer p53 mutation database
(IARC) (Beroud and Soussi, 2003; Olivier et al., 2002). These two databases are invaluable
resources for discerning trends in the p53 mutational spectra of different tumors, although there
are some caveats that must be taken into account. For instance, because many investigators limit
their sequencing efforts to exons 5-9 of p53, the databases tend to be biased towards mutations in
the p53 DBD. Mutations outside the DBD are rare, but they do occur. Also, the samples in
many experiments are pre-screened by immunostaining or other techniques, perhaps leading to a
bias against mutant p53 alleles that do not induce p53 protein accumulation. Nonetheless, the
epidemiology of p53 mutations in sporadic tumors reveals some prominent trends. Certain
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tumor types have high frequencies of p53 mutations. These include cancers of the esophagus,
ovary, colorectum, head/neck, pancreas, lung and skin. Other tumors, such as those arising in
soft tissues, bone, hematological lineages, prostate, kidney, testis and thyroid, have relatively low
frequencies of p53 mutation. It is interesting to note that all of the tumors with high frequencies
of p53 mutation are of epithelial origin while many of those with a low prevalence of mutations
are of mesenchymal or germ-cell origin. Another lesson gleaned from p53 epidemiology is that
different p53 mutations occur at varying frequencies in different types of cancers. For example,
mutations at codon 273 occur in nearly 16% of brain tumors compared to only 6% for codon
175. This may imply that different mutant in p53 confer subtly different functions. Finally, p53
mutations have been linked to poor prognosis in a variety of different tumor types and have been
shown to affect cellular responses to chemotherapeutics (Cho et al., 1994; Levine, 1997; Milner
et al., 1991; Peller, 1998).
At a biochemical level, tumor-associated point-mutations in p53 generally fall into two classes:
'contact mutations' affect p53 residues that make direct contact with DNA, while 'structural
mutations' affect the global structure of the p53 DNA binding domain. Both classes yield
mutant p53 proteins that have lost wild-type function and that frequently accumulate to high
levels in tumor cells. However, structural mutant proteins assume a globally denatured
conformation that exposes novel "mutant-specific" epitopes in the DBD; contact mutant proteins
are less likely to assume the mutant-specific conformation.
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In addition to sporadic tumors, p53 point-mutations also occur in the germline of patients with
Li-Fraumeni syndrome (LFS), a familial cancer predisposition syndrome in which patients
develop a broad spectrum of malignancies including breast carcinomas, soft tissue and bone
sarcomas, brain tumors, leukemias, gastrointestinal carcinomas and a variety of additional
epithelial cancers (Birch et al., 1994; Kleihues et al., 1997; Varley et al., 1997). The mutations
that occur in LFS patients are pretty much the same as those that occur in spontaneous human
tumors, with some subtle differences in overall frequency. Few connections have been made
between geneotype and phenotype in LFS patients. One exception is the R337H allele which is
primarily associated with adrenocortical carcinoma. An analysis of 36 cases of childhood
adernocortical cancer in Brazil found that 35/36 patients harbored a germline R337H mutation in
p53 (Ribeiro et al., 2001). Codon 337 lies within the oligomerization domain of p53 and its
mutation to histidine causes the protein to become extremely pH sensitive and lose the ability to
tetramerize at elevated pH. Cells in the adrenal cortex encounter elevated pH in the course of
normal developmental processes. Therefore, the R337H mutation may inactivate p53 function
specifically in the adrenal cortex (DiGiammarino et al., 2002).
Two prominent models have been proposed to explain the effects of p53 missense mutation in
cancer. The first suggests that hetero-oligomerization between mutant and wild-type p53
polypeptides results in dominant-negative effects on wild-type p53 function. Considerable
biochemical and cell-based data support the ability of different point-mutant alleles to inhibit
wild-type p53 function, but the effects can be complex (Kern et al., 1992). For example, some
alleles of mutant p53 can inhibit the ability of wild-type p53 to transactivate target genes
involved in apoptosis but not those involved in cell cycle arrest (Aurelio et al., 2000).
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Furthermore, the extent to which tumor-derived mutations in p53 confer dominant-negative
effects under physiological conditions is unclear.
The second model of mutant p53 function suggests that p53 mutations actively promote
tumorigenesis independent of wild-type p53 function. This "gain-of-function" model is
supported by several studies in which p53 null cell lines were transformed with mutant p53
constructs, resulting in increased tumorigenic potential (Dittmer et al., 1993; Hsiao et al., 1994;
Pohl et al., 1988; Shaulsky et al., 1991). In addition, many studies have ascribed novel
biochemical properties to mutant p53 that are distinct from the function of wild-type p53. These
include the ability to regulate distinct sets of target genes and the ability to participate in novel
protein-protein interactions (Cadwell and Zambetti, 2001; Chin et al., 1992; Di Como et al.,
1999; Frazier et al., 1998; Gaiddon et al., 2001; Lanyi et al., 1998; Marin et al., 2000; Yang et
al., 1999). Very little is known about the relevance of these observations in vivo.
Substantial efforts have been made to model LFS in mice. We and others engineered mice
lacking expression of the p53 protein. p53 knockout mice are highly cancer-prone and the study
of these mice has yielded significant insight into the cellular and biochemical functions of wild-
type p53. However, in contrast to the broad spectrum of tumors in LFS patients, the tumor
spectrum of p53 knockout mice is fairly restricted; both heterozygous and homozygous knockout
mice develop primarily sarcomas and lymphomas. Carcinomas in these mice are rare,
particularly inp53 null mice (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994). At
least four groups have produced transgenic strains that overexpress mutant p53 from exogenous
promoters (Harvey et al., 1995; Lavigueur et al., 1989; Li et al., 1998; Wang et al., 1998b). In
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each case, mutant p53 transgene expression resulted in accelerated spontaneous or carcinogen-
induced tumor development, supporting a dominant effect for mutant p53 that is distinct from
simple loss-of-function. For example, a p 53 135V transgene conferred accelerated tumorigenesis
and an altered tumor spectrum on p53 +/ + and p53 +/- mice (Harvey et al., 1995). Similarly, Liu
et. al. found an increased incidence of carcinomas and metastatic osteosarcomas, compared to
p53 +/- mice, in mice heterozygous for an endogenous mutant allele of p53 (p53R1 72 1Hg); however,
analysis of these mice was confounded by the presence of an extraneous splice acceptor mutation
(Liu et al., 2000). Also, we previously reported evidence for dominant-negative effects by two
endogenous mutant p53 alleles in mouse embryonic stem cells and in thymocytes produced by
Rag2- 1- blastocyst complementation (de Vries et al., 2002). None of these studies, however,
found clear evidence of gain-of-function effects by mutant p53.
In order to more accurately model LFS in mice and to investigate the potential for dominant-
negative or gain-of-function effects by mutant p53, we constructed and characterized two mouse
strains carrying conditional germline point-mutations of p53. These strains harbor contact or
structural mutations that together comprise two of the three most commonly mutated p53 codons
in human cancer. These strains more closely mimic humans with LFS both genetically and
phenotypically. Moreover, data from these mice provide compelling evidence for gain-of-
function effects by mutant p53.
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RESULTS
Generation of Germline Point-Mutantp53 Mice
Two conditional point-mutant p53 alleles were engineered into the endogenous murine p53
locus. They encode the contact mutant p 53 R270H and the structural mutant p5 3R72H, both of
which are commonly found in spontaneous human tumors and in the germline of LFS kindreds.
(Murine p53 codons 270 and 172 correspond to human p53 codons 273 and 175.) In order to
enable tissue- or stage-specific expression of mutant p53 under physiological conditions,
conditional mutant alleles of p53 were generated by introducing the LoxP-flanked transcriptional
STOP cassette into intron 1 of the p53 gene. This Lox-STOP-Lox (LSL) cassette was used by
our group previously to create a conditional oncogenic allele of K-ras; it efficiently blocks
expression of targeted loci prior to removal of the STOP element by Cre recombinase (Tuveson
et al., 2004). Site-directed mutagenesis was used to introduce an arg-+his mutation at either
codon 270 or codon 172, resulting in the conditional mutant alleles p 53 LSLR270H and p 53 LSL- R 1 72H
(Fig. 1A). These were verified by sequencing the entire p53 open reading frame and all
intron/exon boundries in the targeting vectors (data not shown). Both alleles were targeted into
J1 embryonic stem cells and germline transmission was achieved in multiple clones. Presence of
the STOP cassette in intron 1 of p53 in these mice was determined by PCR (Fig. B), and the
presence of each mutation was reconfirmed by sequencing (data not shown).
In order to study the effects of endogenous expression of the mutant p53 alleles in all tissues of
the mouse, p53 LSLR270H/+ and p53 LSLR72H/+ mice were crossed to Protamine-Cre transgenic mice,
which express Cre recombinase in haploid sperm (O'Gorman et al., 1997). Resulting
p53LSLR270H/+; PrmCrel+ and p 53 LSL R172H+; PrmCrel+ male mice were then crossed to wild-type
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129S4/SvJae females to generate p53 R2 7 0 H/+ and p 53R 172H/+ mice (collectively referred to as
"p53M+" mice). Tail DNA samples from offspring were analyzed by PCR (Fig. 1C).
Successful generation of conditional and germline point-mutantp53 mice was verified by several
means. p53 cDNAs were derived from p53m/ + and p53 LSL' M/+ mouse brains and sequenced. As
expected, both mutant and wild-type alleles were found to be expressed in p 53R270H/+ and
p53R' 7 2 H /+ samples, while only the wild-type allele was expressed in p53LSLR 2 7 0H / + and
p 53 LSL
'R 72H/+ samples (Fig. D, data not shown). In addition, cDNAs derived from p53 R270H / -
and p53R72H/ - primary mouse embryo fibroblasts (MEFs; see below) were sequenced,
confirming the presence of only the desired mutations (data not shown). Quantitative real-time
PCR analysis for p53 confirmed that the point-mutant alleles are expressed at levels comparable
to wild-typep53 in MEFs (Fig. 1E).
Mutant p53 protein often accumulates to high levels in human tumors and some mutant proteins
adopt an altered conformation. In particular, structural mutants assume a partially denatured
conformation that results in the exposure of novel epitopes recognized by mutant-specific a-p53
antibodies. In contrast, contact mutants have been described either as 'flexible' (reactive to both
wild-type- and mutant-specific antibodies) or as fully wild-type in conformation (Webley et al.,
2000; Yewdell et al., 1986). In order to examine the biochemical properties of mutant p53
proteins, mice that express only point-mutant p53 were generated by crossing p53M/+ mice to
p53+/- mice (Jacks et al., 1994) to generate p 5 3 R27 0 H/ - and p53R172H/ - mice (collectively referred
to as p53Ml- mice). These mice appeared grossly similar to p53- 1- mice at birth and throughout
development (see below). They were born in expected Mendelian ratios except for a slight
decrease in the number of p5 3M - females, a phenotype that is also observed in p53 - 1- animals
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due to female-specific exencephaly (Sah et al., 1995). Figure 1F shows a Western blot for p53
performed on MEF whole cell lysates confirming that mutant p53 accumulated to high levels in
these cells. In addition, these experiments also revealed that the contact mutant p53R270H
accumulated to higher levels in p53 - MEFs than the structural mutant p53 R172H . This effect
was reproduced using three different antibodies against p53 (data not shown). As shown in
Figure 1G, the structural mutant p53R 172H was preferentially immunoprecipitated by the mutant-
specific antibody PAb 240 while the contact mutant p53R270H was preferentially
immunoprecipitated by the wild-type-specific antibody PAb 1620.
p53MI+ Mice Develop Distinct Tumor Spectra
In order to evaluate whether the p53"M+ mouse strains are improved models of LFS and to
compare the effects of p53 point-mutation to p53 null mutation, a cohort of 37 p53 R270H/+, 41
p53R172H / + and 37 p53+ - mice were aged and monitored for the onset of malignancy. As shown
in Figure 2a, the life-spans of p 53 R270H/+, p53 R72H/+ and p53+1- mice were similar with mean
survival times of 15.8, 15.2, and 15.4 months, respectively (Kaplan-Meyer Log-Rank Test).
Each mouse was subjected to a complete necropsy and histopathological analysis of all tissues
regardless of whether tumors were apparent. The pathology of each mouse in this study is
available in Supplementary Materials.
The p53MV+ mice demonstrated significant differences in their tumor spectra, both compared to
the p53 +/- mice as well as to each other (Fig. 2b). The p53R2 70H /+ mice had an increased
incidence of carcinomas compared to p53+ 1- mice (X2, p= 0.017). In particular, 7/36 p53R270H/+
mice developed lung adenocarcinomas, including several with malignant features commonly
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seen in human lung adenocarcinoma such as nuclear atypia (5/7), desmoplasia (4/7) and
metastasis (2/7). Other carcinomas found in p53R270 H / + mice included five squamous cell
carcinomas, two hepatocellular carcinomas, a transitional cell carcinoma of the kidney and an
intestinal carcinoma (Sup. Fig. 2A-C). Many of these tumors were invasive or showed evidence
of distal metastases (Sup. Fig. 2D-E). Immunohistochemistry (IHC) was performed on some
tumors to further support their epithelial origin (Sup. Table 1, Sup. Fig. 3A). In contrast to the
p 53R27 0 H /+ mice, only four low-grade carcinomas were found in 37 p53 +/- mice, similar to
previous reports (Donehower et al., 1992; Jacks et al., 1994). The single lung carcinoma
observed in a p53+/ - mouse was well differentiated and lacked severely dysplastic nuclei or
stromal deposition. Pre-malignant epithelial lesions such as adenomas and papillomas were also
more common in the p 53R2 7 0H/+ mice than in the p53+/- mice (Sup. Fig. 1).
In addition to carcinomas, p 53 R270H/+ mice also had an increased incidence of B-cell lymphomas.
5/36 p53R2 7 0H/ + mice developed B-cell lineage tumors (X2, p= 0.031; Sup. Fig. 3B,C). They
generally arose in the spleen or mesenteric lymph nodes and spread through the abdominal
cavity, sometimes invading adjacent organs such as the kidneys and intestines (Sup. Fig. 3B).
Overall, p53R 2 7 0 H / + mice had an increased tumor burden compared to p53+/- mice; 44% of
p53R2 70H + mice had developed multiple tumors at the time of necropsy compared to 19% of
p53 +1- mice (X2, p=0.03).
In contrast to the frequent carcinomas in p 53 R270H/+ mice, the most frequent tumors in the
p53
R I72H/+ mice were osteosarcomas. Roughly twice as many p53 R172H/+ mice developed
osteosarcomas as p53+1- and p53R 2 70H/+ mice (X2 , p= 0.043 for p53+1- mice, p= 0.039 for
90
p53R270H/+ mice). These tumors developed primarily in trabecular regions of vertebrae or
longbones. Diffuse osteopetrosis was commonly observed concurrent with the osteosarcomas.
In addition, the p53R 172H/+ osteosarcomas metastasized more frequently than those in the p53+ /-
or p 53R270H/+ mice, generally to the liver, lung or spleen (Sup. Fig. 2E,F). Only four
osteosarcomas in p53R 72H/+ mice did not metastasize, including two early lesions found in mice
that died from other causes. The p53 R72H/+ mice also developed carcinomas slightly more
frequently than p53 +/- mice (X2, p= 0.38), however, they did not display the high frequency of
lung adenocarcinomas noted in p53R270H/+ mice.
Tumors that develop in humans with hereditary p53 mutations frequently lose the remaining
wild-type p53 allele. It was therefore of interest to determine the status of the wild-type p53
allele in tumors from p53 3m+ mice. The mutant p53 reaction described earlier (Figure 1 c) was
modified to be quantitative by terminating the reaction after 29 cycles rather than 35. The
sensitivity of this assay was confirmed by running a dilution series of p53 / + and p5 3m/M samples
(Figure 2C). PCR analysis of DNA derived from p533v+ tumors revealed evidence of LOH in
10/19 tumors analyzed (4/10 p53R270H/+ and 6/9 p5 3R172H+), further validating these mice as
models for LFS.
Dominant Effects of Mutant p53 in Primary Cells
There are several potential explanations for the differences in tumor spectra between the p53W +
mice and p53+/- mice. Mutant p53 may act in a dominant-negative manner to interfere with the
function of the wild-type p53 allele. Alternatively, the mutant p53 alleles may contribute novel
pro-tumorigenic functions. These two mechanisms are not mutually exclusive. In order assess
91
the dominant effects of endogenous mutant p53, several well established assays for p53-
dependent functions were performed on p53M'+ MEFs and thymocytes. For example, p53 can act
to restrain cell proliferation as p53 -1- MEFs cycle more quickly than wild-type or p53+1- MEFs.
Therefore, we measured cell proliferation in p53M + MEFs by analyzing the fraction of cells in S-
phase via FACS analysis of bromodeoxyuridine (BrdU) incorporation and propidium iodide (PI)
exclusion. As expected, a large fraction of p53- 1- MEFs were in S-phase during exponential
growth compared to wild-type or p53+1- MEFs. Interestingly, both the p5 3R270H / + and p53 R172H/+
MEFs had a larger S-phase fraction than p53 +/- MEFs, with the p53R172H/+ MEFs appearing
comparable to p53- 1- MEFs in this assay (Fig. 3a, solid bars, Sup. Fig. 4a). Evidence of an
elevated proliferation rate inp53Rl72H/+ MEFs was also apparent when they were submitted to the
classical 3T3 passaging protocol (Todaro and Green, 1963). p53 R172H/+ MEFs grew as rapidly as
p53- 1- MEFs for four passages before entering replicative senescence. Immortalized clones
quickly escaped senescence and PCR analysis demonstrated loss of the wild-type p53 allele in
these clones (Sup. Figure 4b; data not shown). p53 is also required for G1 arrest in MEFs after
DNA damage (Kastan et al., 1992). Surprisingly, the DNA damage-induced G1 arrest response
was intact in p53M"+ MEFs: after treatment with the DNA damaging agent doxorubicin, p53Ml+
MEFs arrested in the G phase to a similar extent as wild-type cells (Figure 3a). Thus,
physiological expression of point-mutant p53 in MEFs appears to dominantly interfere with
cellular functions related to basal proliferation but does not affect DNA damage-induced G1
arrest.
As DNA damage-induced G1 arrest in MEFs is primarily dependent on the ability of p53 to
transactivate the cell cycle inhibitor p21, this pathway was investigated in p53M + MEFs. As
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shown in Figure 4A, the amount of total p53 in ntreated p53 ~+ MEFs was elevated compared
to p53+/+ or p53 +/ - MEFs, and increased further upon treatment with doxorubicin. p21 levels,
however, were comparable to those found in pS3+/' MEFs, suggesting that mixed mutant and
wild-type p53 tetramers are competent to transactivate at least some target genes. An IP-
Western for MDM2 supports this notion and also suggests that the accumulation of high levels of
mutant p53 in these cells is not due to a loss of MDM2 transactivation by mutant p53.
Finally, in order to analyze the ability of p53M/+ cells to undergo p53-dependent apoptosis,
primary thymocytes were isolated from 6-8 week old mice. The apoptotic response of p53M +
thymocytes to 5Gy of gamma radiation was assayed by FACS analysis for Annexin-V
expression and propidium iodide exclusion. The relative fraction of viable cells after
doxorubicin treatment is shown in Figure 3B. As expected, p53'- - thymocytes were completely
resistant to radiation-induced apoptosis through 24 hours whereas only 20% of wild-type
thymocytes survived to this time-point. Both p53 R270 H/+ and p5 3 R 172H/+ thymocytes were
partially resistant to gamma-induced apoptosis. The p53"w + thymocytes were more resistant to
apoptosis than p53+- cells, consistent with a dominant effect by point-mutant proteins in
apoptosis. These results are similar to previous experiments on point-mutant p53 thymocytes
generated by Rag2- 1- blastocyst complementation (de Vries et al., 2002).
p53 Gain-of-Function: Mutantp53 Predisposes Mice to Epithelial and Endothelial tumors
To directly evaluate the p53 "gain-of-function" hypothesis in vivo, spontaneous tumor
development in mice expressing only mutant p53 was compared to that in mice lacking p53. If
the point-mutant p53 alleles possess inherent oncogenic functions, p53Ml- mice could have a
more pronounced tumor phenotype than p53 null mice. 41 p53- -, 40 p53R2 70H/- and 45
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p 53R 172H/ - mice were generated as described above. All of the mice required euthanasia or died
by 8.5 months of age, with a mean survival time of 4.4, 4.5 and 4.6 months for the p53 - '-,
p 53 R270H/
- and p5 3 RI72H/- mice, respectively. There was no significant difference in the survival
of p53 mutant mice compared to p53 null mice. (Kaplan-Meyer Log Rank Test, Fig. 5A)
In support of the mutant p53 "gain-of-function" hypothesis, two significant differences were
observed in the tumor spectra of the p53 ~m - mice compared to p53- 1- mice (Fig. 5B). In previous
studies, p53- 1- mice primarily developed lymphomas and sarcomas and rarely developed
carcinomas. Likewise, none of the p53- 1- mice in this study developed carcinomas. In contrast,
carcinomas were observed in 18% of the p53R270H/- mice and 16% of p 53RJ72H/- mice (x2, p=
0.008 for p53R27OH/- and p= 0.015 for p53R72H/-). Carcinomas found in the point-mutant p53
mice arose in a variety of different tissues including lung, small intestine, colon, breast, skin,
liver and pancreas. These tumors developed in mice ranging from 1.5 to 6.9 months of age and,
in one case, two different primary -tarcinoma were observed in the same mouse. Most of the
carcinomas showed evidence of invasion, metastasis or other features commonly seen in
advanced human carcinomas such as desmoplasia and stromal invasion (Fig. 6A-E). In most
instances, the epithelial origin of these tumors was readily apparent through histopathology,
however IHC was also used to support these diagnoses (Sup. Fig. 3E-F, Sup. Table 1).
In addition to epithelial tumors, the point-mutant p53 mice also demonstrated an increased
incidence of hemangiosarcomas (Fig. 5B, Fig. 6F). The p 5 3 R'72H/- mice, in particular, showed a
significant increase to 62% incidence (27/45) compared to 32% (13/41) in the p53 - /- mice (X2, p
= 0.005). These tumors were highly aggressive, demonstrated marked nuclear atypia and stained
positively for the endothelial tumor marker Fli-1 (data not shown).
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Similar to previous studies, 66% of the p53 -' - mice in this study developed hematological
malignancies, primarily T-cell lymphomas. A slight decrease in the incidence of hematological
malignancies was observed in p53W - mice (55% ofp53R2 7 0H/- mice and 50% of p53R72H / - mice),
although there was no shift in the survival time of p53M'- mice with lymphomas. The other
tumors observed in p53'/- mice were found at frequencies similar to that of p53 - mice.
Overall, 32% ofp53 - 1- mice developed multiple tumors compared to 43% ofp53 R270H/ - mice (% 2 ,
p = 0.31) and 57% ofp53R 7 2 H/- mice (x 2, p = 0.02).
Mutant p53 Accumulation in Tumors
Tumors cells from LFS patients often show nuclear accumulation of mutant p53 protein. In order
to determine whether tumors from p53"m+ mice were similar in this respect, IHC for p53 was
performed on tumors from the aging studies. (Sup. Fig. 6A-C, Sup. Table 2). Interestingly,
12/16 carcinomas from p53m+ mice exhibited substantial nuclear accumulation of p53 protein.
Three of the four tumors that did not accumulate p53 were low-grade lung adenocarcinomas.
More advanced lung adenocarcinomas stained positively for p53 accumulation in patches that
correlated with more malignant histology (Sup. Fig. 6C). In addition, 11/13 osteosarcomas in
p53"m+ mice were found to accumulate p53 to high levels in at least a subset of cells.
Several carcinomas that stained positively for p53 also exhibited stromal desmoplasia. In each
case, the stromal cells did not express high levels of p53 (Sup. Fig. 6A,B). Likewise, normal
tissues fromp 53M/+ mice did not show evidence of p53 accumulation. These data might indicate
that residual p53 function in p53 w + mice is sufficient to restrain p53 accumulation in normal but
not neoplastic cells. Alternatively, the tumor cells that accumulated p53 might have lost their
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wild-type p53 allele. Indeed, in determining whether LOH had occurred in p53 M/+ tumors (see
above), it was observed that LOH in a tumor generally correlated with the accumulation of
mutant p53 protein. However, there were several exceptions: tumors were found that had
undergone LOH but did not accumulate mutant p53 and, conversely, that accumulated mutant
p53 but retained heterozygosity. Furthermore, if mutant p53 protein accumulation is dependent
on a loss of wild-type p53 function, it would follow that mutant p53 would accumulate to high
levels in the normal tissues of p5 3M/ - mice, which lack any wild-type p53 function. To test this
directly, IHC for p53 was performed on tumors and normal tissues from p53 w - mice. As shown
in Sup. Table 2, p53 was readily detected in the majority of, but not all, p53f - tumors.
However, in no case was p53 accumulation observed in normal tissues from these mice.
Furthermore, as shown in Sup. Fig. 6D-F, mutant p53 does accumulate in normal tissues of
p53m - mice after gamma irradiation, but only in the same cells and tissues observed to
accumulate p53 in wild-type animals. Thus, tumor associated increases in p53 staining cannot be
ascribed solely to the p53 genotype of the cell but, rather, would appear to reflect a secondary
event that causes mutant p53 stabilization. Interestingly, thymic lymphomas, which occur
frequently in p53 - /- as well as p53M - mice, consistently showed a lack of p53 accumulation,
perhaps indicating that the initiation of this tumor requires only the loss of p53 function.
Loss of Wild-Type Function in p53Ms - Primary Cells
Point-mutant p53 alleles have alternatively been reported to be completely or partially defective
in transactivation (Forrester et al., 1995). In order to determine whether the p53R270H and
p53Rz2H mutants had lost wild-type p53 activity, the cellular assays described above were carried
out on p53M'- and p53- 1- MEFs. No difference was seen between the point-mutant MEFs and
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p53 - - MEFs in basal S-phase fraction or in doxorubicin-induced cell cycle arrest (Sup. Fig. 5A).
p53w' - MEFs were also found to be immortal by 3T3 assay but they were unable to form foci at
high density or to form colonies in soft agar, similar to p53 - - MEFs (Sup. Fig. 5B, data not
shown). Likewise, there was no difference between p53 - /-, p53R270H/- and p53Rl72H/- MEFs in
their abilities to induce colony formation at low density or their abilities to proliferate in low
serum (data not shown). Finally, mutant p53 alleles were defective in inducing apoptosis in
primary thymocytes after gamma irradiation, similar to p53 - /- thymocytes (data not shown).
In order to assess the ability of mutant p53 to transactivate target genes, Western blotting for
p53, p53serl 5, p21 and MDM2 was performed on protein extracts from p53M/- MEFs. Although
mutant p53 accumulated and was phosphorylated in response to doxorubicin treatment, p21 and
mdm2 were not induced in mutant p53 MEFs (Fig. 4b).
Mutant p53 Gain-of-Function in Tumor-Derived Cells
Previous work has demonstrated that overexpression of mutant p53 protein in p53 null cells
results in aggravation of the tumorigenic phenotype of those cells. The reverse experiment,
however, has not been performed on contact or structural mutant p53-bearing cells. We
therefore utilized a conditional lentiviral shRNA expression construct, pSico-p53 (Ventura et al.,
2004), to knock-down mutant p53 expression in an endogenous setting. To allow selection of
cells bearing the conditional shRNA, a puromycin resistance cassette was substituted for the GFP
cassette of pSico-p53, to give pSicoP-p53.
97
In an effort to find a cellular system sensitive to the expression of mutant p53, a cell line, Os l,
was derived from an osteosarcoma metastasis that arose in ap53R 72H/+ mouse. Analysis of DNA
from Os 1 cells indicated that they had lost their wild-type p53 allele (data not shown). Os 1 cells
were infected with pSicoP-p53, selected in puromycin, and then superinfected with either a Cre-
expressing adenovirus (AdCre) or a control adenovirus (AdEmpty). The percentage of cells
infected by AdCre was greater than 90% as assessed by the renewed susceptibility of the cells to
puromycin (the puromycin resistance cassette is lost upon activation of shRNA expression by
Cre). To control for potential side-effects of expressing Cre recombinase, parental Osl cells
were also treated with AdCre (Fig. 7A). The infected cells were expanded and protein was
collected from cells in the presence or absence of the DNA damaging agent (cisplatin). As seen
in Fig. 7B, p53 shRNA expression resulted in substantial knockdown of mutant p53, both before
and after treatment with cisplatin.
In the course of expanding the cells, it was noticed that the p53 shRNA-expressing cells grew
more slowly than the control cells. To quantify this, a proliferation assay was performed on p53
shRNA-expressing and control Osl cells. As seen in Fig. 7C, Osl cells proliferate more slowly
after knockdown of mutant p53. As this experiment took place several passages subsequent to
the initial adenoviral infections, the experiments were repeated just 48 hours after infection with
AdCre or AdEmpty. As seen in Figure 7D, the inhibition of proliferation was even more
dramatic immediately after infection. This effect was visualized by diluting the cells 1:500 with
wild-type MEFs and allowing them to grow to high density (Figure 7E).
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It was previously reported that mutant p53 can bind to and inhibit the fimction of family-member
proteins p63 and p73. In order to determine whether this occurs in Osl cells, p73
immunoprecipitates were probed with an antibody against p53. As shown in Figure 7f, mutant
p53 was coimmunoprecipitated with p73, but not by a mouse antibody specific for an unrelated
protein. Similar results were seen with an antibody against p63 and a second antibody against
p73 (data not shown). Furthermore, qPCR experiments demonstrated an increase in p63 and p73
target gene expression following knockdown of mutant p53 (data not shown). These results
support the inhibition of p63 and p73 by protein-protein interaction as a potential mechanism for
the observed gain-of-function by mutant p53.
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Discussion
Our understanding of the p53 has had a convoluted history. Although it was initially thought to
be a cellular oncogene, a series of observations lead eventually to the classification of p53 as a
suppressor of transformation. While the tumor suppressive functions of wild-type p53 are not in
question, there have been persistent reports that point-mutant p53 proteins can affect
transformation independent of wild-type p53. These studies have led to the suggestion that
point-mutant p53 has gain-of-function oncogenic properties. However, because these
experiments have involved ectopic overexpression of the mutant p53 allele, they have been
interpreted with caution. Here we describe a definitive test for the existence of oncogenic
functions of point-mutant p53.
Several important conclusions can be drawn from the analysis of mice with knock-in alleles of
tumor-derived mutations in p53. First, p53"' + maice are models of Li-Fraumeni syndrome that
better recapitulate the human familial syndrome than do p53 +- mice. Moreover, p53R2 70H/+ mice
develop distinct tumor spectra fromp 53 RI72H/+ mice, indicating that different p53 point-mutations
confer subtly different functions. Specific functional assays on primary cells derived from
p53' + mice also support this conclusion. p53 M/- mice develop tumor spectra distinct from p53
null mice and tumor cells derived from mutant p53 mice are sensitive to the shRNA-mediated
knock-down of mutant p53, strongly supporting a gain-of-function effect by mutant p53.
p53m+ mice are models of Li-Fraumeni Syndrome
Of the twenty or so tumor suppresser genes associated with human familial cancer syndromes,
p53 is unusual in that it is commonly altered through missense mutation rather than deletion and
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because mutant p53 proteins are upregulated i tirore.. A few LFS kindreds have alterations
akin to null alleles of p53. An analysis of seven such families concluded that these patients
developed fewer cancers overall, and at an older age, than LFS patients with point-mutations in
the p53 DBD (Birch et al., 1998). However, a separate study found no difference between point-
mutant and truncation-mutant LFS kindreds (Hwang et al., 2003). The small number of these
patients combined with their diverse genetic backgrounds complicates this analysis. In contrast,
our work shows a clear difference in tumor spectra in p5 3M/+ mice compared to p53 +/- mice.
Although there was no change in survival time of mice with different genotypes, the p53m +mice
developed more tumors and a different spectrum of tumors compared to p53 + /- mice. Moreover,
p53M /+ mice more accurately recapitulate the phenotype of LFS patients in that they develop a
broad spectrum of tumors, including a variety of carcinomas, soft tissue and bone sarcomas,
leukemias and even a glioblastoma multiforine (the most common brain tumor observed in LFS
patients). The most obvious omission froin this tunmor spectrum was breast carcinomas, the most
common tumor in LFS patients. This could be due to the action of a background modifier not
present in the 129S4/SvJae genetic background. Indeed, when crossed to the BALB/c
background, p53 +/- mice develop mammary carcinomas at high frequency (Kuperwasser et al.,
2000). This raises the prospect that crossing the point-mutant p53 mice onto BALB/c or other
backgrounds will further refine the accuracy these models.
Differences between contact and structural mutant p53
While numerous studies have reported biochemical differences between contact and structural
mutant p53 proteins (Halevy et al., 1990; Hinds et al., 1990), our work represents the first clear
evidence of a differential effect on tumorigenesis in vivo. p53R2 70H/+ mice develop an increased
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incidence of carcinomas and B-cell lymphomas compared to p53 +/- mice. p53R 172H/+ mice
develop an increased incidence of metastatic osteosarcomas (and a trend towards more
carcinomas). Among LFS patients, few connections between particular mutations and
phenotypes have been described.
The molecular basis for the difference in tumor spectra between p53R270H/+ and p5 3R172IH+ mice is
unclear, but data derived from primary cells isolated from these mice uncovered some functional
differences between the contact and structural mutant proteins in the presence of wild-type p53.
For example, p 53 R270H/+ MEFs proliferated only modestly faster than p53+1- MEFs while
p53 RI72H/+ MEFs doubled nearly as fast asp53 - 1- cells. In contrast, neither mutant interfered with
the induction of G1 arrest after DNA damage in MEFs.
Dominant effects of mutant p53
In addition to effects on the basal proliferation rate in MEFs, mutant p53 exhibited dominant
effects on radiation-induced apoptosis in thymocytes; p53M/+ thymocytes had levels of apoptosis
intermediate to p53 +/- and p53- 1- thymocytes. The simplest explanation for this effect is that
both p53R270H and p53R172H interfere with the ability of wild-type p53 to transactivate apoptotic
target genes through a dominant-negative mechanism. However, these experiments do not rule
out dominant gain-of-function effects by mutant p53. That is, the decrease in radiation-induced
apoptosis in p53'l + thymocytes may be due to interference with the function of wild-type p53 or
interference with other factors involved in radiation-induced apoptosis.
Similarly, the novel tumor phenotypes of p53M+ mice could be due to either dominant-negative
effects, dominant gain-of-function effects or a combination of both. For example, one
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interpretation of the development of lung carcinomas in p53R270H/+ mice is that this allele confers
a dominant gain-of-function effect because lung carcinomas are rarely observed in p53 - 1- mice.
However, most p53 - 1- mice die before six months of age. Were null mice to avoid other tumors
for 18 months, perhaps they too would be predisposed to lung adenocarcinoma. In order to
assess this properly, p53 function would need to be examined specifically in the lung without
other background tumors. The conditional point-mutantp53 mice presented in this work will be
useful for studying the effects of mutant p53 in particular tissues or at specific developmental
stages.
Mutant p53 gain-of-function
This work presents the first clear in vivo evidence for gain-of-function effects by mutant p53.
Since the initial descriptions of p53 knockout mice, there have been persistent questions as to
why they do not develop more carcinomas when p53 is so often mutated in this class of tumors.
As discussed above, one explanation is that background modifiers that promote the development
of carcinomas in humans may be absent from certain inbred laboratory mouse strains. However,
our data support a model in which epithelial carcinogenesis is enhanced by the production of
point-mutant p53, rather than the loss of p53. p53m'- mice spontaneously develop a variety of
carcinomas in addition to the normal complement of tumors previously associated with p53 null
mutations in mice. Furthermore, mutant p53 accumulation occurred commonly in carcinomas
from p53m - mice but not in lymphoblastic lymphomas. It is also notable that two of the tumors
commonly found in p53 null mice, lymphoblastic lymphomas and teratocarcinomas, rarely
harbor p53 mutations in humans. Rather, both tumors are associated with functional inactivation
of p53, such as through HDM2 overexpression (Eid et al., 1999; Zhou et al., 1995). Likewise,
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HDM2 overexpression is found in over one third of human sarcomas, the third major tumor type
in p53 null mice (Cordon-Cardo et al., 1994; Oliner et al., 1992). These correlations further
support the idea that p53 inactivation (combined with alterations in other genes) is sufficient for
tumorigenic progression in a subset of tissues.
In concurrent work, Guillermina Lozano and colleagues have also generated a p53R172H mouse
through similar techniques (Lang et. al, this issue). Although they observed a similar
spontaneous tumor phenotype in heterozygous mutant p53 mice, they did not observe an increase
in carcinomas or other tumors in p53R172 H /R172H mice. This may be due to differences in strain
background: Lozano's mice were enriched for C57B1/6 while our mice were enriched for
129S4/SvJae.
The data presented here provide strong support for the pro-tumorigenic effects of point-mutant
p53. At the molecular level, several mechanisms have been proposed to explain mutant p53
gain-of-function effects (reviewed in (Cadwell and Zambetti, 2001). For example, mutant p53
may be able to transactivate novel target genes such as mdr, BAG-I, or c-myc. Alternatively,
mutant p53 may participate in novel protein-protein interactions. Perhaps the most well
characterized interaction is with the p53-family members, p63 and p73. These two genes share a
high degree of homology with p53 and are capable of transactivating several p53 target genes in
response to DNA damage. p63 and p73 are also activated by DNA damage, similar to p53
(Irwin et al., 2000; Jost et al., 1997; Yang et al., 1998). Several reports have shown that mutant
p53 can bind to and inactivate p63 and p73 (Di Como et al., 1999; Gaiddon et al., 2001; Marin et
al., 2000; Strano et al., 2000). We also found mutant p53 capable of binding to its family
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members in tumor cells derived from a p53R 17 2 H osteosarcoma metastasis. The multiple splice
variants of p63 and p73 complicate our understanding of their role in tumorigenesis. Although
deletions of p63 or p73 are rare in human tumors, overexpression of ANp63 is common in human
squamous cell carcinomas (Hibi et al., 2000) and overexpression of ANp73 correlates with poor
outcomes in human neuroblastomas (Casciano et al., 2002). Nonetheless, the classification of
p63 and p73 as tumor suppresser genes has yet to be commonly accepted. It is therefore striking
that compound mutation of p53 with either p63 or p73 results in mice bearing tumor spectra
reminiscent of those seen in the mutant p53 mice presented in this study (E. Flores et. al,
submitted). Taken together, these data strongly implicate the inhibition of p63 or p73 as a
potential mechanism for point-mutant p53 gain-of-function.
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MATERIALS AND METHODS
Generation of Conditionally Inactive Mutantp53 Mice
The LoxP flanked conditional STOP cassette (Tuveson et al., 2004) was cloned into the Xhol
site in intron 1 of the murine p53 locus. The 270H missense mutation was generated as
described (de Vries et al., 2002). To generate the 172H missense mutation, the 1.7 kb Xbal-
BamH1 p53 genomic fragment containing exons 4 and 5 were cloned into pBluescript and site-
directed mutagenesis was performed using the Stratagene QuickChange kit with the following
oligonucleotides: (172H mutation in bold) F- 5'-cggaggtcgtgagacactgcccccaccatga-3' R- 5'-
tcatggtgggggcagtgtctcacgacctccg-3'
Targeting vectors were assembled in pBS and the sequences of all exons and intron-exon
boundaries were confirmed by bidirectional sequencing prior to gene targeting in J1 ES cells.
Targeting vectors were linearized at a unique 5' Notl site, and electroporated in to J1 ES cells.
ES cells were selected in 2ug/ml puromycin and appropriately targeted clones were identified
with a 5' external probe and EcoR1 digested genomic DNA. An internal puromycin cDNA
probe confirmed single copy insertion. The presence or absence of the mutation was established
in genomic DNA from the ES cell clones. Germline transmission was achieved in 3/3 clones
harboring the p53 LSLR270H allele and 2/2 clones harboring the p 53 LSLR1 72H allele.
The presence of the 270H mutation was established by PCR amplification of a 565bp genomic
fragment encompassing exons 7 and 8: F- 5'-cgcgccggctctgagtatac-3' R- 5'-
cgcttgcgctccctgggggc-3'. The reverse primer was used for sequencing. 56/182 clones contained
the stop cassette; of these 9/56 contained the novel Msll site and the 270H mutation (de Vries et
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al., 2002). Two clones negative for the Msll site were sequenced and found to harbor
exclusively wild-type p53. The 172H mutation was identified after amplification of a 404bp
genomic fragment that contained exons 5 and 6: F- 5'-tctcttccagtactctcctcc-3'; R- 5'-
aattacagacctcgggtggct-3', with the following primer used for sequencing: 5'-
aagctattctgccagctggcg-3'. 27/182 clones contained the stop cassette, and of these, 13/27
unambiguously harbored the 172H mutation.
To determine the presence of the LSL cassette in intron 1 of p53, genomic DNA was amplified
using the following primers to generate wild-type band of 170bp and a mutant band of 270bp.
WT F- 5'-ttacacatccagcctctgtgg-3', Mutant F- 5'-agctagccaccatggcttgagtaagtctgca-3', R- 3'-
cttggagacatagccacactg-3'. To determine the presence of the recombined alleles of mutant p53,
genomic DNA was amplified using the following primers flanking the integration site of the
remaining LoxP site in p53 intron 1: F- 5'-agcctgcctagcttcctcagg-3', R- 5'-ctt
ggagacatagccacactg-3'.
Aging Study
Aging cohorts were produced by mating p53R270H/ - or p53 R172H/ - mice to p53+1- mice (19 p53+1-
mice and 30 p53- /- mice were derived from the p5 3 R270H cross while 18 p53+/- mice and 14- / -
mice were from the p 53 RI72H cross). Aging mice were between 93% and 97% enriched for the
129S4/SvJae genetic background. Routine testing of sentry mice indicated the colony was
pathogen free. Ill or distressed mice were euthanized by CO2 asphyxiation and all tissues except
skin were fixed in 10% formalin/PBS for 24 hours (soft tissues) or Bouin's fixative for 3 weeks
(bones). Tissues were embedded in paraffin, sectioned at 5 microns, dewaxed and stained with
107
hematoxylin and eosin. Tumors were identified with the assistance of a veterinary pathologist
(R.B.).
Immunoblotting
Standard techniques were employed for immunoprecipitations and Western Blotting. mg
samples were immunoprecipitated with 10gL of FL-393 (Santa Cruz), p53 Ab3 (Oncogene
Research Products (ORP)), p53 Ab5 (ORP), p73 Ab2 (ORP) or mdm2 Ab2 (ORP). Western
Blots were probed with the following antibodies: p53 Ab7 (1:2500, ORP JA1308), SC-1616
(1:2000, Santa Cruz), SC-6426 (1:1000, Santa Cruz), mdm2 Ab-2 (1:1000, ORP).
Immunohistochemistry
Paraffin-embedded tissues were prepared through standard techniques. 5 micron sections for
F4/80 staining were unmasked in 0.00025% trypsin/PBS for 20 minutes, 37°C. For all other
antibodies, 5 micron sections were unmasked in a pressure cooker for 10-minutes in 0.01M
sodium citrate, pH6.0. Endogenous peroxidases were quenched for 10 minutes in 1% hydrogen
peroxide solution in PBS. Staining was performed using the Cadenza system according to
directions (Thermo Shandon, 407340). Slides were incubated with the following primary
antibodies for 12hrs at 4C: p53 Ab7, 1:500 (Oncogene Research Products (ORP), JA1308);
CK8, 1:250 (Research Diagnostics, RDI-PRO61038); CM5, 1:250 (NCL-p53-CM5p ); a-
Smooth Muscle Actin, 1:100 (Research Diagnostics, RDI-ACTINabm-A4); CK14, 1:500
(Covance, PRB-155P), B220, 1:200 (BD Biosciences, #553090); F4/80, 1:200 (MCAP497).
Detection was performed using ABC Peroxidase kits per directions. PAS and Trichrome
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staining was performed using kits from Polyscientifi:; r&D, (K047, K037). Whole-mouse
irradiation was performed with a GammaCell 40 eF-ci.pped with a 137Cs source.
Cellular Assays
Thymocyte apoptosis was performed as described previously (de Vries et al., 2002). For cell
cycle analysis, lx106 MEFs were plated in 10cm2 plates in DME/HEPES + 10% FBS + 5mM L-
glutamine + Pen/Strep. After 24 hours, if indicated, cells were treated with 0.2pg/mL
doxorubicin. After 12 hours BrdU was added to 10I1M for 4 hours. Cells were collected in
trypsin, quenched with medium and washed in PBS; FACS analysis was performed as described
(Kastan et al., 1992). Tumor-derived cell lines were grown on plastic in DME/HEPES + 10%
FBS + Pen/Strep.
Quantitative Real-Time RT-PCR
Total RNA was extracted from cells and tissue with the RNAeasy kit (Qiagen, 74104). 2ug of
RNA was reverse-transcribed using anldo hexamers and Superscript III (Invitrogen, 18080-
044). Quantitative real-time PCR was performed on the ABI 7700 Sequence Detection System
using the SYBR Green kit (Applied Biosystems, 4309155) and the following primers: p53-5':
cccctgtcatcttttgtccctt; p53-3': gggaggagagtacgtgcacataa; p21 -5': gacaagaggcccagtacttcct; p21 -3':
caatctgcgcttggagtgata; P-Actin-5': cttcaacaccccagccatgta; -Actin-3': catcacaatgcctgtggtacg. All
reactions were performed in triplicate with 3-Actin as the standard.
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Lentiviral shRNA Experiments
The GFP cassette was removed from pSico-p33 by ERI/Notl digestion and an EcoRl/Notl
fragment of PGK-Puro was ligated in its place to give pSicoP-p53. Lentiviral infections were
performed essentially as described (Ventura et al., 2004) except that 293 cells were transfected
using the Calphos kit (Clonetech). Recombinant adenoviral stocks were purchased from the
Gene Transfer Vector Core facility of the University of Iowa College of Medicine (Iowa City,
IA). Adenoviral infections used -2000 plaque-forming units of virus per cell.
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Figure 1. Generation, Targeting and Verification of Conditional Point-Mutantp53 Alleles.
(A) The endogenous p53 locus is depicted at top, followed by targeting vectors for the
p5 3 LSLR270H andp 53LSLRl72H alleles. Asterisks indicate the sights of the point mutations. The
integrated mutant p53 alleles are shown at bottom. Restriction sites are indicated: R, EcoRI; B,
BamHI; H, HinDIII; X, Xho; Nd, NdeI, Xb, Xba; S, Sal.
(B) PCR amplification of conditional mutant alleles results in both a 270bp mutant-specific
product and a 166bp control product.
(C) PCR primers flanking the LSL cassette integration site yield a 290bp wild-type band and a
330bp product mutant p53 band.
(D) Sequence-traces from p 53 LSLR270 H/+ (bottom) and p53 R270H/+ (top) mouse brain cDNAs. N
indicates expression of both the wild-type allele (C) and the mutant allele (T).
(E) qRT-PCR analysis of p53 in WT, p53R172 H/ - andp53R 27 H/- MEFs. Histograms depict log2
induction relative to background in p53- /- MEFs and are the average of three different MEF
lines, each assayed in triplicate. Error bars indicate standard error.
(F) Western blot analysis of MEF whole-cell lysates shows accumulation of mutant p53 proteins.
(G) Conformation of mutant p53 proteins was determined by immunoprecipitation of p53
proteins from 1000g of MEF whole cell lysates with 10iL of eitherp53 Ab5 (ORP), p53 Ab3
(ORP) or FL-393 (Santa Cruz), followed by Western blotting with p53 Ab7 (ORP).
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Figure 2. Mice Heterozygous for Mutant p53 Develop Novel Tumors
(A) Kaplan-Meyer plot demonstrates no difference in survival time between p53 +1-, p5 3 R270H/+,
and p53 R172H/+ mice.
(B) Distinct tumor spectra in p53M + mice. Histograms show the fraction ofpS3 +/- (blue),
p 53 R270H/+ (red) and p 5 3 Rl72H/+ mice (green) mice that developed carcinomas, adenomas,
hemangiosarcomas, B-cell lymphomas or osteosarcomas. See Sup. Figure 1 for an expanded
summary of the pathology of these mice.
(C) PCR analysis was performed on matched tumor (T) and somatic (S) DNA samples to look
for LOH. At left is a dilution series of p53M/M and p53+/+ DNA demonstrating the sensitivity of
this assay.
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Figure 3. Dominant effects by mutant p53 in primary cells.
(A) S-phase fraction inp53Ml+ MEFs. Cell cycle analysis was performed on exponentially
growing MEFs. Histograms represent the percent of untreated cells (solid bars) or doxorubicin-
treated cells (hashed bars- 0.2gg/mL, 12hrs) in S-phase as measured by FACS analysis of
bromo-deoxyuridine and propidium iodide incorporation. Histograms show the average values
of four independently derived MEF lines for each genotype. Error bars show standard deviation.
Complete cell cycle data are presented in Sup. Figure 3a.
(B) Apoptosis in thymocytes from p53M + mice. Thymocytes were isolated from 6-9 week old
mice and treated with 5Gy of y-radiation. Apoptosis was measured by FACS analysis of
Annexin-V expression and propidium iodide exclusion. Graph depicts the percentage of viable
cells (Annexin-V negative, propidium iodide negative) at 12 and 24 hours post treatment,
normalized to untreated controls. The average values from at least 3 mice per genotype are
shown.
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Figure 4. p5 3 Target Gene Expression in Mutant p53 Cells
(A) Immunoblots for p53, 4-ser'5-p53 and p21 on MEF whole cell lysates are shown. Mdm2
immunoprecipitates from the same extracts are also shown.
(B) Immunoblots for p53, O-ser 5-p53 and p21 on MEF whole cell lysates are shown. Mdm2
immunoprecipitates from the same extracts are also shown.
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Figure 5. Point-Mutant p53 Mice Develop Novel Tumors Compared to p53 Knockout Mice
(A) Kaplan-Meyer Plot demonstrates no difference in survival time ofp53t p53R2 7 0 H/- and
p53R1 2 H/- mice.
(B) Histograms show the fraction ofp53 - / - (blue), p53R270H/ - (red) and p53R 72H/- mice (green)
mice that developed carcinomas, brain tumors, primitive tumors (mostly teratocarcinomas), soft-
tissue or bone sarcomas, endothelial tumors, or hematological tumors.
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Figure 6. Histopathology of Point-Mutantp53 Tumors stained with hematoxylin and eosin.
(A) A moderately differentiated p53 R 72H/- colon adenocarcinoma with a high mitotic index,
severe nuclear dysplasia (arrows), desmoplasia and stromal invasion. (400X)
(B) A p 53RI7 2H/ - squamous cell carcinoma with well differentiated cells forming a keratin pearl
(K) and poorly differentiated cells alone or in small clusters (arrows) surrounded by tumor
stroma. (400X)
(C) A highly pleomorphic hepatocellular carcinoma (T) from a p53R27 0H/- mouse. Note the
bizarre, oversized nuclei found within the tumor compared to the nuclei of adjacent normal liver
cells (N). (400X)
(D) Intra-lymphatic metastasis (M) from ap53R7 2 H/- colon adenocarcinoma. Arrow indicates
the lymphendothelium. (400X)
(E) Wright-Giemsa stained peripheral blood smear from a p53R 7 2 H /- mouse with a colon
adenocarcinoma. Circulating tumor cells are indicated (T) including an actively dividing,
polyploid cell with a roughly 8N complement of chromosomes. Nearby are a normal neutrophil
(N) and a cluster of platelets (P). (100OX)
(F) A p53R172H/- hemangiosarcoma. (400X)
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Figure 7. Mutant p53 Gain-of-Function in Tumor-Derived Cells
(A) Os cells were infected with pSicoP-p53 and AdCre in order to knock down endogenous
mutant p53 expression. Control cells were infected with AdCre alone or pSicoP-p53 + AdEmpty.
(B) Western blot for p53 in Osl + pSicoP-p53 after infection with AdCre or AdEmpty
demonstrate a strong shRNA-mediated knock-down of mutant p53. The membrane was also
probed with an antibody against vinculin as a loading control.
(C-D) Osl cells proliferate more slowly after mutant p53 knockdown. 3 x 104 cells/well were
plated in 12 well dishes and cells from two wells were counted daily. Experiments were initiated
either three passages after adenoviral infection (C) or immediately following infection (D).
(E) Os 1 cells proliferate to higher density prior to mutant p53 knockdown. Immediately
following adenoviral infection, 2 x 104 Osl cells were diluted into lx 106 wild-type MEFs and
plated in 10cm dishes. After 1 week, cells plates were stained with Wright-Giemsa. Darker
staining in plates without mutant p53 KD reflect the ability of Osl cells to rapidly grow to high
density rather than their ability to form classic foci.
(F) Mutant p53 is coimmunoprecipitated by p73 Ab2 (ORP), but not by a control antibody.
Immunoblot was performed using p53 Ab7.
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Supplemental Figure 1. Full Tumor Spectrum of p53Ml+ Mice. p53Ml+ mice develop distinct
tumor spectra. Histograms represent the fraction ofp53 +1- (blue), p5 3 R270H/+ (red) and
p53 R l72H/+ mice (green) mice that developed the indicated pathologies.
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Supplemental Figure 2. Histopathology ofp 53M+ Mouse Tumors Stained with H&E.
(A) Lung adenocarcinoma in a p53R2 7 0H/+ mouse. D indicates the presence of a desmoplastic
stroma. Arrow indicates a small cluster of tumor cells embedded in tumor stroma. (400X)
(B) Squamous cell carcinoma in ap53 R270H/+ mouse. This highly malignant tumor arose in the
epidermis of the face and invaded through the skull into the brain, destructively penetrating the
cerebellum. (4X)
(C) Metastases from a lung adenocarcinoma in a thoracic lymph node from ap53R 7 2 H/+ mouse.
(400X)
(D) Desmoplasia and stromal invasion in an intestinal adenocarcinoma from ap53R2 70H/+ mouse.
Most of these tumors cells are poorly differentiated and have lost their glandular architecture
although one small structure can be observed at the left side of the panel. (400X)
(E) Osteosarcoma metastases in the liver of ap53RI72Hw+ mouse. (4X)
(F) Osteosarcoma metastasis in the lung of ap53 Rl7 2H+ mouse. (400X)
134

Supplemental Figure 3. Immunohistochemistry onp53M+ and Point-Mutantp53 Tumors
(A) Cytokeratin 14 staining of a squamous cell carcinoma invading the cerebellum of a
p53 R172HI+ mouse (see Supplemental Figure S2b for H&E stain). (200X)
(B) B220 IHC in a p53R270H/+ B-cell lymphoma invading intestinal crypts. (400X)
(C) F4/80 IHC in p53R 72H/+ histiocytic sarcoma cells diffusely infiltrating the sinusoids of the
liver. (400X)
(D) Cytokeratin 8 IHC in a p5 3 R2 7 OH/- colon adenocarcinoma shows cytoplasmic staining in
more well differentiated tumor cells. (200X)
(E) Periodic Acid Schiff staining (in pink) of a p53R27 OH/- acinar pancreatic adenocarcinoma
shows evidence of zymogen granules (arrows) in more well differentiated tumor cells. (1000X)
(F) Trichrome staining on a p53R270 H/- colon adenocarcinoma showing evidence of desmoplasia
(collagen stains light blue). (400X)
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Supplemental Figure 4. 3T3 Immortalization and Cell Cycle Analysis ofp53Mv+ MEFs.
(A) Cell cycle analysis was performed on exponentially growing p3+/+'p53+/-, p53 - ,
p53 270H /+, and p53 Rl72H/+ MEFs. Histograms represent the percent of untreated cells (solid bars)
or doxorubicin-treated cells (hashed bars- 0.2gg/mL, 12hrs) in G1, S or G2/M phases as measured
by FACS analysis of bromo-deoxyuridine and propidium iodide incorporation. Data represents
the average values of four independently derived MEF lines for each genotype.
(B) Immortalization assays were performed onp53+ + ,p53+ - , p53- , p53R27OH/+, andp53R172H/+
MEFs using the 3T3 protocol. Lines represent the average cumulative population doublings for
four independently derived MEF lines for each genotype. Inset shows the first four doublings
more clearly.
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Supplemental Figure 5. 3T3 Immortalization and Cell Cycle Analysis of Mutant p53
MEFs.
(A) Cell cycle analysis performed on exponentially growing p53 +/+ p53-1/-, p53R270H/-, and
p53R172H / - MEFs. Histograms represent the percent of untreated cells (solid bars) or
doxorubicin-treated cells (hashed bars- 0.2gg/mL, 12hrs) in G1, S or G2/M phases as measured
by FACS analysis of bromo-deoxyuridine and propidium iodide incorporation. Data represents
the average values of four independently derived MEF lines for each genotype.
(B) Immortalization assays were performed on p53+ /+ , p53- -, p53R 270H/- and p53R 7 2H/-MEFs
using the 3T3 protocol. Lines represent the average cumulative population doublings for four
independently derived MEF lines for each genotype.
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Supplemental Figure 6. Accumulation of Mutant p53 in Tumor Cells.
(A) p53 IHC on ap53R2 7 ° H/+ squamous cell carcinoma demonstrating strong nuclear
accumulation of mutant p53 in tumor cells but not normal cells. Arrow indicates an aberrant
mitosis. (400X)
(B) p53 IHC on ap53R 27 OH/- hemangiosarcoma. The large, pleomorphic tumor cells accumulate
mutant p53 while surrounding normal cells do not. (400X)
(C) p53 IHC on a p53R 7 2 H/+ lung adenocarcinoma. (L) indicates a less aggressive region of the
tumor, with organized cells that form glandular structures, and smaller, more regular nuclei. (H)
indicates a more aggressive region with poor organization, enlarged and irregular nuclei and
desmoplasia (unstained, white regions). Strong p53 accumulation is restricted to the more
aggressive regions of the tumor. (400X)
(D-F) p53 IHC on normal p53+/+ (D), p5 3 RI7 2 H/ - (E) and p 5 3 R270 H /- (F) intestines. Each panel
presents sections from untreated mice (left) and from mice 24 hours after receiving 8Gy of
whole-body gamma radiation. All six images were acquired with equal contrast and brightness
settings. Mutant p53 accumulates to high levels in many cells of the intestinal crypts after
irradiation. (400X)
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Supplemental Table 1- Indicates immunohistochemistry (IHC) performed on tumors to confirm
their diagnosis as carcinomas.
ID Gn Tumor IHC
K2950 R172H/- Ductal Pancreatic Carcinoma CK8+
K3080 R172H/- Colon Adenocarcinoma CK8+
K3846 R1 72H/- Lung Adenocarcinoma CK8+
K1274 R270H/- Lung Adenocarcinoma CK8+
K1275 R270H/- Pancreatic Acinar Adenocarcinoma PAS+, Flil-
K1521 R270H/- Colon Adenocarcinoma CK8+
K1765 R270H/- Colon Adenocarcinoma CK8+
K3068 R172H/+ Lung Adenocarcinoma CK8+
K3262 R172H/+ Rectal Carcinoma CK8+
K3441 R172H/+ Lung Adenocarcinoma CK8+
K3738 R172H/+ Lung Adenocarcinoma CK8+
K1 074 R270H/+ Lung Adenocarcinoma CK8+
K1074 R270H/+ Squamous Cell Carcinoma CK14+
K1276 R270H/+ Intestinal Adenocarcinoma CK8+
K1280 R270H/+ Lung Adenocarcinoma CK8+
K1438 R270H/+ Squamous Cell Carcinoma CK14+
K1440 R270H/+ Lung Adenocarcinoma CK8+
K1518 R270H/+ Lung Adenocarcinoma CK8+
K1545 R270H/+ Squamous Cell Carcinoma CK14+
K1555 R270H/+ Squamous Cell Carcinoma CK14+
K1674 R270H/+ Squamous Cell Carcinoma CK14+
K1 770 R270H/+ Lung Adenocarcinoma CK8+
K1549 +/- Lung Adenocarcinoma CK8+
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Supplemental Table 2- p53 protein accumulation in mutant p53 mouse tumors. 0- no accumulation, 1- weakly
positive staining 2- strongly positive staining
ID Gntp Tumor p53 ID Gntp Tumor p53
K3436 +/- Bladder Carcinoma ++ K1341 - BCL 0
K1532 +/- Histiocytic Sarcoma + K1661 - BCL 0
K1658 +/- Histiocytic Sarcoma 0 K1313 - Hemangiosarcoma 0
K3424 +/- Histiocytic Sarcoma 0 K1603 - Hemangiosarcoma 0
K1442 +/- Leiomyosarcoma 0 K1733 - Hemangiosarcoma 0
K1549 +/- Lung Adenocarcinoma 0 K1548 - Histiocytic Sarcoma 0
K1549 +/- Osteosarcoma 0 K3442 - Histiocytic Sarcoma 0
K3482 +1- Osteosarcoma 0 K1075 -I- TCL 0
K3659 +/- Osteosarcoma 0 K1527 - TCL 0
K3743 +1- Osteosarcoma 0 K1656 R270H/- Rhabdomyosarcoma ++
K1076 R270H/+ BCL ++ K1519 R270H/- BCL +
K1520 R270H/+ BCL ++ K1668 R270H/- breast carcinoma ++
K1551 R270H/+ BCL 0 K1521 R270H/- Colon Carcinoma ++
K1623 R270H/+ BCL ++ K1765 R270H/- Colon Carcinoma 0
K1730 R270H/+ BCL 0 K1149 R270H/- Hemangiosarcoma ++
K1671 R270H/+ Histiocytic Sarcoma ++ K1620 R270H/- Hemangiosarcoma ++
K1732 R270H/+ Histiocytic Sarcoma 0 K1654 R270H/- Hemangiosarcoma ++
K1782 R270H/+ Histiocytic Sarcoma ++ K1762 R270H/- Hemangiosarcoma ++
K1276 R270H/+ Intestinal Carcinoma ++ K1783 R270H/- HCC 0
K1074 R270H/+ Lung Adenocarcinoma ++ K1274 R270H/- Lung Adenocarcinoma ++
K1280 R270H/+ Lung Adenocarcinoma ++ K1274 R270H/- Myelogenous Leukemia ++
K1440 R270H/+ Lung Adenocarcinoma 0 K1240 R270H/- Osteosarcoma ++
K1518 R270H/+ Lung Adenocarcinoma 0 K1275 R270H/- Pancreatic Carcinoma ++
K1555 R270H/+ Lung Adenocarcinoma ++ K1546 R270H/- Rhabdomyosarcoma 0
K1770 R270H/+ Lung Adenocarcinoma ++ K1668 R270H/- Rhabdomyosarcoma 0
K1518 R270H/+ Myelogenous Leukemia 0 K1245 R270H/- TCL 0
K1277 R270H/+ Osteosarcoma ++ K1279 R270H/- TCL 0
K1551 R270H/+ Osteosarcoma + K1526 R270H/- TCL +
K1611 R270H/+ Osteosarcoma ++ K1600 R270H/- TCL 0
K1770 R270H/+ Osteosarcoma ++ K1657 R270H/- TCL +
K1074 R270H/+ SCC ++ K1876 R270H/- TCL 0
K1438 R270H/+ SCC ++ K1886 R270H/- TCL 0
K1545 R270H/+ SCC ++ K1613 R270H/- Undiff. Neoplasm 0
K1674 R270H/+ SCC ++ K3662 R172H/- BCL 0
K1280 R270H/+ Undiff. Neoplasm ++ K4031 R172H/- BCL ++
K3325 RI 72H/+ BCL 0 K3662 R172H/- BCL 0
K3557 R172H/+ BCL ++ K3080 R172H/- Colon Carcinoma ++
K3653 R172H/+ Pancreatic Carcinoma 0 K2950 R172H/- Pancreatic Carcinoma ++
K3435 R172H/+ Hematological Tumor 0 K3660 R172H/- Hemangiosarcoma ++
K3354 R172H/+ Histiocytic Sarcoma ++ K3825 R172H/- Hemangiosarcoma ++
K3654 R172H/+ Histiocytic Sarcoma 0 K3236 R172H/- Hemangiosarcoma ++
K3068 R172H/+ Lung Adenocarcinoma 0 K4106 R172H/- Hemangiosarcoma ++
K3441 R172H/+ Lung Adenocarcinoma ++ K2927 R172H/- HCC 0
K3738 R172H/+ Lung Adenocarcinoma ++ K3349 R172H/- Histiocytic Sarcoma 0
K3328 R172H/+ Myelogenous Leukemia ++ K3909 R172H/- Leiomyosarcoma 0
K2955 R172H/+ Osteosarcoma ++ K4099 R172H/- Leiomyosarcoma ++
K3265 R172H/+ Osteosarcoma ++ K3846 RI 72H/- Lung Adenocarcinoma ++
K3266 RI72H/+ Osteosarcoma ++ K3919 R172H/- Myelogenous Leukemia ++
K3325 R172H/+ Osteosarcoma ++ K3545 R172H/- Osteosarcoma 0
K3328 RI 72H/+ Osteosarcoma ++ K4027 R172H/- Rhabdomyosarcoma 0
K3354 RI 72H/+ Osteosarcoma ++ K2927 R172H/- SCC 0
K3422 R172H/+ Osteosarcoma 0 K3946 R172H/- SCC ++
K3477 R172H/+ Osteosarcoma ++ K3291 R172H/- TCL +
K3620 R172H/+ Osteosarcoma ++ K3080 R172H/- TCL +
K3262 R172H/+ Rectal carcinoma ++ K3273 R172H/- TCL 0
K3497 R172H/- TCL 0
K3910 R172H/- TCL +
K3552 R172H/- TCL 0
K3850 R172H/- TCL 0
K3946 R172H/- TCL 0
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ABSTRACT
We report the creation of a murine model of spontaneous advanced lung adenocarcinoma
through compound mutation of K-ras and p53 which closely recapitulates several aspects of
advanced human pulmonary adenocarcinoma. We generated conditional knock-in mice with
mutations in K-ras combined with one of three p53 alleles: a contact mutant, a structural mutant
or a null allele. p53 loss strongly promoted the progression of K-ras-induced lung
adenocarcinomas. Strikingly, the contact mutant p53 R270H, but not the structural mutant p53 R'72H
acted in dominant-negative fashion in this system. Furthermore, a subset of these mice also
developed nasopharyngeal carcinoma (NPC). In contrast to the lung tumors, expression of the
point-mutant p53 alleles strongly promotes the development of NPCs compared to simple loss-
of-function.
SIGNIFICANCE
K-ras and p53 mutations are common in human lung adenocarcinomas; the K-ras pathway and
p53 family-members are commonly altered in NPC. Building on these observations, this work
yielded the first murine model of nasopharyngeal carcinoma and the first model of lung
adenocarcinoma to recapitulate the hallmark features of advanced lung cancer. Furthermore, this
work clearly demonstrates the tissue-specific effects of mutant p53. Specifically, while
expression of mutant p53 in the absence of wild-type p53 promoted the development of NPCs, it
did not influence lung tumor development differently than loss of p53 function. The observation
of a dominant-negative effect by p53R270H, but not p53R72H, may explain the over-representation
of codon 273 mutations and the under-representation of codon 175 mutations in human lung
adenocarcinomas.
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INTRODUCTION
Lung cancer is the leading cause of cancer deaths worldwide, with 171,900 new cases and
157,200 deaths predicted for the year 2003 in the United States alone (Jemal et al., 2003). For
treatment purposes lung cancer is divided into two classes: small cell lung cancer, which
comprises -20% of cases, and non-small cell lung cancer (NSCLC), which comprises the
remainder. NSCLC is further subdivided into 3 histologic subtypes: large cell carcinoma,
squamous cell carcinoma and adenocarcinoma. Adenocarcinoma is the single most common
form of lung cancer, comprising -40% of cases (Jemal et al., 2003). The prognosis of patients
with NSCLC is determined mainly by the stage of disease at the time of diagnosis. A 5-year
survival rate of about 50% can be achieved in patients diagnosed with early stage disease that
can be treated surgically. However, in the majority of patients, the cancer has invaded the
surrounding tissues and spread to regional lymph nodes or distant organs by the time of
diagnosis, making their prognosis far worse.
Activating mutations in the K-ras proto-oncogene are found in -30% of human NSCLCs
(Rodenhuis et al., 1988), and are also found in a large percentage of sporadic and carcinogen-
induced lung tumors in mice (Herzog et al., 1997). Recently, several mouse lung cancer models
have been created using conditionally or spontaneously activatable transgenic and knock-in
alleles of oncogenic K-ras (Fisher et al., 2001; Jackson et al., 2001; Johnson et al., 2001a;
Meuwissen et al., 2001). These models have contributed significantly to our understanding of
the role of K-ras in tumor initiation, and in maintenance of the tumor phenotype. However,
these models do not accurately recapitulate all aspects of the human disease. In particular, the
lung tumors that develop in these models resemble early-stage human lung adenocarcinoma.
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Features of late stage disease, including invasion of the surrounding pleura, induction of
desmoplastic stroma and metastasis are not prominent.
Alterations in the p53 tumor suppressor gene are also common in NSCLC, occurring in -50% of
cases (Chiba et al., 1990; Takahashi et al., 1989). Similar to other cancers, the majority of these
alterations are missense mutations that result in the accumulation of high levels of mutant p53
protein. Studies of p53 mutations from a variety of tumors show that missense mutations in p53
occur primarily in the DNA binding domain (DBD). The frequency of mutation at individual
codons can vary dramatically between tumor types. The most common p53 missense mutations
in human pulmonary adenocarcinomas occur in descending order at codons 273, 248, 249, 245,
and 158 (Olivier et al., 2002). Of note, mutations at codon 175 are significantly less common in
lung adenocarcinomas than in other cancers. This may suggest a difference in the tumorigenic
potential of individual mutant p53 proteins in different tissues. Indeed, p53 mutations are
commonly grouped into two classes that display different behaviors in several in vitro assays
(Cadwell and Zambetti, 2001). Class I mutations alter residues that make direct contact with
DNA, while Class II mutations alter residues that are critical for maintaining global domain
structure (Cho et al., 1994). Structural mutants are frequently described as more potent
mutations than contact mutants in promoting cancer. However, in the case of NSCLC, structural
mutations at codon 175 are found at a decreased frequency compared to the contact mutations at
codons 273 and 248.
An alternative explanation for the variation in mutation frequency between tumor types is that
different codons may vary in their exposure and susceptibility to mutagens. For example,
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mutations at codon 249 are found in over 34% of spontaneous hepatocellular carcinomas but in
only 3% of tumors overall. This is due primarily to a common G-T transversion at codon 249
induced by food contamination with aflatoxin B (Bressac et al., 1991; Hsu et al., 1991). In the
case of lung cancer, -90% of tumors are associated with exposure to carcinogens from tobacco
smoke. It has been shown that polycyclic aromatic hydrocarbons found in tobacco smoke, such
as benzo[a]pyrene diol epoxide, preferentially bind to and form adducts with several of the p53
codons frequently mutated in lung cancer, including codons 273 and 248. However, this may not
completely explain the distribution of p53 mutations in lung cancer since these compounds also
efficiently form adducts at codon 175 (Smith et al., 2000). In general, the presence of point-
mutant p53 confers an adverse prognosis in patients with pulmonary adenocarcinoma (Ahrendt et
al., 2003; Mitsudomi et al., 2000).
Tumor-derived p53 mutations can have two broad effects beyond simple loss of function. There
is significant evidence that mutant p53 alleles can act in a dominant-negative manner to inhibit
the function of wild-type p53 through hetero-oligomerization between mutant and wild-type p53
polypeptides. In vitro studies have demonstrated that both classes of mutants can exert
dominant-negative effects on wild-type p53 activity with the effects being stronger for class II
mutants (Sigal and Rotter, 2000). Furthermore, certain point-mutant p53 alleles have been
shown to promote tumorigenesis through gain-of-function effects that are not dependent on wild-
type p53 (Dittmer et al., 1993).
We recently generated two strains of conditional point-mutant p53 mice that allow for
endogenous expression of mutant p53 upon Cre-mediated recombination (Olive et. al, in press,
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Cell). The first strain carries the contact mutation p5 3 R270H (homologous to human p53 R273H)
while the second strain carries the structural mutation p53R172H (homologous to human p53R1 75 H).
Germline point-mutant p53 mice derived from these strains demonstrated a gain-of-function in
the development of epithelial and endothelial tumors. Furthermore, p53270H /+ mice, but not
p53R172 H /+ mice, had a significantly increased incidence of lung adenocarcinomas compared to
p5 3+/ - mice. These data support the notion that the p53R270H mutant drives the development of
lung adenocarcinoma more strongly than the p53R172H mutant. However, the relatively small
number of lung tumors that developed in this study and the high incidence of background tumors
prevented a thorough analysis of this effect. Furthermore, it was unclear from this work whether
the increase in lung adenocarcinomas was the result of a dominant-negative or a gain-of-function
effect by p5 3 R270H, since p53 null mice do not survive for the -18 months it took the
heterozygous mutant p53 mice to develop lung cancer. This distinction requires an assessment
of the influence of mutant and null p53 on lung cancer at comparable time-points.
We report here the creation of an improved murine lung cancer model through the generation of
compound mutant animals with conditional mutations in K-ras and p53. This model closely
recapitulates several aspects of advanced human pulmonary adenocarcinoma not commonly seen
in existing models. To gain further insights into putative dominant-negative and gain-of-
function effects of p53 missense mutations in vivo, we have used this model to directly compare
the oncogenic properties of different p53 mutations (p53R270H p53R172H and a loss-of-function
mutation of p53), in the context of K-ras-induced lung tumors. Our comparison of mutant K-
ras-induced lung tumors with mutant or null alleles of p53 clearly demonstrates a dominant-
negative effect by the p 53 R270H allele that is not conferred by the p5 3 R172H allele. Furthermore,
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we describe here a tissue-specific gain of oncogenic potential conferred by both the p 53Rl72H and
the p 53R 2 70H alleles toward the development of nasopharyngeal carcinoma (NPC).
RESULTS
Generation of Compound Conditional Mice Harboring Various p53 Alleles
In order to assess the effect of p53 mutation or loss on K-ras-induced lung carcinogenesis,
compound conditional mutant mice were generated that harbored the conditional activatable K-
rasG2 D allele (Jackson et al., 2001; Tuveson et al., 2004)(Fig. 1A) and combinations of three
different conditional p53 alleles: p5 3 LS L .R270 H , p53LSLR172H and p 53Flox (Jonkers et al., 2001)(Fig.
1A, Olive et al, in press). Importantly, the use of conditional alleles permits examination of the
effects of these mutations in the emerging tumors of interest without the complications of
widespread tumorigenesis or other effects of germline mutation. In this way, these models more
closely resemble spontaneous tumor development in humans. For clarity, the genotypes of the
compound mutant mice will be described in this paper using the abbreviations shown in Table 1
and referred to collectively as K,P mice. The following compound mutant mice were generated:
K;Fl/+, K;270/+, K;172/+, K;Fl/Fl, K;270/Fl, K;172/Fl (Fig. B). These combinations allow us
to examine the effects of point-mutant p53 proteins in the presence and absence of wild-type
p53, compared to the complete elimination of p53 function. Crosses were designed to minimize
effects caused by mixed genetic backgrounds (Fig. B and Materials and Methods). Cohorts of
K,P compound conditional mutant mice were infected with 5x105 PFU of a recombinant
adenovirus expressing Cre recombinase (AdenoCre) by intranasal instillation and then sacrificed
at various time-points (described below). As expected, all of the mice developed multiple
primary lung tumors following infection with AdenoCre.
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Infection With AdenoCre Induces Recombination of the Conditional Alleles
In order to assess recombination efficiency of each allele when multiple alleles were present,
tumors were dissected from the lungs of K;270/F1 mice, and the genomic DNA was isolated.
Because the only differences between the p53R270H and the p5 3R172H alleles are the sites of the
single base mutations downstream of the LSL cassette, the recombination efficiency of the LSL
cassette in these alleles should be identical. PCR was performed on the tumor DNA samples to
detect successful recombination of the conditional K-ras and p53 alleles. In every tumor, PCR
amplification of the K-ras allele produced a product 40bp larger than the wild-type allele, due to
the single loxP site remaining after Cre-mediated recombination (Fig. 2A). Therefore, the K-
rasG12D allele recombined with 100% efficiency. Similar analyses showed that the p53LSL.R270H
allele recombined in 90% (9/10) of the tumors analyzed (Fig. 2B). The recombination efficiency
of the p53F lox allele was comparable, generating the appropriate PCR product in 80% (8/10)
tumors analyzed (Fig. 2C). The effective genotypes that would result from the recombination of
only one p53 allele for each mouse are delineated in Table 1.
Loss of p53 Function Promotes Malignant Progression of Lung Tumors.
As mentioned earlier, several mouse models of K-ras-initiated lung adenocarcinomas have been
generated that produce low to medium grade lung tumors. The effect of p53 loss was
investigated in two of these models (Fisher et al., 2001; Johnson et al., 2001a); in each model,
crossing onto a p53 null background resulted in an acceleration of tumorigenesis as well as an
increase in cellular pleomorphic and nuclear atypia. However, the mice succumbed to
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overwhelming tumor burden and background tumors consistent with homozygous p53 deletion
prior to the development of more advanced features such as stromal desmoplasia or metastases.
In order to investigate the effects of p53 loss in the conditional K-ras system, without the
induction of background tumors, we evaluated the tumor phenotypes of K;Fl/+ and K;Fl/Fl mice
at various time-points after AdenoCre infection. A cohort of K;Fl/+ mice were euthanized at a
late time-point (26 weeks) after infection with AdenoCre. The tumors present in the K;F1/+ mice
resembled those seen previously in LSL-K-rasG12D single mutant mice, ranging from adenomas
to early stage adenocarcinomas (Jackson et al., 2001). This indicates that the loss of a single
copy of p53 does not significantly affect the progression of K-ras-initiated lung
adenocarcinomas; these mice were therefore used as controls for the remainder of this study.
A cohort of K;Fl/Fl mice was also generated for analysis at the late time-point. However, it soon
became apparent that these mice would not survive for 26 weeks after infection, and they were
instead sacrificed after 19 weeks. In contrast to the K;Fl/+ mice, even at the 19 week timepoint,
all of the K;F1/F1 animals developed advanced pulmonary adenocarcinomas. Histological
analysis of the tumors found a variety of morphologies that were more diverse than those seen in
K-rasG12D single mutant animals. Multiple high-grade tumors were present in each mouse that
ranged in appearance from well-differentiated tumors with papillary architecture in which the
cells maintained an apical basal orientation and uniform nuclei, to highly dysplastic lesions that
had lost their cellular orientation and contained enlarged pleomorphic nuclei. These advanced
tumors contained large sheets of dysplastic cells, abnormal mitoses and multinucleate giant cells.
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In order to quantify the extent of progression of K;Fl/Fl tumors, we devised a grading system by
which to evaluate the stage of every individual tumor in each mouse. Tumors were scored in a
blinded manner on a scale of 1-5 with grade 5 indicating the most advanced tumor phenotype.
The criteria for each grade are as follows: Grade 1 tumors are lesions with completely uniform
nuclei showing no nuclear atypia. Grade 2 tumors contain cells in which the nuclei are uniform
but slightly enlarged and exhibit prominent nucleoli. Grade 3 tumors have cells with enlarged,
pleomorphic nuclei showing prominent nucleoli and nuclear molding. Grade 4 tumors have very
large, highly pleomorphic nuclei exhibiting a high degree of nuclear atypia including abnormal
mitoses and hyperchromatism. These tumors also contain multinucleate giant cells. Grade 5
tumors have all the features of Grade 4 tumors and also show stromal desmoplasia surrounding
nests of tumor cells. Examples of each grade of tumor are shown in Figure 3.
Using this grading scheme to analyze 944 tumors from 12 K;Fl/+ mice and 1161 tumors from 15
K;Fl/Fl mice, we confirmed that loss of p53 resulted in a markedly more severe tumor phenotype
in K-ras-initiated lung adenocarcinomas (Fig. 4A). In addition, K;Fl/Fl tumors demonstrated
several characteristics of human lung tumors that had been lacking in previous murine lung
cancer models (Tuveson and Jacks, 1999). Perhaps most striking was the presence of tumors
containing a large stromal component in which nests of tumor cells could be found growing
within a field of desmoplastic stroma (Fig. 4B). Masson's trichrome staining of these tumors
demonstrated the abundant production of collagen by the stromal fibroblasts (Fig. 4C) and
immunohistochemistry confirmed the expression of smooth muscle actin by the stromal
fibroblasts (data not shown).
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A subset of K;Fl/Fl tumors were highly invasive, growing into the hilus, the heart and the
overlying pleura (Fig 4D). Furthermore, within the tumor mass, blood and lymphatic vessels
were found with tumor cells growing within them (data not shown). Therefore, to determine the
metastatic potential of the tumors we examined the regional lymph nodes. Lymph node
metastases were present over 50% (8/15) of the K;Fl/Fl mice (Fig 4E). A careful histological
examination of all of the organs revealed the presence of distant metastases in a small percentage
of these mice (Fig. 4F).
Having established that p53 loss affects the progression of K-ras-initiated lung adenocarcinomas
at late time-points, we were curious whether this effect was also apparent early in tumor
development. Therefore we examined the lungs of K;Fl/+ and K;Fl/Fl mice six weeks after
infection with 5x105 PFU of AdenoCre. The lungs of K;F1/+ mice contained a spectrum of
lesions ranging from atypical adenomatous hyperplasia (AAH) to small adenomas (Fig. 5A).
AAH is a hyperproliferation of epithelial cells growing along the existing alveolar septae that
does not disrupt the underlying lung architecture (Fig. 3A). The cells in these lesions have
uniform nuclei with no nuclear atypia. The adenomas present in these mice were very small and,
with a few rare exceptions, had regular nuclei (Fig. 5B). AAH and adenomas were also present
in the K;Fl/Fl mice, but these lesions often larger and frequently displayed nuclear atypia (Fig.
5C). Even the smallest of lesions were sometimes found to have aberrant nuclei (Fig. 5D).
Furthermore, rare tumors could be found that contained multinucleate giant cells (Fig 5C). In
order to quantitate these observations, 111 tumors from 12 K;Fl/+ mice and 215 tumors from
K;Fl/Fl mice were graded according to the scheme described above (Fig. 5A). This analysis
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showed a clear shift towards more malignant lesions in the K;FI/Fl mice indicating the
contribution of p53 loss to lung tumor progression occurs very early in tumor development.
The p53R270H Allele Shows Dominant-Negative Effects in Promoting Malignant Progression
Endogenous expression of mutant p53 can result in a gain-of-function effect on tumor
development in some tissues (Olive, et. al, in press). Therefore, we examined whether
endogenous expression of point-mutant p53 in K-ras-initiated lung adenocarcinomas would
result in a more severe tumor phenotype than homozygous deletion of p53. Cohorts of K;270/F1
and K; 172/Fl mice were sacrificed 19 weeks after AdenoCre infection, and their lung tumors
were compared to the K;FI/Fl mice described above. Surprisingly, grading of 841 tumors from
11 K;270/F1 mice and 839 tumors from 10 K;172/F1 mice did not reveal any differences in the
distribution of tumor grades compared to K;FI/Fl mice (Fig. 6A). All three genotypes had
substantially fewer low grade, and more high grade tumors than the K;F1/+ animals sacrificed at
26 weeks post infection. In addition, tumors from the K;Fl/Fl, K;270/F1 and K;172/F1 animals
were highly invasive and frequently metastasized to the thoracic lymph nodes. Together, these
data support the loss of wild-type p53 function as a factor in the progression of lung
adenocarcinoma, but they do not support a gain-of-function effect by point-mutant p53.
The absence of a gain-of-function effect in this system allowed us to cleanly evaluate the role of
dominant-negative effects by mutant p53 in the progression of K-ras-initiated lung
adenocarcinomas. Cohorts of K;270/+ and K;172/+ mice were sacrificed 26 weeks after
AdenoCre infection and compared to the K;Fl/+ mice described above. Grading analysis was
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performed on 932 tumors from 11 K;270/+ mice and 773 tumors from 10 K;172/+ mice.
Strikingly, while the distribution of tumor grades was similar between K;FlV+ and K; 172/+ mice,
the K;270/+ mice displayed a decrease in grade 1 tumors (K;FI/+ = 30+ 6% vs. K;270/+ =12+
3%, mean + SEM, Z2, p=.019) and an increase in high-grade tumors (grade 3,4 and 5 = 28+ 4%
vs. 46+4% x2, p=.018)(Fig. 6B). The tumor grade distribution of the K;270/+ mice fell between
that of the K;Fl/+ and the K;Fl/F1 animals (Fig 6A,B). Therefore, p53R27 H, but not p53R72H,
appeared to act as a partial dominant-negative allele toward the development of high-grade lung
adenocarcinoma.
In order to determine whether this effect also extended to the growth rate of the tumors, we
examined the size of the tumors after 26 weeks of growth. The average number of tumors in the
K;F1/+, K;172/+ and K;270/+ were very similar (79+21, 77+24 and 85+17 respectively). To
calculate tumor size we used the Bioquant Image Analysis system to measure the total area of
tumor in the lung as well as the total area of lung to determine the percent of lung area involved
with tumor. Similar to the tumor grading results, we found that the K;F/+ and the K;172/+ mice
had similar sized tumors, occupying 24% and 27% of the total lung area respectively. However,
tumors in the K;270/+ mice were consistently larger, comprising 36% of the lung area (Fig 4C).
The size difference between K;Fl/+ and K;270/+ mice was statistically significant (p=.024). We
did not compare the tumor size among the K;Fl/Fl, K;172/F1, and K;270/F1 animals, as in most
cases nearly the entire lung was filled with tumor at sacrifice. These findings further support a
dominant-negative effect for the p53R270H allele on lung tumor progression that is not seen with
the p53 R172H allele.
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Upregulation of the Raf/MAPK Pathway Occurs in Advanced Tumors
Immunohistochemical analysis of lung tumors in K;+/+ mice using anti-phospho-MAPK
antibodies demonstrated that increased activation of the MAPK pathway is a late event in the
progression of K-ras-induced murine lung tumors, occurring in only a small subset (3.5%) of
late-stage tumors (data not shown). Studies in primary fibroblasts have linked high levels of
Raf/MAPK activity to Ras-induced premature senescence in part through activation of p 19ARF,
a positive regulator of p53 (Lin et al., 1998). Therefore, we reasoned that mutation of p53 might
allow for earlier and more widespread activation of the signaling pathway, which could account
for its tumor-promoting effects. To address this question, immunohistochemistry was performed
on both early- and late-stage tumors from the K,P mice of all six genotypes using anti-phospho-
p42/44MAPK antibodies.
At six weeks post infection no phospho-MAPK positive tumors were present in any of the
animals evaluated. This indicates that loss of p53 alone is not sufficient to promote upregulation
of the Raf/MAPK pathway. However, immunostaining of late-stage tumors revealed that a
subset of tumors contained large foci of phospho-MAPK positive cells. In some cases entire
tumors were immunoreactive. The percentage of tumors that were phospho-MAPK positive
varied depending on the p53 genotype (Fig. 4D). Roughly half of all the tumors in K;Fl/Fl,
K;172/F1 and K;270/F1 animals stained positively for phospho-MAPK (52.2%, 51.2% and 50.6%
respectively). Strikingly, more than half (53.1%) of the tumors in K;270/+ mice also stained
positively, suggesting that the p53R270H allele acted as a complete dominant-negative allele in this
respect. A mild dominant-negative effect was also seen by the p53 R172H allele as 32.2% of
K; 172/+ tumors were phospho-MAPK positive. In contrast, only 13.7% of p53Fl/+ tumors were
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phospho-MAPK positive. Therefore, while p53 loss alone is not sufficient to promote
upregulation of the Raf/MAPK pathway, mutation or loss of p53 may cooperate with other
events that accumulate during the development of a tumor to allow MAPK upregulation.
Furthermore, the p53R270H and, to a lesser extent, p53R172H alleles both dominantly interfere with
the ability of wild-type p53 to restrain MAPK upregulation.
Wild-type specific LOH in K;270/+ Tumors Despite Dominant-Negative Effects by the
p53R270H allele.
To determine whether the dominant-negative effect of the p53 R270H allele alleviates the selective
pressure to lose the wild-type allele of p53 during tumor progression, we examined the frequency
of loss of heterozygosity (LOH) in p53 F1/+ and p53 R270H/+ tumors. Quantitative real time PCR
analysis was performed on genomic DNA isolated from tumors micro-dissected from the lungs
of K;F1/+ and K;270/+ mice using TaqMan MGB probes. For both genotypes, 100% of the
tumors analyzed (n=l 1 for K;270/+ and n=8 for K;F1/+) showed loss of the wild-type p53 allele
(Supplemental Table 1). Because the microdissection technique required the isolation of larger
tumors, the sampling may have been biased towards more advanced tumors. However, these
data demonstrate that there is still selective pressure for full loss of p53 function despite the
dominant-negative effects of the p53R270H allele, suggesting an incomplete dominance over the
wild-type allele. This is consistent with data from human lung tumors and other tumor types
(Baker et al., 1990).
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Mutant p53 promotes the development of nasopharyngeal carcinomas.
The intranasal instillation method of AdenoCre administration used to generate lung tumors
exposes the entire respiratory tract to the virus. Thus, it is possible that infection and subsequent
recombination of the conditional alleles would occur in cells outside of the lung. However,
analysis of the conditional K-rasGl2D single mutant mice did not provide any evidence of
tumorigenesis in the upper respiratory tract. It is possible that the epithelial cells of the upper
respiratory tract and nasal mucosa are not susceptible to adenoviral infection. Alternatively, the
expression of K-rasGl2D in these cells may not be sufficient to induce tumorigenesis. In fact, in
the course of performing the experiments described above, we observed that K;172/F1 and
K;270/Fl compound mutant mice had a higher mortality than the K;Fl/FI compound mutants,
which could not be explained by differences in their lung tumor phenotype. A small number of
these mice presented with grossly apparent head tumors. Therefore, we systematically examined
the nasal mucosa of these mice for evidence of tumors that might have contributed to their early
lethality. Histological analysis of perisagital skull sections revealed the presence of
nasopharyngeal carcinomas (NPCs) in a subset of the 19 week K;FV/F1, K;270/Fl and K; 172/F1
mice. The NPCs arose in the respiratory epithelium of the sinuses. These tumors were
extremely poorly differentiated with dramatically pleomorphic nuclei and contained large
numbers of multi-nucleate giant cells, giving the tumors a characteristic syncytial appearance.
The nuclei also appeared highly vessiculated and had prominent nucleoli (Fig. 5B).
Furthermore, the tumors were destructively invasive, commonly penetrating through the
cribriform plate and into the olfactory bulb (Fig. 5C).
161
NPC is a form of head and neck cancer arising from the nasal mucosa (Lo et al., 2004).
Although rare in the United States and Europe, NPC is common in Cantonese populations where
it occurs in roughly 1:4000 individuals. The World Health Organization describes three
histological subtypes of NPC: keratinzing squamous (type I), non-keratinizing squamous (type
II) and undifferentiated (type III). The lesions arising in AdenoCre-treated K,P mice are highly
reminiscent of undifferentiated NPC. In particular, the striking syncytial growth pattern and
bizarre, vessiculated nuclei are both prominent in these tumors.
Consistent with their increased mortality, the incidence of NPC was >4 fold higher in the
K;172/Fl (64%) and K;270/Fl (69%) mice than in the p53FI/Fl mice (14%)(Fig 5D). Given the
significantly higher incidence of NPC upon expression of point-mutant p53 compared to loss of
p53 expression, these data provide the most dramatic evidence to date of a gain of oncogenic
potential by point-mutant p53 in vivo.
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DISCUSSION
In this work, we present compound mutant mice incorporating somatically manipulatable
conditional mutations in the K-ras proto-oncogene and the p53 tumor suppresser gene.
Cooperation between oncogenic ras and point-mutant p53 was one of the earliest examples of
genetic interaction between two cancer genes (Parada et al., 1984a). Based on the observation
that both K-ras and p53 are frequently mutated in human tumors, we expect that the K,P
compound mutant mice described in this work will be useful in accurately modeling a number of
different types of cancer, beyond the advanced pulmonary adenocarcinoma and nasopharyngeal
carcinoma described here.
K,P Mice Develop Advanced Lung Adenocarcinoma
The K,P compound mutant mice also successfully recapitulate the pathology of advanced human
pulmonary adenocarcinoma. These mice combine several modeling techniques to achieve this
success. First, the conditional nature of both the K-ras and p53 mutant alleles allows for analysis
of mutant cell behavior in the context of an otherwise wild-type animal. This circumvents the
developmental effects of mutant K-ras expression and the background tumor phenotype of
germline p53 mutation. Second, the delivery of a relatively low titer of AdenoCre prevented the
K,P mice from succumbing to the burden of a large number of low-grade tumors, as occurs in the
sporadic K-ras" models. Finally, the K,P mice utilize compound mutations of the endogenous
K-ras and p53 genes rather than transgenic overexpression of mutant cDNAs. The effect of the
endogenous K-rasG12 D mutation in mouse embryo fibroblasts is substantially different than that
of ectopic overexpression, underscoring the importance of physiologically accurate models
(Tuveson et al., 2004).
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The K,P mutant mice developed lung adenocarcinomas with several feature not commonly
observed in previous models. Not only do the tumors in these mice exhibit a high degree of
nuclear atypia, they also elicit stromal desmoplasia and are invasive and metastatic. Although it
has been shown in other mouse lung cancer models that K-ras and p53 cooperate in the
promotion of tumor growth and progression, the induction of a desmoplastic response and the
development of metastatic disease was not reported (Fisher et al., 2001; Johnson et al., 2001a).
Human pulmonary adenocarcinomas often contain a large stromal component. The
microenvironment in which a tumor resides may play a critical role in tumor growth and
progression, and interactions between cells in the tumor and the microenvironment (stroma) have
been shown to elicit changes in the other's behavior (Elenbaas and Weinberg, 2001; Liotta and
Kohn, 2001). The induction of desmoplastic stroma is commonly seen in NSCLC and may
contribute to disease progression. Correlative studies suggest that stromal production of the cell
adhesion molecule hyaluronan (HA) (Pirinen et al., 2001) correlates with poor prognosis. The
production by stromal fibroblasts of HA and various matrix metalloproteinases (MMPs) involved
in reorganization of the extra-cellular matrix are thought to influence the invasive and metastatic
properties of the tumor (Liotta and Kohn, 2001). Co-culture experiments have shown that
NSCLC cells induce pulmonary fibroblasts to secrete FGF and IL-8 (Anderson et al., 2000;
Mari et al., 1998), suggesting that they may contribute to tumor angiogenesis. Furthermore,
stromal production of thymidine phosphorylase, which has angiogenic activity, correlates with
poor prognosis in early stage NSCLC (Kojima et al., 2002).
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Human NSCLC is highly metastatic. Patients diagnosed with early stage disease that has not
spread to lymph nodes or distant organs have an average 5-year survival of about 50%.
However, only 15% of lung cancer patients are diagnosed at this stage; most are diagnosed with
metastatic disease and have an overall 5-year survival rate only 14%. The current
chemotherapeutic regimens have not been effective in the treatment of advanced NSCLC.
Numerous murine lung cancer models have been created that have provided valuable insights
into the molecular alterations driving lung tumorigenesis. However, because these models do
not generally develop advanced disease, their growth properties and response to therapeutics
may not accurately reflect those of human tumors. Thus, the model described here will provide a
valuable system for the study of lung tumor biology and the pre-clinical testing of novel
therapeutics.
The Role of p53 Loss in Lung Tumor Progression
Although it is generally accepted that p53 mutation is an important event in the development of
lung cancer, the specific contribution of particular p53 mutations has not been previously
analyzed. By comparing the effects of different p53 alleles under identical conditions, we have
established that loss of p53 function is sufficient to promote the progression of K-ras initiated
lung adenocarcinomas in mice. The primary functions of p53 are to respond to cellular stresses
by transactivating genes involved in cell cycle arrest, apoptosis and genome maintenance.
Although we did not determine the contribution of specific p53 effecter pathways, it is unlikely
that the apoptotic functions of p53 are significant in this setting since we could not detect any
differences in the rates of apoptosis within lung tumors of K,P mice by immunostaining for
cleaved caspase 3 (data not shown). In fact, the presence of apoptotic cells in K-ras-induced
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lung tumors was extremely rare even in tumors with wild-type p53, implying either that the
bronchoalveolar epithelia of the lung is not prone to oncogene-induced apoptosis or that the
evasion of apoptosis occurs extremely early in tumor development.
Instead, it appears likely that loss of the genome maintenance and anti-proliferative functions of
p53 are critical to the development of advanced lung adenocarcinoma. One of the most
prominent features of the tumors in K;Fl/F1 mice is the development of severe nuclear dysplasia.
The observation of lesions with prominent nuclear atypia just six weeks after infection with
AdenoCre indicates a rapid accumulation of genetic abnormalities following loss of p53.
Furthermore, loss of p21, a primary effector of p53-mediated cell cycle arrest, was shown to
significantly accelerate tumorigenesis in a c-raf induced mouse model of lung adenocarcinoma
(Fedorov et al., 2003).
In any case, the role of p53 loss appears to be primarily in the progression of lung
adenocarcinomas, rather than their initiation. Lung tumors are extremely rare in p53- /- mice,
presumably due to the early onset of other tumors such as lymphomas and sarcomas. A small
subset of p53 +/- mice does develop lung adenocarcinomas but the tumors are generally solitary
and have a long latency (>18months). Likewise, p53 FVFl mice treated with Adeno-Cre also
develop lung adenocarcinomas, but only 1 to 1 /2 years after treatment (Meuwissen et al., 2003).
Therefore, p53 mutation alone is not sufficient for the initiation of lung cancer. Instead,
activation of K-ras serves to initiate the tumor and p53 loss contributes to the progression. K-ras
activation is also required for lung adenocarcinoma maintenance as withdrawal of doxycycline-
inducable K-ras-4bGl2D resulted in regression of existing tumors. Finally, K-ras activation may
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affect the cell-specificity of tumor development since compound deletion of p53 and Rb in the
lung results in the neuroendocrine tumors characteristic of small cell lung cancer rather than
pulmonary adenocarcinoma (Meuwissen et al., 2003).
p53 2 70 H Acts as a Partial Dominant-Negative Allele
Although p53 loss of function is sufficient to drive tumor progression in K-ras induced lung
adenocarcinomas, p53 is rarely deleted in human lung tumors. Rather, p53 is commonly point-
mutated at specific hot-spot residues in the DNA binding domain in lung tumors as well as many
other cancers. In particular, contact mutations at codons 248 and 273 are very common in
human lung adenocarcinomas. In contrast, an analysis of spontaneous tumors from the IARC
p53 mutation database (v. R9) confirms that codon 175 mutations are substantially
underrepresented in lung adenocarcinomas and non-small-cell lung tumors compared to all
tumors (x2 , p= 0.000026). Previously explanations have focused on the carcinogenic effects of
cigarette smoke on different p53 codons as a mechanism for this variation in the codon
distribution of p53 mutations, especially in light of in vitro evidence that suggested that codon
175 mutations are more potent in oncogenic assays. However, our work found that the p53R270H
mutation is more strongly dominant-negative over wild-type p53 than is the p53R172H mutation
and therefore more effective in tumor promotion.
There are a variety of possible explanations for this effect. For example, p53R 270H may have a
stronger intrinsic capacity to interfere with wild-type p53 than p5 3 R172H . However, our analysis
of mouse embryo fibroblasts heterozygous for endogenous mutant p53 alleles suggested exactly
the opposite effect (Olive et. al, in press). p 53 R172 H /+ MEFs proliferate significantly more rapidly
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than do p53R2 70H + MEFs. Alternatively, p53R270H may accumulate to higher levels in the tumor
cells than p53 1 72H . Most in vitro studies attempt to analyze identical amounts of transfected p53
mutants. However, analysis of endogenous mutant p53 MEFs as well the intestinal crypts of
irradiated mutant p53 mice showed that p53R 270 H consistently accumulates to higher levels than
p53 .72H One final possibility is that p53R 2 7 0H /+ tumors undergo LOH at an earlier point than
p53R172H/ + tumors. This could be due to a specific dominant-negative effect by p53R270H on the
genome maintenance functions of p53. Alternatively, perhaps p53R270H is less strongly
dominant-negative than p53R172H as is suggested by the data on mutant p53 MEFs. In that case,
there could be an increased selective pressure for p53R 270H / + tumors to undergo LOH early in
tumorigenesis. Analysis of p21 and mdm2 levels in p53R270H MEFs found increased levels of
these target genes compared to p53 +/- MEFs, further supporting this hypothesis.
The Role of K-ras and p53 Mutations in Nasopharyngeal Carcinoma
In addition to NSCLC, some of the K,P mice developed nasopharyngeal carcinomas, thereby
establishing the first spontaneous mouse model of NPC. The most prominent etiological factor
in human NPC is infection with Epstein-Barr virus (EBV). The episomal EBV genome produces
several known viral gene products that contribute to NPC. In addition, several genes are known
to be deleted or hypermethylated in NPC cells including pl 6 nk4a, RAR32 and RASSF1 (Kwong
et al., 2002; Lo et al., 1996). RASSF1 is particularly interesting because it is located at 3p21, a
region commonly deleted in both NPC and lung adenocarcinomas. In contrast to human lung
adenocarcinomas, however, mutations in K-ras or p53 are both rare in NPC (Yung et al., 1995).
Instead, it appears that these pathways are frequently altered through other means. For example,
the epidermal growth factor receptor (EGFR), of which the ras pathway is a primary downstream
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effector, is overexpressed in -85% of all NPCs. Likewise, although wild-type p53 accumulates
to high levels in most NPC, p53 is clearly blocked from inducing cell cycle arrest or apoptosis.
Interestingly, both of these effects may be a consequence of EBV infection as recent reports
suggested that the viral protein LMPI can both induce the expression of EGFR through the
activation of NF-KB (Tao et al., 2004) and inhibit the activity of p53, perhaps through
upregulation of the anti-apoptotic protein A20 (Fries et al., 1996; Fries et al., 1999) (Sup. Fig.
1A,B).
Finally, ANp63 has been reported to be overexpressed in 100% of NPCs (Crook et al., 2000).
ANp63 is a dominant-negative variant of the p53 family-member, p63. Previously, it was
suggested that ANp63 may act in a trans-dominant-negative manner to inhibit the function of
wild-type p53 through competition for p53 binding sites. However, more recently, wild-type p53
has been shown to bind to ANp63 through direct interaction of their DNA binding domains,
resulting in the targeted destruction of ANp63 through caspase-mediated protein degradation
(Ratovitski et al., 2001). Therefore, the upregulation of ANp63 in NPC may be explained by
inhibition of wild-type function p53 in these tumors. This model may also help explain the gain-
of-function effects by point-mutant p53 towards NPC development in the K,P mice. Several
groups have shown that mutant p53 can bind to and inhibit the function of TAp63, the full-length,
transactivation competent form ofp63 (Di Como et al., 1999; Marin et al., 2000). Therefore, the
expression of point-mutant p53 may act to inhibit the function of TAp63 in K,P mice, mimicking
the effect of ANp63 overexpression in human NPC (Sup. Fig. 1C).
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These observations suggest that the compound mutation of K-ras and p53 in the respiratory
epithelium of K,P mice is substituting for the effects of EBV infection in the development of
NPC. It also suggests that rather than playing a minor role, the ras and p53 pathways are, in fact,
extremely important in the pathogenesis of NPC.
Tissue-specific Effects of Mutant p53 Function
Endogenous expression of mutant p53 has different effects in different tissues. Previously, we
showed that endogenous expression of mutant p53 in the germline of mice resulted in a gain-of-
function effect on the development of both endothelial and epithelial tumors (Olive, et. al, in
press). In this work, we describe dominant-negative effects by mutant p53 in the pulmonary
epithelium and gain-of-function effects in the respiratory epithelium of the nasopharynx. It is
unclear why mutant p53 failed to produce a gain-of-function effect in K-ras-induced lung
tumors. Lung carcinomas were among those found in germline point-mutant p53 mice, leading
to our original expectation of a gain-of-function effect by mutant p53 in lungs of K,P mice.
However, since the lung adenocarcinomas arising in the K,P mice all harbored activated K-ras,
any effect by mutant p53 on the initiation of lung tumors might be obscured in this system.
Alternatively, the novel pathways affected by mutant p53, for example p63 and p 73 , may be
relatively less important during the development of lung tumors compared to other sites. Given
the prevalence of p53 mutations in human cancer, elucidating the different allele- and tissue-
specific effects of mutant p53 is critical to developing a more complete understanding of
molecular carcinogenesis.
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MATERIALS AND METHODS
Breeding schemes
LSL-K-ras °G 2D mice were crossed to p53FI/+ mice to generate K-rasG12D; p53Fl/+ mice. The
p53R172H and p53R270H strains were each crossed to the p53Fl/+ strain to p53R172H/F1 and
p53 R27OH/Fl mice. By crossing the K-rasG12D;p53Fl/+ mice to the p53R172H/Fl mice offspring of
the following genotypes were generated for use in tumor studies: K-rasG12D;p53Fl/+, K-
rasGl2D;p53R172H/+, K-rasG12DFI/Fl and K-rasGl2D;p53R 172H/Fl. The K-rasG12D;p53Fl/+
mice were crossed to the p53R270H/Fl mice to yield: K-rasG12D; p53Fl/+, K-
rasG12D;p53R27H/+, K-rasG12D;p53Fl/Fl and K-rasG12DR7 0H/F1. Thus comparison of the
properties of each point-mutant allele to the floxed (null) allele was performed between
littermates.
Molecular Analysis of Recombination Efficiency
To assess the efficiency of Cre mediated recombination of the conditional alleles DNA was
prepared from dissected tumors. For the K-ras allele, PCR was performed using the Advantage-
GC-cDNA kit from Clontech with primers flanking the lox-stop-lox cassette: forward primer
K5'-1 = 5'-GGGTAGGTGTTGGGATAGCTG-3' and reverse primer K3'-3 = 5'-
TCCGAATTCAGTGACTACAGATGTACAGAG-3'. The wild-type K-ras allele yields a 265-
bp product and the recombined conditional allele containing a single loxP site yields a 305-bp
product. Analysis of the conditional p53 point-mutant alleles was performed using standard PCR
buffer with primers flanking the lox-stop-lox cassette: forward primer dt020200.1 = 5'-
AGCCTGCCTAGCTTCCTCAGG-3' and reverse primer dtO 11200.3 = 5'-
CTTGGAGACATAGCCACACTG-3'. The wild-type and Flox p53 alleles produce a 291bp
product and the recombined condtional allele produces a 325bp product. PCR analysis of the
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floxed allele was performed using standard PCR buffer with primers flanking the loxP sites in
exons 2 and 10: forward 5'CACAAAAACAGGTTAACCCAG-3' and reverse 5'-
GAAGACAGAAAAGGGGA GGG-3'. The recombined allele yields a 612-bp product; no
product is produced from the wild-type allele.
AdenoCre Infection
Mice were infected with 5x10^5 PFU of AdenoCre virus at 6-8 weeks of age. AdenoCr:CaPi co-
precipitates were prepared as described (Fasbender et al., 1998). Mice were anesthetized with
avertin. AdenoCr:CaPi co-precipitates were administered intranasally in two 62.5ul instillations.
The second instillation was administered when breathing rates had returned to normal.
Tissue Harvesting
Mice were sacrificed by C02 asphyxiation. The trachea was exposed and the lungs were inflated
with formalin. Trachea, heart and lungs were removed en mass and placed in formalin. The
remaining organs were then removed and placed in formalin. All tissues were fixed in formalin
overnight at room temperature and then placed into 70% ethanol and sent for processing through
paraffin. Once processed each lobe of the lung was cut in a set pattern and embedded in paraffin.
Remaining organs were embedded according to standard protocols.
Immunohistochemistry and Trichrome Staining
All lungs were sectioned in the same fashion; 5 step sections were taken at 100um apart, with 5
unstained sections taken after section 3. P53 immunohistochemistry was performed following
Trilogy dewaxing/unmasking according to manufacturer's instructions. p53 CM5 rabbit
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polyclonal antibody (Novo Castra) was used at a 1:500 dilution in Tris-Buffered Saline + Tween-
20 (.05%). Sections were incubated in primary antibody overnight at 4C. Staining was
completed with an HRP-anti-rabbit kit (Vector Labs) according to manufacturer's instructions.
For smooth muscle actin immunohistochemistry unmasking was not required. Sections were
incubated overnight at 40 C in Anti-Smooth muscle actin (Reasearch Diagnostics Inc.) diluted
1:100. For phospho-MAPK immunohistochemitsry high temperature citrate buffer unmasking
was performed. Sections were incubated overnight at 4C anti-phosph-p42/44MAPK (Cell
Signaling) diluted 1:100. Trichrome staining was performed using a Masson's Trichrome kit
from Poly Scientific R&D, following manufacturer's instructions.
Tumor Grading
Tumor grading was performed without knowledge of genotype on the level 3 section of each
lung. Each tumor was given a score of 1-5 based on pre-determined criteria regarding nuclear
morphology and stromal component. Grade 1 = completely uniform nuclei showing no nuclear
atypia. Grade 2 = nuclei are uniform but slightly enlarged and exhibit prominent nucleoli.
Grade 3 = enlarged, pleomorphic nuclei showing prominent nucleoli and nuclear molding.
Grade 4 = very large highly pleomorphic nuclei exhibiting a high degree of nuclear atypia
including abnormal mitosis and contain multi-nucleate giant cells. Grade 5 = highly
pleomorphic nuclei and stromal desmoplasia surrounding nests of tumor cells. Grading was
performed in the absence of knowledge of p53 genotype.
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Tumor size measurement
Lung and tumor areas were determined using Bioquant Image Analysis software in manual
measurement mode.
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Figure 1. Generation of K,P Compound Mutant Mice
A) Diagram of K-ras andp53 Conditional Alleles. The LSL-K-rasGl2D allele contains an
activating mutation at codon 12 and a Lox-Stop-Lox (LSL) cassette inserted into intron 0
upstream of the transcriptional start site. The p53LSL'R172H and p53 LsR270H alleles contain an
Arg--His mutation in exons five and eight, respectively, and a LSL cassette inserted into
intron 1. The p53Flox allele encodes the wild-type p53 protein and contains LoxP sites
flanking exons 2 and 10.
B) Breeding Scheme. LSL-K-rasG 12D mice were crossed to p5 3 Fl/+ mice to produce LSL-K-
ras 12D; p53 Vi +mice (K;Fl/+). The p53Ls L ' 72H andp53 LSL.R 27 H strains were each crossed to
the p 53Fl/ strain to produce p53R 72/F 1andp53R270/FI mice. By crossing the K;F1/+ mice to
the p53R72H/Fl and to the p5 3 R270 /Fl mice, offspring of the following genotypes were
generated for use in tumor studies (abbreviated genotypes used): K;Fl/+, K;FI/F, K;172/+,
K; 172/F1, K;270/+, K;270/F1.
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Figure 2. PCR Analysis of recombination efficiency of conditional alleles. Genomic DNA was
isolated from 10 different K;270/F1 tumors (lanes 1-10).
A) To assess recombination of the LSL-K-rasGl2D allele, PCR was performed using primers
flanking the LSL cassette. The recombined K-rasGl2D allele and the wild-type allele yield
305 bp (top arrow) and 265 bp (bottom arrow) products respectively.
B) PCR analysis of the p53 locus using primers flanking the LSL cassette in intron 1. The 335
bp product (arrow) is produced from the recombined conditional allele. An asterisk indicates
an unrecombined sample.
C) PCR analysis of the p 53 F1 allele using primers flanking exons 2 and 10. The recombined
p53 F1 allele produces a 612 bp product. No product is produced from the unrecombined
allele, as indicated by the asterisks.
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Figure 3. Tumor Grades in K,P Compound Conditional Mutant Mice.
A) At right, a region of advanced adenomatous hyperplasia (AAH), adjacent to normal lung
(left). Hyperplastic cells are enlarged and may accumulate slightly, but generally follow the
underlying lung architechture.
B) Grade 1 lesions form a solid tumor but have regular nuclei.
C) Grade 2 lesions may have slightly irregular nuclei and prominent nucleoli.
D) Cells in Grade 3 lesions exhibit pleiomorphic nuclei, prominent nucleoli and nuclear molding.
E) Grade 4 lesions have enlarged, pleiomorphic nuclei (single arrows), abberrent mitoses
(double arrows), and tumor giant cells (triple arrows).
F) Grade 5 lesions exhibit all the criteria of Grade 4 lesions as well as nests of tumors cells
surrounded by a desmoplastic stroma.
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Figure 4. Loss of p53 results in progression of K-ras-induced lung adenocarcinomas. Slides are
stained with hematoxylin and eosin unless otherwise indicated.
A) Distribution of tumor grades in K;FI/+ mice (blue bars) and K;Fl/Fl mice (red bars).
Histograms represent the percent of total tumors for each grade. Error bars indicate standard
error.
B) A region of stromal desmoplasia with invasion of tumor cells in a Grade 5 tumor. (200X)
C) Masson's Trichrome stained section of a tumor with tumors cells (red with black nuclei)
invading a region of collagen-containing stroma (blue). (400X)
D) Section of a lung adenocarcinoma (T) invading into adjacent cardiac muscle (C). (200X)
E) Section of a lung adenocarcinoma metastasis (M) in a thoracic lymph node. (100X)
F) Section of a distal lung tumor metastasis (M) to the kidney. Arrows indicate normal
glomeruli in the kidney. Dashed line indicated the boundary of the metastasis.
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Figure 5. Effects of p53 Loss are Apparent Six Weeks After AdenoCre Infection. Slides are
stained with hematoxylin and eosin.
A) Distribution of tumor grades in K;F1/+ mice (blue bars) and K;Fl/F1 mice (red bars).
Histograms represent the percent of total tumors for each grade. Error bars indicate standard
error.
B) Section of a lesion from a K;Fl/+ mouse, six weeks post infection with 5x105 pfu of
AdenoCre. Nuclei are regular and retain apical/basal polarity.(400X)
C) Section of a lesion from a K;Fl/Fl mouse, six weeks post infection with 5x105 pfu of
AdenoCre. Several enlarged cells with aberrant nuclei are indicated with arrows.(400X)
D) An example of a very small lesion from a K;Fl/Fl mouse, six weeks post infection with 5x105
pfu of AdenoCre. Tumor cells have irregular nuclei, including one enlargerd, aberrant cell
(arrow). (400X)
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Figure 6. Dominant-Negative Effects by the Contact Mutant 5 3R 2 70 H .
A) Distribution of tumor grades in K;Fl/Fl mice (blue bars), K; 172/F1 mice (green bars) and
K; 172/Fl mice (red bars). Histograms represent the percent of total tumors for each grade.
Error bars indicate standard error.
B) Distribution of tumor grades in K;F1/+ mice (blue bars), K;172/+ mice (green bars) and
K; 172/+ mice (red bars). Histograms represent the percent of total tumors for each grade.
Error bars indicate standard error.
C) Area of tumors in K;F1/+ mice (blue bars), K; 172/+ mice (green bars) and K; 172/+ mice (red
bars). Histograms represent the percent of lung area occupied by tumors.
D) MAPK activation in K,P mice. Histograms show the percent of tumors with positive staining
for -MAPK in the indicated genotypes.
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Figure 7. AdenoCre Infection of K,P mice Results in Nasopharyngeal Carcinoma (NPC).
Slides are stained with hematoxylin and eosin.
A) A small NPC is shown developing in the nasal mucosa. (100X)
B) Section of an NPC from a K;270/F1 mouse. These tumors develop dramatically pleiomorphic
nuclear atypia. (400X)
C) Section of an NPC invading the brain. Dashed line indicates the former location of the
cribriform plate. The arrow indicates the leading front of the NPC invading into the remains
of the olfactory bulb, which resulted in the accumulation of hemorrhaged blood (H). (40X)
D) Histogram shows the fraction of K;Fl/Fl, K;172/F1 and K;270/FI mice that developed NPC.
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Supplementary Figure 1. Diagram of Molecular Pathways Involved in NPC. The diagrams
depict the potential impacts of mutations or EBV infection on the K-ras and p53 pathways. Red
arrows indicate down-regulation of a pathway. Green arrows indicate up-regulation of a
pathway.
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Chapter 4
Overview and Conclusions
195
The focus of this thesis is the function of tumor-associated mutant alleles of p53 and their use in
generating accurate mouse models of human cancer. To this end, we engineered two strains of
mice with conditional mutant p53 alleles targeted to the endogenous locus. The results of
activating these conditional alleles were explored in the context of the entire animal and
specifically in a K-ras-initiated model of lung cancer. These separate approaches provided
complementary information about the basic biology of p53 and its role in tumorigenesis.
MUTANT P53 FUNCTION
Gain of function by endogenous mutant p53
The mutant p53 gain-of-function hypothesis has long been a topic of controversy. It was our
intent to rigorously test the hypothesis in a physiologically accurate way. We therefore
performed a very simple genetic analysis by comparing mice expressing only mutant p53 to mice
lacking p53. The development of novel tumors in p53w- mice is the first in vivo demonstration
of a gain of oncogenic potential by mutant p53 and should go a long way towards establishing
the mutant p53 gain-of-function hypothesis. The increased incidence of nasopharyngeal tumors
is also supportive of the p53 gain-of-function hypothesis. However, the possibility also exists
that the increase in NPCs found in K,270/F1 and K,172/F1 mice is the result of non-cell
autonomous haplo-insufficiency. That is, the non-infected cells of K,270/Fl and K,172/Fl mice
were phenotypically K-ras+/'; p53+/'. In contrast, the non-infected cells of K,F/Fl mice were K-
ras+/'; p53+/+. In theory it is possible that NPCs are influenced by non-intrinsic factors that are
dose-sensitive to p53. Although such an effect has never before been reported, the only way to
rule it out will be to repeat the NPC experiment on K,FI/Null mice and affirm that they do not
have an increased incidence of nasopharyngeal carcinomas.
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p53M/' mice develop tumors of epithelial origin in addition to the tumors commonly observed in
p53 null mice. This brings to mind the prevalence of p53 point-mutations in different types of
sporadic human tumors; the types of tumors that most frequently harbor p53 mutations are all of
epithelial origin while most of the tumor types with low rates of p53 mutations are derived from
the mesenchyme or from germ cells. This may imply that certain epithelial tissues are
specifically susceptible to those aspects of mutant p53 biology that are distinct from p53 loss.
Epithelial tumors are also thought to require higher rates of genomic instability than tumors of
hematopoietic lineages (Loeb, 1991; Renan, 1993) and p53 mutations are known to be associated
with genomic instability. This may be simply due to a loss of apoptotic surveillance of damaged
cells through inactivation of wild-type p53 function or it could be related to a specific function of
mutant p53 (Zhivotovsky and Kroemer, 2004). The latter possibility is supported by an
experiment in which p53 / SAOS-2 cells were stably transfected with inducible mutant p53
expression plasmids and then treated with N-(phosphoacetyl)-L-aspartate (PALA) over the
course of 16 population doublings. PALA toxicity can be overcome through amplification of the
carbamoyl-P-synthetase (CAD) gene, so this assay acts as an indirect measure of genomic
instability. Each of three cell lines bearing different inducible alleles of mutant p53 were found
to have an increased frequency of gene amplification when mutant p53 protein expression was
induced, supporting a gain-of-function effect by mutant p53 on genomic instability (El-Hizawi et
al., 2002).
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The mechanism by which mutant p53 could induce genomic instability remains speculative.
However, wild-type p53 was shown to directly interact with and activate topoisomerase I, a
protein that plays a direct role in managing DNA topology, in a transient but tightly regulated
manner. In contrast, this interaction was reported to be constitutive in a cell line harboring
mutant p53 (Gobert et al., 1999). Since topoisomerase I has been implicated in causing
illegitimate recombination (Zhu and Schiestl, 1996), hyperactivation of topoisomerase I could
play a role of mutant p53 mediated genomic instability. Alternatively, the inhibition of p63 and
p73 by mutant p53 could affect any role in regulating genome stability that the two p53 family-
member genes harbor; expression array profiling found that several genes involved in DNA
repair were activated following expression TAp73a (Fontemaggi et al., 2002).
We also found evidence for a gain-of-function effect by mutant p53 through experiments
performed on a cell line from a mutant p53 osteosarcoma. The induction of cell cycle arrest
following shRNA-mediated knockdown of mutant p53 provides an ideal system for mechanistic
studies of mutant p53 function. Some of these cells also appear to undergo apoptosis following
p53 shRNA activation based on the appearance of highly refractile cells by light microscopy
(personal observation).
Several experiments should be performed in order to follow up on these initial observations. To
begin, FACS analysis for cleaved caspase-3 expression can be used to determine the presence or
absence of apoptotic cells following shRNA induction. Other apoptosis assays could also be
performed to look for Annexin-V cell-surface expression, the presence of a subG1 population by
propidium iodide staining or the presence of DNA laddering. Also, the precise nature of the cell
198
cycle arrest should be worked out by BrdU/PI incorporation or 3H-thymidine incorporation. The
accumulation of tumor cells in a particular stage of the cell cycle following mutant p53
knockdown might provide evidence for the activation of a particular cell cycle checkpoint.
At the molecular level, if mutant p53 inhibits the function of p63 and p73, then expression of p63
and p73 target genes should rise following shRNA-mediated knockdown of mutant p53.
Preliminary experiments to assess p63 and p73 target gene expression by qRT-PCR supported
this prediction, but they require verification (personal observation). An even more stringent
experiment would be to perform p63 or p73 chromatin immunoprecipitations to determine
whether p63 and p73 binding to target gene promoters increased upon mutant p53 knockdown.
It may also be useful to assess the effects of mutant p53 on global gene expression. Having
derivatives of the same cell line before and after mutant p53 knockdown should help to reduce
the background noise that is common in expression arrays.
The osteosarcoma cell described in this work, as well as other tumor cell lines that were derived
from mutant p53 mice, could also be used to identify proteins that interact with mutant p53 using
immunoprecipitation and mass spectroscopy. In recent years, p53 has been reported to
participate in several direct protein-protein interactions involving the core DBD. These include
interactions with TAp63, TAp73, ASPP1, 53BP1, BRCA1 and Bcl-2/Bcl-XL (Chai et al., 1999;
Di Como et al., 1999; Gorina and Pavletich, 1996; Joo et al., 2002)(Ute Moll, unpublished
results presented at the 12th International p53 Workshop, Dunedin, New Zealand). One of these
interactions, between fragments of p53 and ASPP1, has been visualized using X-ray
crystallography (Gorina and Pavletich, 1996). This and other published p53 crystallographic
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studies have been invaluable in understanding the basic properties structural properties of p53. It
would be a great advantage to have more crystal structures of p53 participating in protein-protein
interactions. It would be especially interesting to see a structure of full-length p53 in order to get
an idea of how the three independently folding regions of p53 interact with one another. An
attempt to crystallize p53 in complex with the small DNA circles described by Carole Prives
might have some success as this interaction is far stronger than p53 binding to linear DNA and
involves the coordination and binding of multiple regions of p53, including the non-specific
DNA binding domain of the CTD. It would also be extremely interesting to observe the protein-
protein interactions between mutant p53 and p63 or p73 (this might be accomplished using just
the core domain fragments of each protein). This might give an idea as to whether it would be
possible to chemically inhibit the interaction between mutant p53 and p63/p73. By inhibiting
this interaction, p63 and p73 might then be free to act as tumor suppressors. Their function
could then be further augmented either by genotoxic agents or perhaps even the nutlin
compounds. Since p63 and p73 do interact with Mdm2, it would be interesting to know whether
the nutlin compounds can activate p63 and p73 in addition to p53.
Dominant Effects by Mutant p53
This work also reaffirmed that mutant p53 can act dominantly in the presence of wild-type p53 to
promote tumorigenesis. Mice heterozygous for p53 point mutations develop more tumors than
heterozygous knockout mice in both the germline and lung adenocarcinoma studies. Although a
distinction between dominant-negative effects and dominant gain-of-function effects could not
be made in the germline study, a partial dominant-negative effect was established for the
p53R270H mutant in the progression of K-ras initiated lung adenocarcinomas. Furthermore,
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dominant effects by mutant p53 were apparent in cell cycle experiments on MEFs and apoptosis
experiments on primary thymocytes. Whether these cellular assays are indeed indicative of
dominant-negative effects by mutant p53 could be established by performing p53 chromatin
immunoprecipitations for p53 target genes in the p53/' + cells.
It should be noted that the term "dominant-negative p53" is deceptive. The tumor-associated
mutations in p53 do not act as pure dominant-negative alleles as there is substantial evidence
from this work and others that mutant p53 cannot fully inhibit the function of wild-type p53
when they are expressed at comparable levels. Indeed, the mere fact the LOH occurs fairly
frequently in the tumors of LFS patients proves that there is a selective pressure to lose the
remaining wild-type allele of p53. The incomplete dominant inhibition of wild-type p53 by
mutant p53 may reflect a partial transcriptional activity by p53 tetramers composed of both
mutant and wild-type p53 polypeptides. Alternatively, it may reflect a residual pool of fully
wild-type tetramers arising through the random association of four wild-type p53 polypeptides.
This latter case becomes substantially more probable if it is true that the initial dimerization of
p53 occurs co-translationally (Nicholls et al., 2002). An interesting experiment could be
performed that would address this possibility in vivo using published mouse strains. The Hupki
mice, created by swapping exons 4-9 of human p53 into the murine p53 locus, produce a fully
functional chimeric p53 protein that is six residues shorter than the endogenous p53 allele (based
on genome data from Ensembl)(described in Chapter 1- mouse models of p53). By crossing
Hupki mice to the germline mutant p53 mice to get p53M/HUpki mice, one should be able to
distinguish how many differently sized populations of p53 proteins occur by non-denaturing
PAGE and immunoblotting. If tetramerization occurs completely randomly, there should be five
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different populations of p53 tetramers in a 1:4:6:4:1 ratio, reflecting tetramers containing 0,1,2,3
or 4 mutant subunits. However, if irreversible cotranslational dimerization occurs in vivo, then
only three populations should be found in a 1:2:1 ratio. Furthermore, the DNA binding activity
of each of these populations could also be tested using DNA affinity immunoblotting. Following
the addition of biotinylated DNA (containing p53 target sites) to cell lysates from p53 u/Hupki
cells, a streptavidin immunoprecipitation will pull down only those populations of proteins that
successfully bind to DNA. p53 immunoblotting of the immunoprecipitates under non-denaturing
conditions would then distinguish which populations of tetramers bound to p53 target sites. This
experiment could be performed with a variety of different p53 response sites in order to examine
the dominant-negative effects of mutant p53 on different genes.
Mutant p53 protein accumulation
The observation that p53w - mice do not accumulate mutant p53 protein in their normal tissues,
or even in many of their tumors, suggests that there is an in vivo regulatory mechanism for p53
protein stability that is not strictly dependent on the Mdm2/p53 autoregulatory loop. In contrast,
p53- or p53 w+/ MEFs have elevated levels of p53 protein even in the absence of DNA damage.
What is the mechanism by which mutant p53 protein levels are kept in check in vivo? One
possibility is that p53-independent Mdm2 activation plays an important role in vivo.
Alternatively, another protein such as JNK may regulate mutant p53 accumulation. One
interesting observation comes from the K,P lung cancer models. Immunohistochemical staining
for p53 in the lung tumors that develop in K,270/F1 mice and K,172/F1 mice found that only a
subset of tumors accumulated mutant p53. This subset tended to include the more advanced
tumors from these mice. Interestingly, staining of adjacent serial sections of lung with p53 and
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phospho-ERK antibodies found that all of the tumors that accumulated mutant p53 also had
expression of phospho-ERK. This might suggest that the MAPK pathway could intersect with
the regulators of mutant p53. Preventing the accumulation of mutant p53 could be useful in
tumors types where mutant p53 actively promotes tumorigenesis.
MOUSE MODELLING OF HUMAN CANCERS
By targeting the compound mutation of both K-ras and p53 to the lungs, we were able to create
mouse models of lung adenocarcinoma that accurately recapitulate the phenotypes of human
lung cancer. In particular, tumors arose in the K,P mice that had advanced features of human
lung adenocarcinoma, including nuclear atypia, tumor giant cells, stromal desmoplasia, invasion
and metastases. These successes reflect the careful targeting of the exact mutations found in
human cancers to the appropriate cellular compartment.
Mouse models of cancers have found broad use as an educational tool for discovery. The K,P
mouse models of lung cancer have already provided several important lessons regarding the
biology of lung adenocarcinomas. As expected, these experiments confirmed that loss of p53
strongly promotes the progression of lung adenocarcinomas. However, the presence of mutant
p53 does not confer a gain-of-function effect on the promotion of lung tumors. It should be
noted that these experiments were designed in a way that might not detect a gain-of-function
effect by mutant p53 on lung adenocarcinoma initiation. For example, if mutant p53 in some
way inhibits DNA repair pathways, then its expression might promote the acquisition of K-ras
mutations. Such an effect would obviously promote the initiation of lung adenocarcinomas but
would not be detected by the experiments performed in this work.
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It was also found that the p5 3R270H allele has a partial dominant-negative effect on the
progression of K-ras induced lung adenocarcinomas while the p53R172H allele does not. This may
explain why codon 273 of human p53 is more frequently mutated in human lung
adenocarcinomas than codon 175.
Finally, it should be noted that even in the K,Fl/Fl mice, only a small subset of tumors possessed
the most malignant features of lung cancer such as stromal desmoplasia, invasion and metastasis.
This suggests that further genetic alterations must occur for the tumor to fully progress. Future
analyses of the genetic abnormalities in these tumors, including expression profiling and CGH,
may provide insight into the further events required for progression. One possibility that I find
interesting is a comparison of the genetic abnormalities occurring in K,+/+ lung tumors versus
K,Fl/Fl lung tumors. If the loss of p53 from a tumor obviates the need for a particular genetic
alteration, one might expect that some abnormalities would be found in the K,+/+ tumors that
would not be found in the K,Fl/Fl tumors. This could provide insight into what losing p53 truly
accomplishes for the tumor.
Use of mouse models in preclinical drug testing
To date, mouse models of cancer have primary been used for learning about the biology of
cancer. However, accurate mouse models may also be useful as preclinical models for drug
discovery and development. Clinical testing of drugs is an extraordinarily expensive endeavor.
In the year 2000, the mean out-of-pocket cost to perform Phase I, II and III trials on a single
investigational compound was 15.2, 23.5 and 86.3 million dollars, respectively (DiMasi et al.,
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2003). For this reason, a great amount of effort is devoted to trying to predict which compounds
will be the most successful. The current standard for preclinical testing is the use of xenograft
models. This is a low standard. Xenograft models are extremely ineffective for predicting drug
efficacy in humans. Therefore in order to be useful, we need only demonstrate that mouse
models of cancer are more predictive of efficacy in humans than xenograft models.
Mouse models have a number of advantages over xenografts. For example, in every tumor that
arises in a genetically engineered mouse model, one or more of the genetic alterations in that
tumor are identified a priori. In contrast, generally very little is known about the genetic
abnormalities present in a xenograft tumor. This information could be extremely useful when
testing rationally targeted drugs. Small, initial trials could be given more power by selecting the
subset of patients most likely to be responsive to a particular drug, i.e. those harboring tumors
with particular mutations.
Another benefit is that genetically matched primary cells or tumor cells can be cultured from a
mouse for use in high-throughput cellular screens. Relevant reporter molecules can even be
engineered directly into the mouse model to facilitate screening. Indeed, several rounds of
screening could be used in order to assay different aspects of the tumor biology. Intermediate-
throughput screens could conceivably be designed using 3D organ culture or tumor explants.
Testing on the organismal level could then commence using a small number of compounds that
have been vetted in a series of genetically matched systems. One way to help validate whether
any of these screens are predictive will be to test all the drugs that have been used in humans to
treat a particular cancer as controls. If cisplatin is an ineffective drug when used in humans
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against a particular cancer, one should verify that it is also ineffective against the mouse model
of that cancer. As always, when working with mouse models, one should, at all times, be guided
by the human disease.
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